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I. Abstract 
 
Histone modifications represent one of the main layers which determine gene regulation. 
According to the type of modification we can discriminate repressive histone marks, which 
correlate with gene silencing; from active histone marks, which promote gene activation.  
Beyond H3K27me3, which is mostly responsible for silencing of developmental genes, 
H3K9me3 and H4K20me3 marks are also associated with repressive functions; however they 
mainly accumulate at constitutively silenced chromatin regions (heterochromatin). 
Noteworthy, H3K9me3 is also found outside heterochromatin. Here, SETDB1 is the histone 
methyltransferase responsible for its establishment.  
To investigate the role of H4K20me3 repressive mark we used Suv420h2 knockout mice; 
while H3K9me3 functions were examined in the context of B cell development and during 
haematopoiesis by generating Setdb1
Mb1
 and Setdb1
Vav
 conditional knockout mice. 
Suv420h2 knockout mice showed increased spleen size. Immunophenotyping of the 
main splenic populations highlighted the presence of germinal center B cells which produced 
substantial amounts of self-reactive antibodies. Additionally, we could also detect a 2 fold 
increase in follicular helper T cells, which are known to initiate the germinal center reaction. 
Generation of Suv420h2 knockout; VavBcl2 mice, which bypass apoptosis via Bcl2 
overexpression, allowed us to verify whether we could enhance the spontaneous germinal 
center formation by releasing apoptotic restraints. Importantly, these animals robustly 
confirmed, with better resolution, the phenotype observed in Suv420h2 deficient mice.  
Altogether, these data suggested that loss of SUV420H2-mediated H4K20me3 promoted 
spontaneous germinal center formation in the spleen. 
Setdb1
Mb1
 mice exhibited impaired B cell development as we observed enhanced 
apoptosis during pro B to pre B cell transition. Bone marrow transplantation, together with in 
vitro assay confirmed that this defect is cell-autonomous; therefore Setdb1 is intrinsically 
required during B cell development. RNA-Seq analysis of pro B cells revealed massive 
upregulation of two specific classes of retroelements, known as MuLVs and MMLV30, upon 
Setdb1 depletion. Interestingly, ChIP-Seq analysis revealed that SETDB1 and H3K9me3 both 
localized across these endogenous retroviral sequences, indicating that SETDB1 is required to 
silence these elements in pro B cells. Since ectopic expression of retroviral elements is known 
to cause apoptosis, we generated Setdb1
Mb1
; VavBcl2 mice.  In these animals, pro B cells 
overcome programmed cell death and, notably, B cell development is partially rescued as 
demonstrated by the presence of mature B cells in the spleen.  
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In conclusion, we propose that ectopic expression of endogenous retrovirus due to Setdb1 loss 
blocks B cell development.   
 Setdb1
Vav 
mice were severely underdeveloped and died within 4-5 weeks after birth. 
Analysis of hematopoietic cells in the spleen and bone marrow highlighted the complete 
absence of mature lymphocytes in contrast to an abnormal expansion of the myeloid cells 
compartment. Common lymphoid progenitors were virtually present in the absence of Setdb1, 
however they did not progress further to generate mature B and T cells. Differently, common 
myeloid progenitors showed a clear bias towards granulocytes macrophage differentiation. 
Additionally, we found that the hematopoietic stem cells were detectable only till the 3
rd
-4
th
 
week after birth; in fact, they vanished approximately before Stedb1
Vav
 mice died.  
Preliminary experiments performed in vitro suggested that all these hematopoietic defects are 
cell-intrinsic; however bone marrow transplantations will confirm this assumption with better 
confidence.  
Altogether these data show that Setdb1 depletion (1) impairs lymphopoiesis downstream 
common lymphoid progenitors, (2) induces a bias toward myeloid differentiation and (3) 
prevents hematopoietic stem cells maintenance; suggesting a potential role of Setdb1 in 
lineage commitment and hematopoietic stem cell maintenance. 
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II. Zusammenfassung  
 
Histonmodifikationen sind eine Form der Genregulation. Es gibt repressive und aktivierende 
Modifikationen; die Ersteren sind mit Gensupression und die Zweiten mit gesteigerter 
Genexpression assoziiert. 
Während die H3K27 Trimethylierung für die Supression von Genen verantwortlich ist, die in 
der Embryonalentwicklung eine Rolle spielen, haben die H3K9- und H4K20 Trimethylierung 
suppressive Eigenschaften in anderen Bereichen des Genoms. Diese beiden Modifikationen 
sind meist in konstitutiv supprimiertem Chromatin (sog. Heterochromatin) zu finden. 
Zusätzlich ist eine H3K9 Trimethylierung auch außerhalb von Heterochromatin anzutreffen. 
Dort ist die Methyltransferase SETDB1 für die Etablierung dieser Modifikation 
verantwortlich.  
Um die Rolle der supressiven H4K20 Trimethylierung untersuchen zu können, wurden 
Suv420h2 Knockout-Mäuse erzeugt. Die Funktion der H3K9 Trimethylierung wurde 
stattdessen in Setdb1
Mb1
 und Setdb1
Vav
 Mäusen beleuchtet, da diese eine Charakterisierung 
während der B-Zell-Entwicklung und der Hämatopoese erlauben. 
Suv420h2 Knockout-Mäuse zeigen eine vergrößerte Milz. Im Rahmen einer 
Immunophänotypisierung der Haupt-Milzzellpopulationen konnten Keimzentrums-B-Zellen 
identifiziert werden, welche große Mengen an selbstreaktiven Antikörpern produzierten. Des 
Weiteren konnte auch eine zweifache Vermehrung der follikulären T-Helferzell-Population 
detektiert werden, welche bekanntermaßen die Keimzentrumsreaktion initiiert. Suv420h2 
Knockout- VavBcl2 Mäuse, welche die Apoptose durch überexprimiertes Bcl2 hemmen, 
wurden dahingehend überprüft, ob durch die Apoptosehemmung die Rate der spontanen 
Keimzentrumsreaktion erhöht werden kann. Es bestätigte sich der aus den Suv420h2 
defizienten Mäusen bekannte Phänotyp in diesen Tieren sehr klar und deutlich. Daraus lässt 
sich schließen, dass der Verlust der von SUV420H2 vermittelten H4K20 Trimethylierung die 
spontane Keimzentrumsreaktionsrate in der Milz erhöht. 
Die phänotypische Analyse der Setdb1
Mb1 
Mäuse ergab eine gestörte B-
Zellentwicklung welche sich durch eine erhöhte Apoptoserate während der pro-B – zu prä-B-
Zellreifung auszeichnet. Knochenmarktransplantations- und in vitro Experimente konnten 
zeigen, dass dieser Defekt spezifisch für die B-Zellpopulation ist. Setdb1 stellt sich somit als 
essenzieller Faktor für die B-Zellreifung dar. Die Auswertung von RNA-Sequenzierungsdaten 
einer Setdb1 Knockout pro-B-Zellpopulation ergab eine signifikante Expressionserhöhung von 
MuLV- und MMLV30 retroviralen Elementen. Des Weiteren zeigte die ChIP-Seq-Analyse die 
Kolokalisation von SETDB1 mit H3K9 Trimethylierung in diesen endogenen retroviralen 
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Sequenzen an, was darauf hindeutet, dass SETDB1 für die Stilllegung dieser Elemente in pro-
B-Zellen verantwortlich ist. Da die ektopische Überexpression retroviraler Elemente 
bekanntlich Apoptose induziert, wurden Setdb1
Mb1
; VavBcl2 Mäuse gezüchtet, in welchen pro-
B-Zellen den programmierten Zelltod überstehen können. Bemerkenswerterweise konnten 
diese Tiere die B-Zellreifung teilweise wieder durchführen, was sich durch die Anwesenheit 
von reifen B-Zellen in der Milz zeigte. Daraus lässt sich schließen, dass eine durch den Setdb1 
Verlust induzierte ektopische Expression von endogenen retroviralen Elementen die B-
Zellentwicklung blockiert. 
Setdb1
Vav
 Mäuse waren physisch deutlich unterentwickelt und starben innerhalb von 4-
5 Wochen nach der Geburt. Die Analyse der hämatopoetischen Zellpopulationen in der Milz 
und im Knochenmark zeigte die völlige Abwesenheit von reifen Lymphozyten und eine 
auffällige Erhöhung der myeloiden Zellzahl an. In Abwesenheit von Stedb1 waren myeloide 
Vorläuferzellen zu finden, die sich allerdings nicht zu reifen B- und T- Zellen entwickelten. 
Stattdessen differenzierten diese myeloide Vorläuferzellen vermehrt zu Granulozyten und 
Makrophagen. Zusätzlich konnten hämatopoetische Stammzellen nur bis zur 3.-4. Woche nach 
Geburt detektiert werden. Diese Zellpopulation verschwindet kurz vor dem Ableben der 
Stedb1
Vav
 Mäuse.  
Vorläufige in vitro Daten deuten an, dass all diese Phänotypen auf zellintrinsische Defekte 
zurückzuführen sind. Mittels Knochenmark Transplantationsexperimenten kann dies genauer 
untersucht werden.  
Zusammenfassend zeigen diese Daten, dass die Setdb1 Depletion (1) die Lymphopoese 
unterhalb der Ebene der lymphoiden Vorläuferzellen stört, (2) die myeloide Differenzierung 
präferenziell fördert und (3) die Selbstvermehrung von hämatopoetischen Stammzellen 
verhindert. Diese Phänotypen legen nahe, dass Setdb1 eine wichtige Rolle während der 
Determination der Zellliniendifferenzierung und Stammzell-Selbstvermehrung spielt.  
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 Introduction 1
1.1 Epigenetic modifications: several ways to regulate gene expression 
 
The semantic of the word epigenetics can be directly deduced from the etymologic analysis of 
the term. The Greek prefix epi-, which precedes the word genetics, indicates something which 
is beyond, outside of; thus the expression epigenetics means beyond genetics.  
In the field of biology, such term was first used by Conrad Waddington (1905–1975), who is 
given credit for coining the term, defining epigenetics as “the branch of biology which studies 
the causal interactions between genes and their products, which bring the phenotype into 
being”. With this description, Waddington implied that although different organisms have 
almost identical DNA sequence, there must be something else, beyond genetics, which 
determines their different phenotypes (Dupont et al., 2009; Goldberg et al., 2007; Waddington, 
1942). 
As time passes, this term evolved and developed, encompassing many other meanings as result 
of the big progresses which have been achieved during the past years in the field of molecular 
biology. The most recent and comprehensive meaning of the word epigenetic was discussed 
during a meeting (December 2008) hosted by the Banbury Conference Center and Cold Spring 
Harbor Laboratory. Here, a group of experts attempted to deliver a consensus definition of 
„„epigenetics‟‟ which formalized in the following statement: “An epigenetic trait is a stably 
heritable phenotype resulting from changes in a chromosome without alterations in the DNA 
sequence” (Berger et al., 2009). Although this definition is understandable and broadly 
accepted from people of the field, biologists with different expertise and background might 
have some difficulties to comprehend how changes in gene expression, which are possibly 
inheritable, occur without any modification of the DNA sequence. To circumvent these 
difficulties, it would be appropriate, at this point, to explain more in detail how epigenetics 
modifications occur and what they are. 
According to the molecular machinery which mediates them, epigenetic modifications can be 
classified in three main categories: DNA methylation, nucleosome positioning and histone 
modifications (Portela and Esteller, 2010).  
1.1.1  DNA methylation 
 
The chemical deposition of methyl groups on DNA is a process known as DNA methylation. 
DNA methylation mainly occurs on the cytosine residues belonging to cytosine/guanine pairs 
(CpGs), where nucleotides are separated by only one phosphate group. In mammals, 60-90% 
of CpG dinucleotides are methylated (Kass et al., 1997) .  
Introduction  
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DNA methylation is mainly associated with transcriptional repression and it plays an essential 
role in important biological processes, such as genomic imprinting, X-chromosome 
inactivation, suppression of repetitive elements and gene silencing (Newell-Price et al., 2000; 
Robertson, 2005; Straussman et al., 2009).  
The enzymes which catalyse the transfer of the methyl group on the DNA belong to the family 
of DNA methyltransferases (DNMTs). In mammals, five DNMTs have been described:  
DNMT1, DNMT2, DNMT3A, DNMT3B DNMT3L; however among them only DNMT1, 
DNMT3A and DNMT3B possess methyltransferase activity (Bestor, 2000).  
DNMT3A and DNMT3B are de novo DNA-methyltransferases responsible for the 
establishment of a new methylation pattern during early stages of embryo development, when 
paternal and maternal DNA are deprived of all pre-existing methylation profiles (Okano et al., 
1999).  
Once that the new methylation profile has taken shape, it needs to be kept each time cells 
replicate their DNA during the cell cycle (S phase). At this stage the newly synthesized 
genome consists of a hybrid DNA molecule which contains and old methylated strand, and a 
new one without methyl groups. To restore the methylation pattern on the newly synthesized 
strand, the methyltransferase DNMT1 is recruited at replication foci to maintain the 
methylation pattern previously established by DNMT3A and DNMT3B (Bostick et al., 2007; 
Chuang et al., 1997) (Fig. 1.1).  
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Figure 1.1  DNA methylation 
Upon fertilization maternal and paternal DNA are demethylated. In the blastocysts DNMT3A and 
DNMT3B will establish a new methylation profile which will be kept in the organism by DNMT1. 
1.1.2 Nucleosome positioning and histone modifications  
 
Chromatin is the way eukaryotic DNA and protein are packed inside cell nuclei. The essential 
units which give shape to the chromatin are the nucleosomes; structural blocks consisting of 
an octamer containing two copies of the 4 main histones (H3, H4, H2A and H2B) around 
which 147 base pair of DNA are enfolded (Luger et al., 1997). All histones are nuclear 
proteins characterized by a spherical shape which harbour N-terminal tails carrying different 
kinds of covalent modifications on different amino acid residues.  
The fact that DNA is highly packed around histones has a strong impact on the 
transcriptional level. Nucleosomes, in fact, represent a physical barrier which prevents access 
of transcription factors to their binding sites in the genome (Jiang and Pugh, 2009). Depending 
on the position of nucleosomes along genes, transcriptional blockage can occur at different 
moments during transcription. Indeed, nucleosomes positioned at the transcriptional start site 
(TSS) of a gene prevent the binding of protein complexes involved in the initiation of the 
transcriptional event (Cairns, 2009); while nucleosomes located in the gene body or distant 
from the TSS will inhibit later stages of gene expression (transcriptional elongation) (Subtil-
Rodriguez and Reyes, 2010). When transcription begins, nucleosomes are relocated along 
DNA sequence, allowing the binding of the transcriptional machinery (Jiang and Pugh, 2009; 
Segal and Widom, 2009; Struhl and Segal, 2013) (Fig. 1.2 a). 
Nucleosome mediated gene regulation has been extensively studied in yeast, and many 
progresses have been made in understating the molecular basis of this phenomenon and which 
chromatin remodelers are involved (Segal and Widom, 2009; Struhl and Segal, 2013). 
However, whether this mechanism occurs also in mammal still remains an open question.  
Differently from nucleosome positioning, histone modifications and the impact they 
have on gene expression have been studied in a broader spectrum of organisms, mammals 
included. Histone tails undergo post-transcriptional modifications on specific amino acid 
residues, where several types of functional groups are covalently bound. In the past decades, 
many histone modifications, such as methylation, acetylation, ADP-ribosylation, 
ubiquitination, citrullination and phosphorylation have been identified (Kouzarides, 2007). 
Among these, methylation and acetylation are better described and have been confirmed to 
alter DNA-protein interaction, influencing transcription (Dupont et al., 2009).  
During the last years many ChIP-Seq experiments have been performed to map histone 
modifications genome-wide (Schones and Zhao, 2008). Interestingly, their distribution 
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strongly correlates with specific transcriptional states, supporting the assumption that histone 
marks play a crucial role in regulating genes (Strahl and Allis, 2000) . 
 Chromatin can be distinguished in transcriptionally repressed chromatin and 
transcriptionally active euchromatin. Repressed chromatin is marked by the presence of 
methylated lysine residues that associate with transcriptional inactivation (H3K9me3, 
H3K27me3, and H4K20me3). Euchromatin, on the other side, is enriched either with 
methylated (H3K4me3, H3K36me3, and H3K79me3) or acetylated (H3K9ac, H3K14ac, 
H3K18ac, H3K23ac, H4K5ac, H4K8ac, H4K12ac, and H4K16ac) lysine residues which 
correlate with gene expression (Dupont et al., 2009).  
 
 
 
Figure 1.2 Nucleosome positioning and histone modifications influence transcription 
a) Nucleosome positioned at TSS. Transcription is OFF. Upon binding of chromatin remodelers 
nucleosomes move elsewhere and free TSSs allowing binding of the transcriptional machinery.  
b) Repressive histone marks package chromatin in a close configuration preventing transcription. 
Active histone marks, instead, release compacted chromatin giving access to transcription factors to 
initiate transcription. 
 
The establishment of these histone modifications all over the DNA sequence is a process 
anything but trivial as it involves the assembly of big protein complexes, such as MLL 
(H3K4me3) or the Polycomb protein complex (H3K7me3) in response to certain stimuli. The 
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group-transferase activity is attributed only to the enzyme which is recruited in such 
complexes and is essential for the establishment of histone tails modifications. However; the 
presence of other factors not directly involved in histone tail modification is also crucial for 
complex assembly, reaction dynamics and sequence targeting in a context dependent manner 
(Glass and Rosenfeld, 2000; Rosenfeld et al., 2006; Smith and Shilatifard, 2010). This has 
been largely demonstrated in mice or cell lines by loss of function experiments. In fact, the 
depletion of non-enzymatic factors which are part of these epigenetic complexes is sufficient 
to impair the establishment of histone modifications (Ang et al., 2011; Dou et al., 2006; Faust 
et al., 1995; Katada and Sassone-Corsi, 2010; Pasini et al., 2004; Rampalli et al., 2007). 
Significantly, loss or reduction of histone marks induce changes in transcription (Kouzarides, 
2007), supporting the hypothesis that the histone modifications represent one of the main 
layers which regulates gene expression (Fig. 1.2 b).   
1.1.3 Histone modifications during development 
 
Because histone modifications play a pivotal role in fine-tuning gene expression, they are 
often investigated in the context of development and differentiation (Dambacher et al., 2010). 
These two biological processes involve massive transcriptional changes driven by specific 
transcription factors. Up to the present, several publications have already revealed a lot about 
the importance of transcription factors during developmental transitions (Dambacher et al., 
2010), but we still lack some knowledge about their interplay with the chromatin environment 
(Fig. 1.3). 
 
 
 
Figure 1.3 Transcription factors (TF) determine cell commitment 
Transcription factors set out transcriptional networks which promote developmental switches and 
terminal differentiation. 
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Developmental switches as well as cell differentiation require activation of many lineage 
specific genes; therefore at many sites of the genome active histone modifications have to be 
installed to generate a permissive chromatin environment. So far, the best investigated histone 
methyltransferases associated with gene activation are MLL1-5 (Mixed-Lineage-Leukaemia), 
the Thritorax homologs in Drosophila (Yu et al., 1998). MLLs mediate H3K4me3 
establishment via its C-terminal SET domain, promoting gene expression (Krivtsov and 
Armstrong, 2007; Milne et al., 2002). Similarly to other histone methyltransferase, MLLs 
cooperates in a big complex with many other proteins, such as WDR5, RbBP5 and ASH2L, 
which support the enzymatic activity (Dou et al., 2006). Likewise Trithorax complex in 
Drosophila, MLL1-5 target important developmental factors in vertebrates. In particular, loss 
of MLLs prevents activation the homeotic genes, a group of transcription factors traditionally 
used as model to study developmental gene regulation (Milne et al., 2002; Yu et al., 1995). 
In order to study the developmental function of distinct MLL family members, several 
knockout mice have been generated.  Mll1 knockout (ko) mice die during embryogenesis, 
between E12.5 and E16.5, probably due to abortive expression of some homeotic genes (Yu et 
al., 1998; Yu et al., 1995). Remarkably, disruption of only one MLL1 allele (Mll1 
heterozygous mice) is already sufficient to induce several defects as retarded growth, 
haematopoietic abnormalities, defects in the axial skeleton formation and sternal 
malformations (Yu et al., 1995). To verify whether the observed developmental defects were 
linked to MLL1 methyltransferase activity, mice carrying the Mll1 gene depleted of the SET 
domain (Mll1∆SET) have been also investigated. Surprisingly, these animals are viable and 
fertile; demonstrating that the role of MLL1 during development is only partially linked to its 
enzymatic activity (Terranova et al., 2006). However, expression of some homeotic genes was 
reduced in Mll1∆SET mice, indicating that MLL´s gene activation function is directly linked 
to the enzymatic properties of MLL1 (Terranova et al., 2006). Developmental defects during 
embryogenesis have also been observed upon disruption of Mll2 gene. Mll2 ko mice showed 
embryonic lethality at E11.5 due to growth retardation, apoptosis and developmental delay. 
However, this phenotype is milder compared to MLL1 loss of function. Although Mll1 and 
Mll2 are both essential during embryogenesis, their depletion results in different phenotypes 
and misregulation of different sets of homeotic genes; indicating that these two factors control 
independent aspects of embryogenesis (Glaser et al., 2006).   
Notably, Mll1 ko embryos fail in expanding the hematopoietic stem cell compartment 
and loss of only one Mll allele also results in hematopoietic defects, supporting the idea that 
Mll1 has a defined role in this context (Yu et al., 1995). Unfortunately, embryonic lethality 
blocked any exploratory attempt to elucidate function of MLL1 in adult tissue. For this 
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purpose, conditional deletion has been adopted to study Mll1 functions in the context of adult 
development, specifically during haematopoiesis. Tissue-specific deletion of Mll1 was 
achieved in two independent studies, using different strategies (Jude et al., 2007; McMahon et 
al., 2007). Noteworthy, the usage of different hematopoietic specific cre recombinases resulted 
in inconsistent phenotypes. However, in both works, the observation that Mll1 is important for 
HSCs functions and self-renewal was a common denominator (Jude et al., 2007; McMahon et 
al., 2007), corroborating the hematopoietic defects observed in the embryos. 
 A broad range of hematopoietic anomalies have been also observed upon loss of Mll5 (Liu et 
al., 2009). Although Mll5 ko mice showed some postnatal lethality and were clearly 
distinguishable by reduced size, surviving animals evolved as healthy adults (Madan et al., 
2009). Remarkably, hematopoietic anomalies were observed in three independent publications 
where different strains of Mll5 ko mice were generated via comparable knockout approaches. 
Intriguingly, each of the knockout strain exhibited a big variety of hematopoietic defects, 
spanning from impaired long term repopulation capabilities of hematopoietic stem cells to eye 
infection caused by impaired neutrophil functionality (Heuser et al., 2009; Madan et al., 2009; 
Zhang et al., 2009). Outside the hematopoietic context, other investigators underlined the 
importance of MLL3-4 mediated gene activation during fat generation. In fact, it seems that 
these two proteins are included in the so called ASCOM complex, which mediates PPARγ-
dependent adipogenesis (Lee et al., 2008).  
Although the importance of active histone marks is unquestionable, cell commitment 
also requires silencing of lineage inappropriate genes/transcripts. Thus, formation of 
repressive chromatin is also necessary to ensure proper differentiation (Dambacher et al., 
2010).  
Transcriptionally inactive regions are clearly distinguishable by the presence of H3K27me3 
and H3K9me3. Even though these histone modifications both correlate with repressive feature, 
they mutually exclude each other at transcriptionally inactive chromatin. This has been 
demonstrated in different cell types by genome-wide studies which consistently confirmed that 
H3K9me3 and H2K27me3 co-occupancy is hardly found throughout the genome (Kim and 
Kim, 2012; McEwen and Ferguson-Smith, 2010). Consequently, it is reasonable to assume 
that H3K9me3 and H2K27me3 associate with completely different sets of genes and that the 
protein complexes which establish these marks work independently. 
 H3K27me3 is mostly associated with promoter of developmental genes (Voigt et al., 
2013). At these sites, H3K27me3 establishment is mediated by the Polycomb group proteins 
(PcGs) repressive complex. These proteins were first identified in Drosophila melanogaster as 
repressors of the homeotic and segmentation genes (Lewis, 1978; Moazed and O'Farrell, 1992; 
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Pelegri and Lehmann, 1994; Ringrose and Paro, 2004). Several PcG proteins are highly 
conserved in mammals and can be distinct in two classes according to the protein complexes 
they associate with and to the function they exert (Bracken and Helin, 2009).  
The establishment of H3K27me3 is mediated by the PCR2 complex. In mice, the enzymatic 
activity within this complex is held by the histone methyltransferase enhancer of zeste 
homologue 2 (EZH2) in immature cells and enhancer of zeste homologue 1 (EZH1) in 
terminally differentiated cells. These two histone methyltransferase work together with 
embryonic ectoderm development (EED) and suppressor of zeste 12 homolog (SUZ12), the 
other two components of the PCR2 complex (Margueron and Reinberg, 2011).  On the other 
end, the PCR1 complex is in charge to recognize and target H3K27me3, propagating it and 
stabilizing it. Recognition of H3K27me3 marks is mediated by one of the chromodomains 
contained in the core proteins (PCs) (Fischle et al., 2003; Min et al., 2003). Other members of 
the PRC1 complex are PSC (Posterior sex combs), PH, SCML (Sex combs on midleg) and 
RING proteins. In particular, the latter is responsible for the H2A ubiquitination on the lysine 
119. This modification prevents the binding of the FACT protein complex, which mediates 
nucleosomes disassembly (Belotserkovskaya and Reinberg, 2004; Wang et al., 2004).  
Although PRC1 and PCR2 complexes have a strong association with H3K27me3, the 
mechanism which recruits them at the target sites and the way they stabilize chromatin 
repression are still under debate. 
The first attempt to study H3K27me3 during mouse development was made by 
O´Caroll and colleagues, whom tried to generate at first Ezh2 deficient mice. Loss of Ezh2 
resulted in embryonic lethality between day 7 and day 8.5. Inability to work with embryonic 
tissues prompted ESCs generation from Ezh2 ko blastocyst to study EZH2 function at the 
cellular level. However, even this option was negated by the impossibility to derive ES cells 
from Ezh2 deficient blastocysts (O'Carroll et al., 2001). More recently, alternative deletion 
strategies to disrupt Ezh2 allele allowed the generation of Ezh2 ko ESCs, demonstrating a non-
essential role of EZH2 in ESC establishment and maintenance (Shen et al., 2008). Curiously, 
Ezh2 ko ES cells did not show activation of those genes where H3K27me3 was lost, probably 
due to lack of site specific transcription factors. Furthermore, Ezh2 ko ESCs kept residual 
H3K27me3 which was found to be maintained by EZH1, indicating that this enzyme is used as 
a backup H3K27 histone methyltransferase to protect key developmental genes and to retain 
pluripotency, preventing unwanted differentiation (Shen et al., 2008). 
EZH2 has also been investigated during haematopoiesis. Deletion of Ezh2 in early B cells 
development perturbs B cell differentiation; however the mechanisms which leads to this 
phenotype has been associated to aberrant VDJ recombination rather than altered gene 
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expression due to loss of H3K27 methyl marks (Ezhkova et al., 2009). Ezh2 depletion seemed 
to have no impact on mature B cells development and functionality. Yet, the marked increased 
expression of the enzyme in the very specialized germinal center B cell population prompted 
further investigations. Indeed, the supposition that loss of Ezh2 in mature B cells does not 
induce any phenotype is valid, but limited to the B cell steady-state. Beguelin et al. 
demonstrated that Ezh2 cko B cells are incapable to generate germinal centers, very 
specialized structures containing highly proliferating antibody producing B cells which are 
formed upon immune challenge. This deficiency was attributed to loss of H3K27me3 
repressive mark on those genes which drive germinal center B cells to terminal differentiation 
in plasmablasts (Beguelin et al., 2013).  
Lastly, developmental mechanisms linked to Polycomb-mediated repression have been 
elucidated in the context of skin development. Here, EZH2 controls proliferation and prevents 
premature differentiation of progenitor cells repressing specific genes (Ezhkova et al., 2009).  
Beyond H3K27me3, H3K9me3 and H4K20me3 are the other repressive histone marks which 
accumulate at non-coding regions (centromeres and telomeres) where they are sequentially 
deposited by the histone methyltransferase SUV39H and SUV420H (Dambacher et al., 2013). 
Notably; outside these regions, H3K9me3 is also found and the histone methyltransferase are 
known to take charge of its establishment is SETDB1. However, differently from H3k27me3, 
the role that H3K9me3 plays during developmental transition is still poorly investigated.   
1.2 Haematopoiesis: a good tool to study chromatin functions 
 
Haematopoiesis is the biological process during which multipotent hematopoietic stem cells 
(HSCs) generate all blood cells, which are classified as lymphoid (T, B and NK) or myeloid-
erythroid cells (granulocytes, macrophages, erythrocytes and megakaryocytes). In mouse, 
HSCs start to be differentiated from the haemogenic endothelium at day 8.5 of embryonic 
development to relocate afterwards in the foetal liver, where they remain until birth (Clements 
and Traver, 2013).  After birth, the bone marrow gradually becomes the main source of the 
HSCs (Mikkola and Orkin, 2006). Here, B and myeloid cells accomplish to develop, while T 
cell progenitors leave this site and travel through the blood stream to complete differentiation 
in the thymus (Janeway, 2008a). Since bone marrow and thymus support early stages of 
haematopoietic development, they are defined as primary or central hematopoietic organs. 
When blood cells have reached a certain degree of maturity at these sites, they leave to 
reposition in the peripheral or secondary hematopoietic organs (spleen, tonsils, Payer´s patches 
and lymph nodes), where they terminally differentiate in immune effectors. 
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Central and peripheral haematopoiesis define the spatiotemporal axis along which a lot of 
differentiation takes place. In fact, they both include highly controlled developmental switches 
that are coordinated by transcription factors via establishment of new gene expression patterns. 
Each developmental stage can be identified by surface marker expression, allowing the 
purification of well-defined hematopoietic subpopulation. The possibility to isolate distinct 
subpopulations by FACS analysis and the multiplicity of differentiation events, make of the 
haematopoiesis an ideal system to study development. 
1.2.1 Central haematopoiesis  
 
In the bone marrow HSCs are retained in specific niches where they are maintained and 
regulated (Ding and Morrison, 2013; Morrison and Scadden, 2014). Their potential to generate 
all differentiated blood cells is determined by the exit from the quiescent state which 
characterizes them. In fact, HSCs retain a low-proliferating profile until the blood system has 
to be refilled and/or the HSCs pool has to be expanded (Wilson et al., 2008). Each time HSCs 
proliferate, they asymmetrically divide in self-renewing copy of themselves and multipotent 
progenitors without self-renewing features (Beckmann et al., 2007; Brummendorf et al., 1998; 
Takano et al., 2004). The exit from the quiescent state results from a complex interplay 
between cell intrinsic and cell extrinsic events. On one side, bone marrow microenvironments 
continuously provide external signals which dictate the transcriptional landscapes that have to 
be settled during each developmental stage. On the other side, transcription factors represent 
the cell intrinsic interface which mediates the cross talk between signalling and transcriptional 
changes. 
 Loss and gain of function studies broadly investigated the role that different transcription 
factors play during haematopoiesis (Orkin and Zon, 2008), allowing to outline the hierarchical 
differentiation model (Fig. 1.4). Although this model is constantly challenged by new 
discoveries, the importance of transcription factors in orchestrating hematopoietic cell 
commitment is undeniable.  
The most striking property of HSCs is to self-renew. In mice, this capability was discovered 
by long term reconstitution experiments where HSCs have been serially transplanted over a 
long period of time, without losing their potency (Iscove and Nawa, 1997; Lemischka et al., 
1986). Defective HSCs self-renewal was often linked to inability to maintain quiescence (Li, 
2011; Pietras et al., 2011). Loss of the transcription factors GFI1, E2A BMI and LDB1, for 
example, directly resulted in activation of cell cycle genes. This event released HSCs from 
quiescence and impaired HSCs long term repopulation capabilities, due to ablation of cell 
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cycle restraints (Hock et al., 2004; Li et al., 2011; Park et al., 2003; Semerad et al., 2009; Zeng 
et al., 2004). Alteration of proliferation and apoptosis, induction of hypoxia and oxidative 
stress due to respective depletion of Evi1, FoxOs and Zfx genes also resulted in unwanted 
HSCs cell cycle entry; however the pathways which led to loss of quiescence were, in these 
specific cases related to cellular stress rather than direct cell cycle related-genes derepression 
(Galan-Caridad et al., 2007; Goyama et al., 2008; Tothova et al., 2007). 
 HSCs quiescence is also controlled by signalling events. Indeed, more recent work 
demonstrated that HSCs dormancy is perturbed in Pbx1 ko mice as a consequence of aberrant 
expression of genes associated to TGFβ pathway (Ficara et al., 2008). Additionally, 
constitutive expression of β-catenin; a key component of Wnt signalling pathway; also caused 
hematopoietic stem cell failure induced by enforced cell cycle entry (Scheller et al., 2006).  
Long term HSCs (LT-HSCs) which lost self-renewal properties become multipotent 
progenitors (MPPs). During this transition all HSCs gradually turn into short term HSCs (ST-
HSCs) with limited self-renewal ability (Adolfsson et al., 2001; Yang et al., 2005). Differently 
from LT-HSCs, MPPs cannot self-renew but are still multipotent. These cells embody the first 
hematopoietic branch point where cells start to be hijacked towards myeloid or lymphoid fate.  
The possibility to isolate very well defined hematopoietic subpopulations via 
immunophenotyping allowed to investigate in vivo and in vitro their differentiation potential 
and to identify the transcription factors which are determinant for lineage choice. LT- and ST-
HSCs are included in the Lin- Sca+, c-kit+ (LSK) population. Within these cells the 
expression of FLT-3 (FMS-related tyrosine kinase 3) seems to mark the gradual loss of 
myeloid potential. LSK FLT3+ cells are known as lymphoid multipotent primed progenitors 
(LMPPs) and retain lymphoid-myeloid potential but are incapable to produce megakaryocytes 
and erythrocytes (MegE) (Adolfsson et al., 2005; Nutt and Kee, 2007; Welner et al., 2008). 
Flt3 ko and Flt3l ko mice both significantly reduce production of B cell precursors together 
with impaired myeloid differentiation (Mackarehtschian et al., 1995; McKenna et al., 2000), 
indicating that Flt3 expression is important for lymphoid multipotent primed progenitors 
specification. Up to know no transcription factors have been identified as definite regulators of 
the MPPs to LMPPs transition; however there are some beliefs that the ETS (E26 
transformation-specific or E-twenty-six) family member PU.1 (Sfpi1) might be one of those 
(Nutt and Kee, 2007). Sfpi1 ko mice died during late embryogenesis and showed severe 
impairment of myeloid and lymphoid lineage, indicating that PU.1 functions are required at 
very early developmental stages (McKercher et al., 1996; Scott et al., 1994). Artificial 
introduction of Sfpi1 in Sfpi1 ko foetal liver cells rescued the hematopoietic defects in both 
lineages. Interestingly, this resulted in differentiation of macrophage which highly expressed 
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ectopic PU.1 and B cells expressing significant lower amount of the protein, moving the 
hypothesis that PU.1 dosage is determinant for myeloid versus lymphoid lineage choice 
(DeKoter and Singh, 2000). 
In support of this hypothesis, Rosenbauer and colleagues demonstrated that reduced Pu.1 
expression achieved by deletion of its enhancer upstream regulatory element (URE) caused 
significant loss of myeloid and conventional B cells (B2) while B1 cells, which are only 
involved in humoral response, were increasing with aging (Rosenbauer et al., 2006). 
 
 
 
 
 
Figure 1.4 Hierarchical model of hematopoietic development 
Hematopoietic stem cells lose their self-renewal properties and start to differentiate giving rise to all 
blood cells. Each developmental step is defined by the expression of one or more transcription factors 
which expression is stage dependent. 
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Surprisingly, conditional deletion of Sfpi1 in committed B cell (Polli et al., 2005; Ye et al., 
2005) or Sfpi1 inactivation in sorted CLPs (Iwasaki et al., 2005) did not interfere with the B 
cell differentiation program, indicating that PU.1 is dispensable for late B cell development.  
Besides PU.1, another essential transcription factor which determines lymphoid fate 
specification is the DNA binding protein IKAROS, encoded by Ikzf1 gene (Molnar and 
Georgopoulos, 1994). As previously described, Ikaros deficient mice showed severe 
impairment of lymphopoiesis due to complete abrogation of the B cell compartment and 
defective T cell development, while the myeloid compartment is unaffected (Georgopoulos et 
al., 1994; Georgopoulos et al., 1992; Georgopoulos et al., 1997; Wang et al., 1996). Notably, 
while Pu.1 deficient mice lack myeloid and lymphoid cells, Ikaros loss of function only 
affects lymphoid specification, suggesting that Ikaros comes after Pu.1 in the lymphoid 
transcriptional hierarchy (Nutt and Kee, 2007). In the first place, B cell loss in Ikaros deficient 
mice was attributed to lack of LMPPs which were not detectable due to loss of Flt3 expression 
(Nutt and Kee, 2007) . However, artificial expression of a reporter construct carrying Ikaros 
regulatory elements in wild type and Ikaros deficient progenitors suggested that LMPPs are 
only virtually lost, supporting the idea that Ikaros promotes lymphopoiesis downstream 
LMPPs (Yoshida et al., 2006). Significantly, B cell developmental defects could also be 
detected in transgenic mice carrying an Ikaros hypomorphic allele or an Ikaros allele deprived 
of the DNA binding domain. In these animals, B cells arrested during pro B to pre B and pre B 
to immature B developmental transition, respectively (Joshi et al., 2014; Kirstetter et al., 
2002).  
In the light of the most recent discoveries intersecting roles of PU.1 and IKAROS have been 
proposed to determine lymphoid fate; however the exact mechanisms which modulate the 
expression of these two transcription factors and the way they conveys progenitors to specific 
fates, are still poorly understood (Nutt and Kee, 2007). 
Current models support the idea that PU.1 and IKAROS work in concert to promote FLT3 
expression on cell surface (Singh et al., 2005). FLT3 high cells (LMPPs) are considered the 
earliest lymphoid progenitors (Welner et al., 2008). Indeed, 60% of LMPPs generate nature 
killer (NKs) cells and 31% start to express lymphoid transcripts (Welner et al., 2008). 
Although 38% of LMPPs still possess myeloid-lymphoid potential, a percentage of these cells 
it is already restricted to the lymphoid lineage (Mansson et al., 2007). This subpopulation 
represent the early lymphoid progenitors  (ELPs) which are characterized by loss of VCAM 
surface marker and individual or synchronized expression of lymphoid specific genes, as 
recombination activating gene 1 (Rag1), interleukin-7 receptor-α  (Il-7rα) and the terminal 
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deoxynucleotidyl transferase (Dntt) (Igarashi et al., 2005; Lai and Kondo, 2006, 2007; Medina 
et al., 2001). ELPs are the joining link between LMPPs and common lymphoid progenitors 
(CLP), the next hematopoietic branch point where B, T and NK cell fate is determined in vivo; 
(Allman et al., 2003; Harman et al., 2006; Kondo et al., 1997) but not in vitro, as sorted CLPs 
still show limited myeloid potential (Balciunaite et al., 2005; Nutt and Kee, 2007; Rumfelt et 
al., 2006; Traver and Akashi, 2004). CLPs are typically defined by surface expression of 
inteleukin-7 receptor-α (IL-7Rα). IL-7Rα ligand is the interleukin-7 (IL-7), the cytokine which 
sustains proliferation and survival of developing lymphocytes (Dias et al., 2005; Kikuchi et al., 
2005). Once IL-7Rα engages IL-7, a cascade of phosphorylation events takes place, 
culminating in the recruitment of STAT5A and B.  These, are IL-7Rα pathway restricted 
transcription factors which activate the antiapoptotic proteins BCL2, BCL-XL and MCL-1 
(Clark et al., 2014; Heltemes-Harris et al., 2011; Kikuchi et al., 2005; Malin et al., 2010). Now 
on, downstream IL-7Rα signalling, a group of well investigated transcription factors start to 
orchestrate B and T cell development.  
E2A, EBF1, FOXO1, MYB; MIZ and PAX5 are the most well characterized transcription 
factors which coordinate B cell development. Particularly, MYB and MYZ mediate B cell 
survival and proliferation induced by activation of the IL-7Rα pathway (Fahl et al., 2009; 
Kosan et al., 2010; Thomas et al., 2005) ; while all the other factors work in concert to carve B 
cell specific transcriptional networks. CLPs commitment to the B cell fate is signed by the 
expression of E2a and Ebf1 (Kee, 2009).  In mouse, individual depletion of these factors 
results in similar phenotypes, like early B cell developmental arrest at comparable stages and 
lack of expression of many B cell-associated genes (Bain et al., 1994; Gyory et al., 2012; Li et 
al., 1996; Vilagos et al., 2012), indicating that E2A and EBF1 transcription factors have a 
cognate role in B cell determination (O'Riordan and Grosschedl, 1999; Seet et al., 2004). 
Notably, developmental arrest shown by E2a deficient B cell could be rescued by 
Ebf1overexpression but not vice versa, indicating that E2A works upstream EBF1.  Indeed, as 
demonstrated via ectopic expression in macrophages, E2A specifically binds to Ebf1 distal 
promoter (α-promoter), inducing transcriptional activation (Roessler et al., 2007). EBF1 
induces a new wave of gene expression which drags cells to the pro B cell stage passing 
through the pre-pro B precursors (Lin et al., 2010; Rothenberg, 2010; Zandi et al., 2008). 
During this transition, two central events take place: the immunoglobulin heavy chains start to 
rearrange and the B cell master regulator PAX5 is transcribed (Cobaleda et al., 2007; 
Medvedovic et al., 2011). Although very little is known about the mechanisms which lead to 
Pax5 gene activation, genetic analysis designated EBF1 and STAT5 as direct Pax5 regulator 
(Hirokawa et al., 2003; O'Riordan and Grosschedl, 1999). Intriguingly, Pax5 expression is 
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concomitant with increased level of Ebf1. This is due to a feed forward system, where Ebf1 
raises its own expression by directly binding its distal α-promoter and by activating Pax5 
expression. Indeed, PAX5 boosts Ebf1 transcription via binding its proximal (β) promoter, 
which is different from the one target by E2A, suggesting that distinct complexes induce Ebf1 
expression at different developmental stages (Nutt and Kee, 2007; Roessler et al., 2007). The 
discovery that E2a expression is promoted by EBF1-mediated suppression of the inhibitory 
factor Id2 and Id3 (Thal et al., 2009); the finding that Ebf1 expression is increased and 
maintained by PAX5 during B cell development (Fuxa et al., 2004)  and the fact that PAX5 
binding sites often co-localize in the genome with EBF1 (Lin et al., 2010), strongly suggest 
that B cell commitment is established by a self-reinforcing circuit where several transcription 
factors teamwork to set out the right transcriptional pattern (Singh et al., 2005).  
Although E2a and Ebf1 truly initiate B cell specification and their absence results in loss of B 
cell specific transcripts; PAX5 is the real guardian angel of B cell development (Cobaleda et 
al., 2007; Nutt et al., 1999). Pax5 ko B cells block at early pro B cells stage (Urbanek et al., 
1994); as they exhibited B220 and c-KIT (CD117) markers on their surface (Nutt et al., 1997) 
and expressed the transcriptional ancestors E2a and Ebf1 together with all their target genes 
(Cobaleda et al., 2007). The surprising possibility to expand in vitro Pax5 ko cells (Nutt et al., 
1997) revealed very interesting feature of them as, for example, lack of B cells commitment 
(Cobaleda et al., 2007). In fact, while coculture with stromal cells and IL-7 simply propagated 
Pax5 ko B cells as B220+, c-KIT+ precursors; culture medium implemented with non-
lymphoid cell stimulating cytokines induced transdifferenation into myeloid and NK cells 
(Nutt et al., 1999). Moreover, Pax5 ko B cells could be serially transplanted in recipient mice, 
denoting recovery of self-renewing features (Rolink et al., 1999).  
In wild type cells PAX5 is a transcriptional repressor and activator at the same time (Cobaleda 
et al., 2007). This double role has been featured by transcriptional analysis which showed 
downregulation of B cell specific genes and upregulation of lineage inappropriate transcripts 
in Pax5 ko B cells (Nutt et al., 1999; Nutt et al., 1998). These results strongly suggest that 
commitment does not only involve gene activation, but also requires a tight control over those 
transcripts which might alter cell fate. For example, ectopic expression of the a PAX5 target 
gene Flt3 hinders B cell development (Holmes et al., 2006), demonstrating that PAX5 is not a 
simple inducer of B cell specific transcript, but it is rather a calibrator which establishes and 
maintains B cell transcriptional networks (Cobaleda et al., 2007). 
Noteworthy, depletion of all transcription factors so far described impairs VDJ recombination, 
a hallmark of B cell differentiation (Bain et al., 1994; Fuxa et al., 2004; Kee, 2009; Lin and 
Grosschedl, 1995; Nutt et al., 1997). This process, in fact, consists in laborious rearrangement 
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of the immunoglobulin gene loci to achieve the production of functional immunoglobulins. 
Failure in VDJ recombination results in an irreversible developmental block (Schatz and Ji, 
2011). RAG enzymes play a central role in this process as they are responsible for recognition, 
excision and repair of the recombining immunoglobulin regions (Schlissel, 2003). Indeed, Rag 
ko mice showed complete abortion of VDJ recombination (Mombaerts et al., 1992; Shinkai et 
al., 1992). Altogether, these evidences outline the presence of two important check points 
during B cell commitment: PAX5 mediated gene regulation and VDJ recombination. 
During the pro B cell stage, early VDJ combinatorial events generate a productive heavy chain 
which is temporary expressed on the cell surface together with the surrogate light chain (SLC) 
components λ5 and VpreB, forming the pre B cell receptor (pre-BCR) (Melchers, 2005). This 
event marks pro B to pre B cell transition. 
 As soon as it reaches the cell surface, the pre-BCR binds bone marrow stromal cell antigens 
with high affinity, delivering proliferative signal inside pre B cells through the cytosolic 
domain (Herzog et al., 2009). At the same time the pre-BCR also triggers a negative feedback 
which represses the transcription of the surrogate chain λ5, thus preventing further pre-BCR 
assembly (Parker et al., 2005). This repression is induced by indirect SLP65 mediated 
activation of Irf4 and Irf8 which induce expression of Ikaros and Aiolos to downregulate λ5 
(Lu et al., 2003; Ma et al., 2008; Ochiai et al., 2013; Thompson et al., 2007). Meanwhile pre B 
cells start rearranging the immunoglobulin light chains, which will replace the surrogate ones 
to assemble the definitive B cell receptor, (Herzog et al., 2008; Herzog et al., 2009; Ma et al., 
2006); generating differentiated B cells. These cells are now ready to leave the bone marrow 
reaching the target peripheral organ through the blood stream. 
T cell development requires thymic environment to occur. For this reason lymphoid 
progenitors leave the bone marrow and start seeding the thymus (Miller, 1961; Takahama, 
2006). Although is not clear whether there is a specific T cell progenitor population already in 
the bone marrow, CLPs and ELPs are the lymphoid precursors which show T cell potential in 
vivo and in vitro (Bhandoola et al., 2007; Welner et al., 2008). The branching point when T 
cell separate from B cells is marked by the expression of NOTCH receptors (Radtke et al., 
2004). There are four different NOTCH proteins in mammals, NOTCH 1-4 which can bind 
five different ligands: DELTA-like 1-3-4 and JAGGED 1 and 2 (Hayday and Pennington, 
2007). Notch ligands are mainly expressed by thymic epithelial cells (TECs), restricting T cell 
lineage specification to the thymus (Jenkinson et al., 2006). Interestingly, depletion of Notch1 
induces B cell differentiation in the thymus (Radtke et al., 1999), while its overexpression 
results in ectopic T cell development in the bone marrow (Pui et al., 1999). These observations 
indicate that potentially T and B cell can differentiate in either places and that the B versus T 
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cell choice determination are mainly dictated by the microenvironment cells are sitting in. 
Because a detailed explanation of T cell developmental mechanisms goes beyond the 
explanatory scope of this introduction, they won´t be further described. However; many 
aspects of this topic have been reported in the following reviews (Bhandoola et al., 2007; 
Carpenter and Bosselut, 2010; Hayday and Pennington, 2007; Rothenberg, 2007; Schlenner 
and Rodewald, 2010; Takahama, 2006). 
Although LMPPs still retain myeloid potential (Mansson et al., 2007), common 
myeloid progenitors (CMPs) are the main source of myeloid and erythroid cells. Definition of 
CMPs from MMPs marks the other big branching point during hematopoietic development 
(Akashi et al., 2000). CMPs have the potential to differentiate in granulocytes macrophage 
progenitors (GMPs) and megakaryocyte erythrocyte progenitors (MEPs), which will 
terminally differentiate in granulocyte/macrophages and megakaryocytes/erythrocytes, 
respectively (Akashi et al., 2000; Iwasaki and Akashi, 2007). We have already mentioned that 
PU.1 dosage in MMPs might be determinant to resolve the lymphoid-myeloid dichotomy 
(DeKoter and Singh, 2000). Although this concept struggled to be accepted, recent work 
confirmed that PU.1 mediated myeloid restriction is dosage dependent (Kueh et al., 2013). 
However; differently from B cells that decrease Pu.1 expression at the transcriptional level, 
Pu.1 transcripts raise in CMPs via lengthening cell cycle duration without direct regulation of 
gene expression (Kueh et al., 2013). Although high dosage of Pu.1 marks the branch out form 
the lymphoid lineage, it has been observed that Pu.1 deficient mice lack lymphoid and 
myeloid cells but still develop megakaryocytes and erythrocytes (Dakic et al., 2005; Iwasaki et 
al., 2005). This implies that PU.1 initiates the myeloid commitment but it is not involved in 
the specification of the erythroid lineage. Moreover, it has been noted that within CMPs 
(which have both myeloid and erythroid potential) Pu.1 expression was heterogeneous. 
Precisely; CMPs which showed high Pu.1 levels exhibited myeloid potential, while Pu.1-low-
expressing cells differentiated in megakaryocytes/erythrocytes. These observations reinforced 
the idea that Pu.1 might be important for myeloid but not erythroid lineage specification (Back 
et al., 2005; Nutt et al., 2005). Consequently, we deduce that either some CMPs immediately 
downregulate Pu.1 transcripts to initiate the erythroid program as soon as they diverge from 
lymphopoiesis, or the erythroid fate is held by other progenitors (Adolfsson et al., 2001; 
Rosenbauer and Tenen, 2007).  
A model system to study myeloid versus MegE choice was provided by the MEPE26 avian 
cells (Graf et al., 1992; Laiosa et al., 2006). This cell line was established by E26 virus 
transformation and carries and Myb-Ets oncogene. Upon oncogene activation, these cells 
differentiated in either erythrocytes or thrombocytes (the avian megakaryocytes), while 
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induction of RAS or proteinase C pathways resulted in the production of myeloblasts (Graf et 
al., 1992). Interestingly, the transition to myeloblasts was associated to the downregulation of 
GATA1, a MegE related gene. Enforced expression of GATA1, instead, redirected meyloblasts 
to the erythroid fate and, vice versa, overexpression of the myeloid related gene PU.1 
reprogrammed MegE into myeloblasts (Kulessa et al., 1995; Nerlov and Graf, 1998).  
These results indicate that PU.1 and GATA1 antagonize each other‟s during the myeloid-
erythroid diatribe and changes in PU.1:GATA1 ratio is sufficient to redifferentiate cells to the 
alternative fate (Laiosa et al., 2006). More recent work demonstrated that PU.1 versus GATA1 
competition occurs via protein-protein interaction (Nerlov et al., 2000; Rekhtman et al., 1999; 
Zhang et al., 1999). In fact, PU.1 is able to inhibit GATA1 functions preventing binding to 
erythroid genes (Stopka et al., 2005; Zhang et al., 2000) and; similarly, GATA1 binds PU.1 
preventing transcription of PU.1 related genes (Nerlov et al., 2000; Zhang et al., 1999). 
GATA1 is; therefore, a crucial transcription factor during erythroid fate determination (Xu and 
Orkin, 2011). Indeed, Gata1 deficient mice showed a strong development block during foetal 
erythropoiesis, which results in embryonic lethality caused by anaemia (Fujiwara et al., 1996; 
Pevny et al., 1991). These defects can be compensated by Gata2 and Gata3 overexpression, 
probably due to their compensatory role in the absence of Gata1 (Takahashi et al., 2000). 
Additionally, impaired expression of Gata1 specifically in megakaryocytes strongly reduced 
platelets production and resulted in abnormal megakaryocytic growth (Shivdasani et al., 
1997).  
Another transcription factor essential for MegE differentiation is FOG1 (friend of GATA1). 
As the name already suggests; FOG1 teamworks with GATA1 to induce transcription of target 
genes. FOG1 deficient mice show a phenotype which closely resembles the one observed upon 
loss of Gata1 (Tsang et al., 1998; Tsang et al., 1997); however loss of Fog1 resulted in a 
stronger phenotype which completely abolished megakaryocytes differentiation (Tsang et al., 
1998). As proof of the fact that FOG1 function during megakaryopoiesis is strictly linked to 
GATA binding, transgenic mice carrying GATA proteins incapable to bind FOG1 have been 
produced. These animals also lack megakaryocytes, similarly to Fog1 deficient mice (Chang 
et al., 2002).  
Once MegE precursors are committed, they still have to branch out from each other to 
terminally differentiate in erythrocyte and megakaryocyte. The candidate proteins which seem 
to play a role in this regards are the cross-antagonizing factors FLI-1 and EKLF (Starck et al., 
2003).  
Augmented PU.1 expression together with its interaction with other factors induces 
myeloid fate, converting CMPs in granulocyte macrophage progenitors (GMPs) (Mak et al., 
 Introduction  
 
24 
2011). This transition is defined by C/EBPα, the transcription factor responsible for GM 
(granulocytes/macrophages) related-gene activation in combination with PU.1 (Friedman, 
2002). Complete C/EBPα depletion leads to postnatal lethality, as mutant mice survived only 8 
hours after birth (Wang et al., 1995). Analysis of the hematopoietic compartment in the new-
borns and in the embryonic foetal liver displayed specific loss of granulocytes, particularly 
neutrophils and eosinophils (Zhang et al., 1997). This phenotype was confirmed in adult mice 
where induced loss of C/EBPα abrogated GMP production but did not affect later stages of 
myeloid differentiation (Zhang et al., 2004), indicating that this factor is not required during 
late myelopoiesis where, maybe, other C/EBP family members play a role (Laiosa et al., 2006; 
Zhang et al., 2004). Once CMP to GMP transition has happened; some cells will become 
granulocytes (eosinophils, basophils and neutrophils) others macrophages. Granulocytes 
versus macrophage choice seems to be dictated by the transcription factor GFI1, which 
function is essential for neutrophil differentiation and for shutting down 
macrophage/monocytes related transcripts (Hock et al., 2003). The remaining granulocytes, 
basophils (mast cells) and eosinophils, will end their differentiation program by respectively 
increasing Gata1 (Nei et al., 2013) and Gata2 expression (Harigae, 2006; Iwasaki and Akashi, 
2007; Orkin and Zon, 2008). 
1.2.2 Peripheral haematopoiesis  
 
Mature hematopoietic cells are released into the blood stream from bone marrow and thymus 
(Janeway, 2008b). Some of them will constantly recirculate in the extracellular fluids as 
sentinels responsible for body first line defence (innate immunity); others instead will populate 
peripheral organs to build up the adaptive immune answer. Innate immune answer is mediated 
by immune effectors like granulocytes, mast cells, macrophages, dendritic cells (DCs), natural 
killer (NK) cells and soluble factors, such as complement proteins. All together these 
components have the capability to recognize generic pathogen structures, mediating their 
demolition and extinction. By contrast, the adaptive immune system enrols certain cell types, 
such as B, T and dendritic cells, which are able to build up a specific immune answer to fight 
those pathogens which bypass the innate recognition barrier (Dranoff, 2004; Janeway, 2008b; 
Janeway, 2001). 
Adaptive immune answer is taking place in peripheral organs, particularly spleen and lymph 
nodes. These organs are populated by different cells types that remain in a quiescent state until 
an immune challenge awakens them from dormancy. Peripheral organs architecture is depicted 
in Fig. 1.5. Grossly, it consists of compartmentalized areas called red and white pulp, where 
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cells are retained by in loco produced cytokines. The white pulp is the compartment which 
includes a layer of T cells, which sits in the T cell zone; and an inner roundish structure called 
follicle, containing follicular B cells. The red pulp instead, contains erythrocytes and other 
blood cells (like macrophages, and granulocytes and dendritic cells). In the spleen white pulp 
and red pulp are separated by the marginal zone, a specialized area which contains B cells and 
macrophages involved in the innate immunity (Mebius and Kraal, 2005; Mueller and Germain, 
2009; von Andrian and Mempel, 2003). 
 
 
 
Figure 1.5 Schematic structures of spleen and lymph node 
 
Upon immune challenge T and B cells start to proliferate and differentiate in very specialized 
effectors which are suited to initiate a pathogen specific immune reaction (Janeway, 2008b; 
Janeway, 2001). For example, T cell encounter with pathogens will induce (1) their activation 
and (2) their cytokine-instructed differentiation in T helper 1 (TH1), T helper 2 (TH2), T 
helper 17 (TH17), follicular helper T cells (TFHs) and regulatory T cells (T regs) (Sethi et al., 
2013; Swain et al., 2012; Zhou et al., 2009). Remarkably, the instructive role of the cytokines 
in this context will results in the expression of specific transcription factors, which will 
polarize CD4+ dormant T cells to a unique destiny (Lu et al., 2011; Zhou et al., 2009). The 
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cytokine responsive transcription factors which determine T cells fates are summarized in Fig. 
1.6. 
 
 
Figure 1.6 T helper cell subtypes 
Upon antigen presentation by APCs, naive CD4+ T cells are polarized to specific fates through the 
expression of specific transcription factors. 
 
Within the different T helper cells subtypes, TFHs drew the attention of many investigators 
during the past ten years. Maybe this is due to the special role they fulfil in initiating and 
maintaining the cell-mediated immune response. The discovery of TFHs dates back to 2005 
when Vinuesa and colleagues showed that inactivating mutation in the roquin gene, known as 
sanroque mutation, resulted in the brake out of inflammatory T cells and spontaneous germinal 
centers formation. This phenotype was caused by the loss of roquin repressing function over 
the costimulatory receptor ICOS, which was thereafter designated as a TFHs hallmark 
(Vinuesa et al., 2005). The identification of TFHs as a clearly distinguished population which 
mediates the adaptive immune answer opened a new chapter in the T cell biology field. In fact, 
many efforts have been made to reveal the molecular mechanisms which sit behind TFHs 
differentiation and, even if many details are still missing, a lot of results which clarified many 
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aspects of TFHs commitment and function have been already achieved (Liu et al., 2013; Ma et 
al., 2012b; Nutt and Tarlinton, 2011; Vinuesa and Cyster, 2011).  
 
1.2.2.1 The germinal center reaction: molecular mechanisms 
    
Adaptive immunity is the way the immune system learns fighting unknown microorganisms 
and keeps memory of them. In fact, when immune germline receptors fail to recognize 
incoming pathogens, the body starts to generate a broad spectrum of new receptors seeking the 
best one out (Janeway, 2008b). This process takes place in secondary lymphoid organs and it 
is known as germinal center reaction (Nutt and Tarlinton, 2011; Vinuesa and Cyster, 2011).  
The priming force which prompts germinal center response is given by antigen presenting 
cells (APCs). The most specialized APCs are DCs which have the main task to upload on their 
surface parts of the processed pathogens and present them via cognate interaction to CD4+ T 
cells (Vinuesa et al., 2010) (Fig. 1.7; 1.). 
A special subclass of DCs, called follicular dendritic cells, is able to move around the 
peripheral organs until reaching the T cell zone (Heesters et al., 2014). Here, T cells will start 
to be engaged by DC receptors, stabilizing their contact (Celli et al., 2007). At this point T 
cells are no longer dormant and they start proliferating and transcribing specific genes which 
will slowly provide them typical TFHs features (Liu et al., 2013).  
A very recent discovery identified the imprinted gene Achaete-scute complex homolog 2 
(Ascl2) as one of the earliest initiator of TFHs commitment. In fact, Ascl2 deficient mice fail 
in producing TFHs, preventing germinal center reaction. Molecularly, this was due to the loss 
of ASCL2-mediated activation of the Cxcr5 gene (Liu et al., 2014). This gene encodes a 
surface molecule which is not expressed on naive T cells and is responsive to CXCL13, a 
cytokine which is produced in the follicular zone. CXCR5R expression on T cell surface starts 
to mobilize them towards the B cell follicles, their final destination (Hardtke et al., 2005). In 
homeostatic condition, Cxcr5 is kept silent because naive CD4+ T cells express the 17-92 
mirna clusters, which targets Cxcr5 transcripts. CXCR5 expression on TFHs surface, in fact, 
requires BCL6, the transcriptional repressor that mediates transcriptional silencing of mir17-
92 cluster, allowing Cxcr5 expression (Yu et al., 2009). BCL6 is considered one of the master 
regulators of TFH cells differentiation (Nurieva et al., 2009). Indeed, its repressive activity 
inhibits the establishment of TFH cell fate antagonists, as for example the germinal center 
inhibitor BLIMP1 (Johnston et al., 2009; Shaffer et al., 2000; Tunyaplin et al., 2004). 
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Figure 1.7 Schematic representation of germinal center reaction 
1) APCs present the antigen to CD4+ T helper cells committing them to the TFH fate. 2) TFHs leave 
the T cell zone and start to migrate towards the follicles. 3) Before entering the follicular zone TFH 
engage B cells which are located at the periphery of the follicle or B cells which started to migrate 
outside the follicular zone. This event results in the production of generic immunoglobulin belonging 
to the IgM and IgG1 class. 4) TFHs enter the follicular zone engaging a strong binding with follicular 
B cells. This interaction will induce class switch recombination and somatic hypermutation to produce 
the most specific immunoglobulin against the pathogen. 5) Once the reaction is completed B cells start 
to differentiate in antibody secreting plasma cells and memory B cells. 
 
Moreover, BCL6 seems to exert inhibitory function by binding promoter regions of Tbx21, 
Rorc and Gata3 genes, which respectively associate with TH17, TH1 and TH2 cell fate 
(Harris et al., 1999; Nurieva et al., 2009; Yu et al., 2009). The importance of BCL6 during 
TFH cells differentiation has been broadly demonstrated in vivo by using animal models which 
lacked or overexpressed the transcriptional repressor. As expected, Bcl6 deficient mice 
strongly inhibits TFHs differentiation and germinal center formation, while enforced 
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expression of Bcl6 in CD4+ naive T cells promoted the establishment of TFHs signature 
(Fukuda et al., 1997; Yu et al., 2009). 
The initial T:DC cells interaction also leads to production of certain cytokines which support 
TFHs differentiation and maintenance, such as IL-21 and IL-6 (Crotty, 2011; Eto et al., 2011; 
Nurieva et al., 2008). Their initial activation seems to be controlled by STAT3, a 
transcriptional regulator in absence of which TFHs are severely reduced, probably due to the 
aberrant production of TFH related cytokines (Ma et al., 2012a). On the way to the follicles, 
TFHs will carefully establish and sustain their transcriptional program maintaining high level 
of IL-21, which transcription is supported by other transcriptional regulator, such as BATF, c-
MAF and IRF4 (Bauquet et al., 2009; Betz et al., 2010; Bollig et al., 2012; Ellyard and 
Vinuesa, 2011; Kwon et al., 2009; Li et al., 2012).  While moving towards the follicles (Fig. 
1.7; 2.), T cells will already encounter antigen-specific B cells which got activated and started 
to migrate towards the T cell zone due to upregulation of CCR7, a receptor attracted by the T 
cell zone chemokine CCL12 (Fig. 1.7; 2. and 3.). Already at this site, TFHs will start 
engaging B cells, initiating the extrafollicular reaction, which is also supported by IL-21 
(MacLennan et al., 2003; Odegard et al., 2008; Vinuesa et al., 2010). At the next stage, 
extrafollicular B cells get activated; however they will not be able to produce pathogen 
specific immunoglobulin, but only low-affinity antibodies with low level of hypermutation 
(MacLennan et al., 2003). Now, TFHs are about to enter the follicular area as CXCR5 high, 
ICOS high, PD-1+ cells which can be clearly discriminated by FACS from the other CD4+ T 
cells. Terminally differentiated TFHs are now ready to engage follicular B cells (Vinuesa and 
Cyster, 2011) (Fig. 1.7; 4.). This interaction will last a sufficient amount of time to induce the 
rearrangement of new, more specific immunoglobulin via two processes known as class switch 
recombination and somatic immunoglobulin hypermutation (Kinoshita and Honjo, 2001). 
Importantly, the strength of the B:T cells binding will represent an initial parameter to exclude 
those B cells which are weakly compatible to T cell surface marker. A strong binding will 
provide a survival signal which will allow production of new specificity while, at the opposite, 
a feeble interaction will induce cell death to avoid likely generation of unwanted self-reactive 
antibodies (Klein and Dalla-Favera, 2008; Nutt and Tarlinton, 2011).  
Activated germinal center B cells also require the establishment of specific transcriptional 
networks which prevent their premature differentiation in antibody secreting plasma cells. In 
this regard, several transcriptional regulators have been identified as crucial for the germinal 
center B cells maintenance. They include PAX5, MITF, BCL6, MTA3 and BACH2 (Shapiro-
Shelef and Calame, 2005). 
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Beyond its function during early B cell development, PAX5 is also essential for later stage of 
B cell development (Horcher et al., 2001; Nutt et al., 2001). During germinal center formation, 
this master regulator exerts activating function on the activation-induced cytidine deaminase 
(AID), the enzyme which generates a new antibody repertoire mediating somatic 
hypermutations and class switch recombination processes (Gonda et al., 2003). Additionally, 
PAX5 also represses the X-box-binding protein 1 (Xbp-1), an essential factor which activates 
the plasma cells secretory program (Reimold et al., 1996). Another positive regulator of 
germinal centers development is microphthalmia-associated transcription factor (MTIF). In the 
absence of MTIF, B cells induce Blimp1 expression and undergo extemporaneous production 
of plasma cells (Lin et al., 2004). Probably, this is due to Irf4 upregulation which promotes 
plasma cell differentiation. Notably, IRF4 has been found be important either for germinal 
center formation or for plasma cell specification. This double function connects with dosage-
dependent activation of the Irf4 gene, as low and high Irf4 expression levels respectively 
associate with germinal center B cell and plasma cell differentiation (Ochiai et al., 2013). 
The exhaustion of the germinal center reaction coincides with an increase of Prmd1, the gene 
which encodes BLIMP1 (Kallies et al., 2004). This protein is an inhibitor of germinal center 
reaction and is required for plasma cell differentiation (Shapiro-Shelef et al., 2003). In fact, 
BLIMP1 is a zinc finger protein which activates plasma cells related genes (Sciammas and 
Davis, 2004; Shaffer et al., 2004) as Blimp1 overexpression has been shown to induce 
spontaneous plasma cell differentiation (Turner et al., 1994). Direct Blimp1 repression is 
mediated by BCL6 which is highly expressed in germinal center B cells (Cattoretti et al., 
1995; Tunyaplin et al., 2004). Indeed, BCL6 repressive function is essential for germinal 
center formation since Bcl6 deficient B cells do not form any germinal center (Dent et al., 
1997). Specifically, BCL6 mediates direct repression of Blimp1 via antagonizing the activity 
of AP-1 and STAT3 transcriptional activators (Reljic et al., 2000; Vasanwala et al., 2002). 
Moreover, BCL6 repressive function on Blimp1 promoter was also found to be mediated by 
MTA3 (metastasis-associated 1) interaction, as MTA3 knock-down does not affect Bcl6 
expression but activate plasma cell specific genes (Fujita et al., 2004).  Besides MTA3; 
BACH2 has also been found to interact with BCL6. Genome-wide analysis showed that they 
cooccupy the cis-regulatory sequence of Blimp1, likely inactivating it (Huang et al., 2014). 
Bach2 deficient mice also fail to form germinal centers and they do not activate AID (Muto et 
al., 2004).  
Extinction of the germinal center response will induce plasma cell differentiation through 
activation of appropriate genes, as Blimp1, Xbp-1 and Irf4 (Shapiro-Shelef and Calame, 2005). 
Newly formed plasma cells will either survive as antibody-secreting cells or will persist as 
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memory B cells, the archive of the immune system (McHeyzer-Williams et al., 2012; 
Radbruch et al., 2006)(Fig. 1.7 5.). 
1.3 The histone methyltransferase SETDB1 
 
SETDB1 and SUV39H are the histone methyltransferases which establish H3K9 tri-methyl 
marks (O'Carroll et al., 2000; Rea et al., 2000; Schultz et al., 2002). Although they associate 
with the same histone modification, these enzymes work in different part of the genome. 
SUV39H-dependent H3K9me3 is highly enriched at pericentromeric region, while, outside 
these areas, the same methyl mark seems to be established by SETDB1 (Bilodeau et al., 2009; 
Dambacher et al., 2010; Karimi et al., 2011).  The methyltransferase activity of SETDB1 is 
given by the presence of a pre-SET, SET post-SET domain; while the Tudor domain and 
MBD (methyl-CpG-binding) domain mediate protein-protein interaction and binding to 
methylated DNA, respectively (Chen et al., 2011; Kang, 2014) (Fig. 1.8). 
 
 
 
Figure 1.8 The histone methyltransferase SETDB1 
 
Remarkably, Setdb1 ko mice die at perimplantation (Dodge et al., 2004), demonstrating 
that SETDB1 mediated silencing is essential at very early stages of mouse development. 
Unfortunately, the fact that Setdb1 ko embryos die before implantation hinders the possibility 
to perform in vivo analysis. To circumvent this issue, mouse models which conditionally 
delete the protein in adult tissue have been generated. Consistently with the phenotype 
observed in Setdb1 ko embryo, deletion of the enzyme during adult development strongly 
interferes with cell differentiation. For example, conditional ablation of Setdb1 alleles in the 
brain leads to decreased H3K9me3 and aberrant gene expression, resulting in severe brain 
defects and early lethality (Tan et al., 2012). More recently, a developmental role of SETDB1 
has been identified in the context of bone development. Here, mesenchyme specific deletion of 
Setdb1 causes ectopic hypertrophy, apoptosis and terminal differentiation of articular 
chondrocytes, predisposing articular cartilage to degeneration (Lawson et al., 2013b). 
Intriguingly, using the same knockout scheme, the same group also showed that lack of 
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SETDB1 inhibits differentiation of mesenchymal stem cells in osteoblasts (Lawson et al., 
2013a).  
Because of technical limitations and/or lack of material, most of the in vivo SETDB1-related 
phenotypes are carefully described but poorly explained at the molecular level. Thus, up to 
now, all experiments to elucidate SETDB1 molecular functions have been performed in vitro, 
mostly in mESCs.  
In 2002, Schultz et al. revealed that in NIH/3T3 cells SETDB1 mostly localize at euchromatic 
regions, where it binds the corepressor KAP1 (KRAB associated protein 1) (Schultz et al., 
2002).  KAP1 recruitment at euchromatin is mediated by KRAB-ZNF proteins, which 
specifically recognize their corresponding cis-regulatory elements across the DNA (Iyengar et 
al., 2011). KAP1 binding to KRAB-ZNFs is an obligated step to induce transcriptional 
repression (Groner et al., 2010; Sripathy et al., 2006). In fact, this protein will become the 
anchor bolt for the assembly of several repressive complexes which will ultimately mediate 
gene silencing (Friedman et al., 1996; Schultz et al., 2002). The identification of SETDB1 as a 
novel transcriptional repressor that localizes at euchromatin to induce gene silencing, arouse a 
great deal of interest in understanding which regions in the genome are SETDB1 targets. The 
first study in this direction was performed in mouse embryonic stem cells (mESCs). Here, 
high-throughput shRNA screening approach spotted SETDB1 as one of the most important 
chromatin regulator which stabilize mES cells state. Interestingly, following genome-wide 
analysis showed that SETDB1 and H3K9me3 cooccupied developmental genes, possibly 
inhibiting their transcription (Bilodeau et al., 2009). These findings launched SETDB1 as the 
candidate chromatin modifier, responsible for silencing lineage inappropriate genes during 
development transitions. However; more recent publications challenged this belief; providing 
convincing experimental evidences that this histone methyltransferase mainly represses 
endogenous retroviral elements (ERVs), a class of proviral sequences stably integrated in the 
genome (Karimi et al., 2011). Indeed, it has been shown that Setdb1 deficient mES cells highly 
transcribed ERVs (in particular IAP elements), and that these elements are directly repressed 
by SETDB1. Interestingly, contemporary loss of DNMTs, minimally affected the 
transcriptional activity over these regions, indicating that the pathway which mediates their 
silencing is DNA methylation-independent (Karimi et al., 2011). Because SETDB1 interacts 
with the co-repressor KAP1, ChIP-Seq experiments have been performed to investigate 
whether KAP1 also binds ERVs genomic regions, mediating their silencing. Notably, in ES 
cells, KAP1 localized on ERVs LTR promoters, supporting the idea that these regions are 
mainly silenced by the KRAB-ZNFs/KAP1 repression system. Consistently with these 
findings, KAP1 deficient mES cells significantly upregulated ERVs (especially IAP elements), 
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demonstrating that KAP1 is also necessary for ERVs silencing (Rowe et al., 2010). Although 
the presence of SETDB1 and KAP1 seems to be a constant for retrotransposons silencing, the 
KRAB-ZFN proteins which mediate KAP1 recruitment might be specific for specific classes 
of retrotransposons. ZFP809, for example, has been identified as one of the KRAB-ZFN 
which specifically binds retroviral DNA sequences inducing de novo silencing upon KAP1 
recruitment. This occurs via ZFP809 recognition of the primer binding site (PBSs) 
complementary to proline tRNA (PBSPro), which is specifically contained in a class of 
elements called murine leukaemia virus (MLVs) (Wolf and Goff, 2009). However, other 
endogenous retroviruses contain distinct PBSs which are recognized by other ZFPs, indicating 
that KAP1 recruitment is mediated by alternative KRAB-ZNFs which are retrotransposon 
specific (Rowe and Trono, 2011).  
Although we are gaining more and more knowledge about SETDB1 functions; it remains a 
contentious whether it is a repressor of developmental gene, a main retrotransposon silencer, 
or both. Moreover, all in vivo phenotypes resulting from Setdb1 depletion are broadly 
described but not yet clarified at the molecular level. In conclusion, the reasons why SETDB1 
is so essential during development are not yet elucidated and they still represent an open 
challenge for people working in this field. 
1.4 The histone methyltransferases SUV420H 
  
H4K20 tri-methyl marks mainly accumulate at chromatin regions which have to be silenced.  
In MEFs, SUV420H1 and SUV420H2 have been identified as the histone methyltransferases 
that mainly act as nucleosomal H4-K20 trimethylating enzymes. In fact, knock-down of both 
Suv420h1 and Suv420h2 selectively impairs H4K20 trimethylation at constitutively silenced 
chromatin (heterochromatin), where this histone mark is typically acquired together with 
H3K9me3 (Dambacher et al., 2013; Schotta et al., 2004). The importance of H4K20me3 in 
heterochromatin formation has been recently underlined in our group. We observed that 
H4K20me3 is essential for pericentromeric recruitment of choesin, a protein complex which 
ensures correct separation of sister-chromatids, avoiding mitotic defects due to aberrant 
chromosome segregation (Hahn et al., 2013).  
Beyond playing a structural role in heterochromatin formation, H4K20me3 is also essential 
during development.  Suv420h ko mice, in fact, show perinatal lethality, demonstrating that 
this repressive mark is required during postnatal development. Additionally, conditional 
deletion of these enzymes in the hematopoietic system impaired pro to pre B cell transition 
and resulted in defective immunoglobulin class switch recombination (Schotta et al., 2008). 
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More recently, further evidences regarding the importance of H4K20me3 during development 
have been provided in Xenopus. In this regard, Nicetto et al. demonstrated that morpholino-
mediated disruption of suv420h1 and suv420h2, resulted in neuroectoderm differentiation 
defects. This failure was consequent to ectopic expression of the pluripotency gene Oct25, a 
direct target of Suv420h mediated gene repression (Nicetto et al., 2013).  
Although SUV420H functions are not extensively elucidated in the context of development, it 
seems that H4K20me3 is required for proper cell differentiation.  
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 Results (I) 2
2.1 Spontaneous germinal center activation in Suv420h2 knockout (ko) 
mice 
 
2.1.1 Suv420h2 ko mice show enlarged spleen  
 
To better understand the role that H4K20me3 plays in the context of immune regulation, we 
used Suv420h2 ko (d/d) mice as model system and compared them to wild type mice (+/+). To 
ensure that both genotypes had the same genetic background, we first crossed +/+ mice with 
d/d mice. This breeding scheme generated 100% of heterozygous mice (+/d), which were then 
intercrossed, producing in the same littermate +/+, d/d and +/d mice, with frequencies of ¼, ¼ 
and ½, respectively (Fig. 2.1 a). Suv420h2 ko mice appeared normal and were born following 
regular Mendelian ratio.  
Because we wanted to investigate the role that the repressive chromatin mark H4K20me3 
plays in the immunological context, we started examining the main hematopoietic organs. 
Although bone marrow cellularity and thymus size were normal, we noticed that Suv420h2 ko 
spleens were enlarged. Suv420h2 ko spleens weighted nearly 30-40% more than wild type 
spleens and the organ cellularity was also comparably increased (Fig. 2.1 b and c).  Increased 
spleen size can be explained by developmental defects; therefore we investigated whether 
hematopoietic populations were affected in bone marrow and thymus, the central 
hematopoietic organs where B, myeloid-erythroid and T cells develop, respectively. 
Immunophenotyping of the main cell populations in these organs showed that all 
developmental transitions were intact and that each population was generated with normal 
frequency in the absence of Suv420h2 (Table1).  
2.1.2 Suv420h2 ko B cells spontaneously initiated the germinal center reaction 
 
Because any defect during early immune development could explain spleen enlargement, we 
investigated all splenic populations in a cohort of animals which included 17 to 22 weeks old 
mice. Spleen is a peripheral hematopoietic organ which mainly contains lymphocytes; 
therefore we started examining B and T cells using general markers. CD19 was used to detect 
B cells, while CD4 and CD8 were used to discriminate helper from cytotoxic T cells. 
Surprisingly, Suv420h2 T and B cells frequencies were normal when compared to wild type 
mice (Fig. 2.2 b). 
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Even though the spleen mainly contains B cells, staining with general markers might not be 
sufficient to discriminate all subpopulations, therefore we started examining more in detail all 
B cell compartment.  
IgD and IgM markers were used to test whether B cell development was affected in the spleen.  
As shown in Fig. 2.2 c and d immature, transitional and mature Suv420h2 ko B cells resulted 
to be unaltered. 
 
 
 
Figure 2.1 and Table1 Suv420h2 ko mice show enlarged spleen and unaltered central 
haematopoiesis 
a) Breeding scheme adopted to obtain wild type and Suv420h2 ko mice with the same genetic 
background. b) Spleen weight (n=13) and c) hematopoietic organs cellularity from wild type, 
Suv420h2 het and Suv420h2 ko mice (n=13). ***P < 0.001, **P < 0.01, *P < 0.05 (unpaired two-tailed 
Student‟s t-test). Table1. B and T cells population frequencies during development. Numbers represent 
percentage of living cells with related standard deviations. 
 
Within the mature B cell population, follicular and marginal zone B cells can be further 
distinguished. These, are very specialized cells involved respectively in cell-mediated and 
innate immunity. Marginal zone (B220+, CD21 high, CD23 low) and follicular B cells 
(B220+, CD23+, CD21 low) were then tested in Suv420h2 ko spleen, but again any difference 
could be detected in cell numbers or markers distribution (Fig. 2.2 e and f).  
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Further analysis were also performed to investigate granulocytes, macrophages, dendritic cells, 
natural killer and erythroid populations but none of them resulted to be impaired (data not 
shown). All these data are supported by the fact that Suv420h2 ko spleen architecture is 
unaltered (Fig. 2.2 a); yet they still do not explain why we observe spleen enlargement in the 
absence of Suv420h2. 
 
 
 
Figure 2.2  Main splenic B cell populations are unaltered in Suv420h2 ko mice 
a) Microscopic picture showing spleen architecture. Slides were stained with the proliferation marker 
ki67 b) Splenic B (CD19+) and T (CD4+ or CD8+) cell populations (n=6). c) Flow cytometry analysis 
of B cell development in the spleen. Immature (B220+IgM+ IgD-/low), trans B (B220+, IgD+, IgM+) 
and mature B (B220+, IgD++, IgM+/low) cells (n=6). d) Statistics form c). e) Marginal zone (B220+, 
CD21+, CD23-/low) and follicular zone (B220+, CD21-/low, CD23+)  B cells (n=6). f) Statistics form 
e). 
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Increased organ size and cellularity correlate with increased cellular proliferation. To 
understand whether this was the case in Suv420h2 ko spleens, we tested spleen sections for 
presence of the proliferation markers ki67. Suv420h2 ko spleens resulted highly positive for 
ki67, confirming the hypothesis that some of the Suv420h2 ko splenocytes are highly 
proliferative (Fig 2.2 a). Notably, ki67+ cells were mostly located in the follicles, regions of 
the spleen where follicular B cells sit, although we also observed extrafollicular proliferation. 
Follicles are spleen areas where, upon immune challenge, germinal center reaction takes place.  
When germinal center reaction occurs, follicles start to proliferate, generating the very 
specialized germinal center B cells, which main task is to produce the most specific antibodies 
against pathogens. These cells have the distinctive feature to express on their surface PNA and 
FAS (CD95), two typical germinal center markers. When we checked whether Suv420h2 ko  B 
cells were positive to these markers, we noticed that a PNA+, FAS+ B cell population popped 
up in our FACS plot, while in wild type  mice the same population was not present (Fig. 2.3 
a). Remarkably, Suv420h2 het mice showed an intermediate germinal center activation; in 
fact, in average, the percentage of PNA+ FAS + cells in heterozygous mice  was in between 
wild type and Suv420h2 ko, indicating that the observed phenotype correlated with the dosage 
of Suv420h2 (Fig. 2.3 a-c).  
Germinal centers get activated only in response to immune stimuli. These are mainly peptides 
derived from processing of pathogens, which are first presented by DCs to the TFH cells, 
which will transfer the information to B cells, inducing their proliferation and priming 
production of very specific antibodies.     
Because Suv420h2 ko mice show germinal center activation in the absence of immune stimuli, 
they are likely to produce autoreactive antibodies which might recognize self-antigens, a 
phenomenon which often associates with autoimmunity. When antibodies start to be produced, 
they are released in the blood stream; therefore if Suv420h2 ko B cells undergo spontaneous 
germinal center reactions, the randomly produced antibodies can be detected in the mouse 
sera.  In order to test this hypothesis, we isolated serum from blood of wild type and Suv420h2 
ko mice and tested it on mouse embryonic fibroblasts (MEFs) for the presence of self-reactive 
antibodies.  Autoreactivity was detected using an anti-mouse secondary antibody conjugated 
with a green fluorochrome. Suv420h2 ko sera recognized and bound many self-antigens 
expressed by MEFs, as shown by the strong green signal detectable; while wild type 
antibodies hardly recognized self-antigens (Fig. 2.3 d). 
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Figure 2.3 Germinal center activation in Suv420h2 ko spleen 
a) FACS plots showing germinal center B cells (B220+, PNA+, FAS+). b) Statistics of germinal center 
B cells calculated as % of the B220+ cells (n=27). NS, not significant and ***P < 0.001 (unpaired two-
tailed Student‟s t-test). c) Total numbers of PNA+ FAS+ cells (n=13). ***P < 0.001 and *P < 0.05 
(unpaired two-tailed Student‟s t-test). d) MEFs stained with wild type or Suv420h2 ko sera. Secondary 
detection was performed using Alex488 antibody. e) Preliminary ELISA results to test IgM and IgG1 
titres. ELISA was performed in collaboration with Strobl laboratory (Helmholtz Zentrum, Munich).  
 
Mouse models for autoimmunity, in general, produce self-reactive antibodies which bind to 
very specific antigens and this specificity allows categorizing, in most of the cases, the type of 
autoimmune disease. Instead, Suv420h2 ko mice recognized a broad spectrum of antigens, 
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from the nucleus to the cytosol, suggesting that whatever signal is inducing autoantibodies 
production, it does not results in generation of immunoglobulins with unique specificity.   
Although we proved the existence of autoreactive antibodies in Suv420h2 ko mice, we still 
lack understanding about the amount of immunoglobulins produced and the class they belong 
to. To better address this point we performed a preliminary ELISA test for the most common 
class of immunoglobulins (IgM, IgG1, IgG2a, IgG2b). Suv420h2 ko mice showed a significant 
increase in IgM and IgG1 production, whereas IgG2a and IgG2B were not significantly 
changed (Fig. 2.3 e and data not shown). IgM and IgG1 are produced in substantial amounts 
as soon as the germinal center reaction starts upon B cell encounter with TFHs; while the other 
two classes of immunoglobulins, IgG2a and IgG2b, are produced upon activation of Th1. 
All together these data indicate that loss of Suv420h2 results in spontaneous activation of 
germinal center B cells, thus lack of repressive mark H4K20me3 make cells more prone to 
switch to an active state. 
2.1.3 Suv420h2 ko B cells response to external stimuli is comparable to wild type cells 
 
To verify whether Suv420h2 ko B cells can be activated more easily than wild type, we 
cultured splenic B cells in vitro using several kinds of immunostimulants to trigger all 
different pathways which lead to B cell proliferation. 
Before stimulation, B cells were stained with carboxyfluorescein (CFSE). This molecule is 
incorporated by the cells and retained in the cytosol. Cells which go through cell cycle will 
dilute the dye by half and every division steps will be visualized as a clear peak in a FACS 
histogram.  
After 3 days of stimulation, B cells were analysed by FACS. All dead cells were excluded by 
staining with the viability dye 7-Aminoactinomycin (7AAD) and the living ones were checked 
for CFSE dilution. As it shown in (Fig. 2.4), B cells responded to all provided stimuli in a way 
which was comparable to wild type B cells. 
Additionally, to investigate changes in gene expression we performed microarray analysis on 
bulk B cells populations. All deregulated genes were only moderately affected and 
unfortunately, none of them could be directly linked to the increase in proliferation we 
observed in vivo (Appendix, Results I). 
Because the analysed population was a mixture of different cell types, which might have 
different networks of gene regulation, we also looked at candidates which showed minor 
changes in gene expression. Also in this case, none of them could be attributed to the observed 
phenotype. 
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Figure 2.4 In vitro stimulated Suv420h2 ko B cells behave comparably to wild type cells.    
a) b) c) and d) MACS depleted splenic B cells stained with CFSE were cultured in the presence of  
different immunostimulants: CpG (10 µM); LPS (5 µg/ml); IL4 (10 ng/ml) CD40 (2,5 µg/ml) and IgM 
(10 µg/ml). After 3 days cell were analysed by FACS to test CFSE dilution. Each peak corresponds to 
one cell division. 
 
2.1.4 Follicular helper T cells are overrepresented in Suv420h2 ko spleen  
 
Our in vitro data indicated that spontaneous germinal center activation in Suv420h2 ko  mice 
seemed not be dependent on intrinsic defects inside B cells; therefore other possibilities had to 
be explored to understand which mechanisms is corrupted in Suv420h2 ko  spleens. 
IgM and IgG1 antibodies, which are increased in Suv420h2 ko mice, are linked to initial stages 
of germinal center activation. Because this reaction strongly depends on the interaction 
between TFHs and quiescent B cells, we investigated whether follicular helper T cells were 
affected. TFHs are newly discovered T cells which have specific gene signatures compared to 
other T populations and a still not fully understood differentiation pathway. These cells 
differentiate form CD4+ naive T cells upon interaction with the dendritic cells which present 
them the antigens. This cooperation prompts transcriptional changes which allow the 
expression of a group of genes which promote migration of TFHs from the T cell zone to the 
follicles. Once TFHs have reached the follicular zone they are fully differentiated and are 
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clearly distinguishable from other T cells due to CXCR5, CD4, PD1, and ICOS expression on 
their surface. 
When we tested TFHs in Suv420h2 ko mice, we found that these cells were present in the 
spleen with higher frequencies compared to the wild type. Wild type CD4+ cells contained 
around 2% TFH cells. Within Suv420h2 ko CD4+ population, instead, this percentage was 
increased more than two folds (Fig. 2.5 a and b). 
 
 
Figure 2.5 TFHs are expanded in Suv420h2 ko spleens 
a) TFHs (CD4+, CXCR5+, PD1+) population in wild type and Suv420h2 ko spleens. b) TFHs 
frequencies shown as percentage of CD4+ cells (n=13). **P < 0.01 (unpaired two-tailed Student‟s t-
test). c) Splenic TFHs absolute numbers (n=7). *P < 0.05 (unpaired two-tailed Student‟s t-test). d) 
Resting naive T cells (CD4+, CD62L high, CD44-/low, CD25-) cells, T effector-like (CD4+, CD44+, 
CD62L low, CD25-)  and memory T cells ( CD4+, CD44+, CD62L+, CD25-) frequencies. e) Total cell 
number of all T cell subpopulation shown in d) (n=4) NS, not significant (unpaired two-tailed 
Student‟s t-test). f) FACS histogram depicting ICOS expression on TFHs surface.  
 
Importantly, all Suv420h2 ko TFHs expressed high level of ICOS, the main follicular T cells 
marker, confirming cell identity (Fig. 2.5 f). Additionally; we also checked whether other T 
cells populations were affected by increased presence of TFHs in Suv420h2 ko spleens. We 
stained CD4+ cells with CD25, CD44 and CD62L. These markers are used to differentiate 
resting naive T cells (CD4+, CD62L high, CD44-/low, CD25-) cells, T effector-like (CD4+, 
CD44+, CD62L low, CD25-)  and memory T cells (CD4+, CD44+, CD62L+, CD25-). While 
undifferentiated resting T cells were not affected, within the CD4+, CD25- cell population we 
observed effector-like and memory T cell with higher frequency (Fig. 2.5 d and e).  
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Because increased TFHs and germinal center B cells which produce autoantibodies can be the 
premise for autoimmune diseases onset, we aged Suv420h2 ko mice for 1 year. Over this 
period, animals were periodically checked to monitor whether any immune related disorder 
arose.  Suv420h2 ko mice did not develop any evident disease with aging, and analysis of 
major immune populations did not show evident anomalies (data not shown).  
2.1.5 Release of apoptotic checkpoints exacerbates germinal center activation in 
Suv420h2 ko mice 
 
Suv420h2 ko mice showed spontaneous activation of B cells in the spleen. Even though this 
condition correlates with autoimmune disease or with inflammatory state, we detected no sign 
of disease during aging. This can be explained by different reasons: (1) the observed germinal 
center reaction was not strong enough to induce disease; (2) germinal center B cells were 
eliminated by apoptosis; (3) cells involved in regulation of immune response were able to keep 
the germinal center B cells under control; (4) a combination of all. These possibilities are all 
plausible, but most of them difficult to proof.   
Because it is already known that germinal center B cells undergo massive physiological 
apoptosis upon T cell engagement, we assumed that extemporaneous germinal center 
activation in Suv420h2 ko  mice did not results in a massive inflammation or autoimmune 
disease, because cells are cleared away via programmed cell dead. 
To understand whether releasing the stringency of the apoptotic pathway would exacerbate the 
germinal center activation in Suv420h2 ko mice, we crossed Suv420h2 ko with VavBcl2 
transgenic mice, generating Suv420h2 ko; VavBcl2 mice.  
VavBcl2 transgenic mice express the antiapoptotic Bcl2 under the control of Vav promoter, 
which is active throughout all haematopoiesis. These animals develop splenic germinal center 
hyperplasia, a phenotype which consists in a significant enlargement of the spleen and an 
unrestrained amplification of germinal center B cells. Germinal center hyperplasia brakes out 
in VavBcl2 mice when they are 18 weeks old (Egle et al., 2004). Because at this stage 
germinal center are completely enlarged, any additional phenotype due to loss of Suv420h2 in 
the VavBcl2 background could have been masked by the fact that spleens are already too 
compromised. In this regard, we choose to analyse spleens from 8-10 weeks old mice. In 
average, VavBcl2 spleens weighed 0.2 grams; 3 fold more than wild type spleens. When we 
weighted Suv420h2 ko; VavBcl2 spleens, we appreciated that their size was increased by 1/3 
compared to VavBcl2 mice.  
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Figure 2.6 VavBcl2 mice show premature germinal center overexpansion in the absence of 
Suv420h2 
a) Spleen sections from 8 weeks old mice were stained with haematoxylin/eosin to check spleen 
organization and ki67 to check proliferation. b) Percentage of splenic B220+ cell population checked 
by FACS. c) Flow cytometry plot depicting germinal center B cells (B220+, PNA+, FAS+). d) 
Statistics from c) (n=14). **P < 0.01 (unpaired two-tailed Student‟s t-test). 
 
To better investigate whether reduced apoptosis could contribute to amplify Suv420h2 ko 
germinal center B cells proliferation, we stained spleen sections with haematoxylin/eosin to 
check any significant change in organ architecture was detectable. Although Suv420h2 ko 
VavBcl2 spleens maintained their structure, and all regions were still distinguishable, we 
noticed that all germinal centers were significantly enlarged and that they all contained highly 
proliferating cells; while VavBcl2 showed only minimal signs of germinal center hyperplasia 
(Fig. 2.6 a). Then, we started investigating PNA+ FAS+ B cells in Suv420h2 ko; VavBcl2 
mice. Consistently with what we observed in the spleen sections, VavBcl2 mice did not 
produce many PNA+ FAS+ B cells. Suv420h2 ko; VavBcl2 mice, instead, showed a clear 
amplification of this cell population, although overall, splenic B cells were comparable to 
VavBcl2 mice (Fig. 2.6 b-d).  
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All together these data demonstrate that (1) loss of Suv420h2 anticipates and exacerbates 
VavBcl2 mice germinal center hyperplasia and that (2) apoptosis is one of the constraints 
which prevent full expansion of Suv420h2 ko germinal center B cells. 
2.1.6 Suv420h2 ko; VavBcl2 mice have increased proportion of follicular helper T cells 
 
In previously published work, Egle et al. demonstrated that Bcl2 overexpression under control 
of a specific B cell promoter does not result in spontaneous activation of the germinal centers. 
These data proved that excessive germinal center formation in the VavP-Bcl2 mice could not 
be simply a function of the amount of transgenic Bcl2 in B cells, but rather other splenic 
populations are capable to induce uncontrolled B cell proliferation (Egle et al., 2004).  In the 
same work, VavP-Bcl2 mice were crossed with GK5 mice, which lack CD4 cells. Like GK5 
mice, bitransgenic VavP-Bcl2-GK5 mice had no CD4+ T cells.  When age-matched 
littermates were analysed at 18 weeks of age, it became clear that germinal centers were not 
detectable by histology. This finding suggested that expansion of the germinal centers in 
VavP-Bcl2 mice and the substantial increase in the frequency of activated B cells is dependent 
on CD4+ T-cell help.  
Because germinal center reaction is strictly connected to the presence of TFHs in the follicles 
we first investigated TFHs in the VavBcl2 spleens. Surprisingly, VavBcl2 TFHs were 
comparable, in percentage, to the wild type population (Fig. 2.7 a). This observation suggests 
that the signal which primed germinal center hyperplasia in VavBcl2 mice did not come from 
TFHs; therefore another population of T helper cells must induce B cell proliferation. Because 
Suv420h2 ko; VavBcl2 mice showed an increase in germinal center formation when compared 
to VavBcl2, we asked if these additional PNA+ FAS+ B cells were induced by TFHs. 
Remarkably, Suv420h2 ko; VavBcl2 TFHs were consistently increased by 3 folds (Fig. 2.7 a 
and b).  
Suv420h2 ko; VavBcl2 bitransgenic mice represent another context were we could confirm, 
with better resolution, what we already observed in Suv420h2 ko mice. Moreover, these mice 
represent a very useful tool to perform in vitro analysis and additional molecular studies, as 
increased spleen cellularity will allow us to harvest enough material for further investigation. 
In fact, although Suv420h2 ko mice have increased TFHs and germinal center B cells, the total 
number of cells might be still limiting. 
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Figure 2.7 TFH cells are significantly expanded in Suv420h2 ko; VavBcl2 spleen 
a) TFH cells (CD4+, CXCR5+, PD1+) population comparison between VavBcl2 and Suv420h2 ko; 
VavBcl2 ko spleens. b) Frequencies of TFH cells shown as percentage of CD4+ cells (n=6). ***P < 
0.001 (unpaired two-tailed Student‟s t-test). c and d) FACS plot and statistics (n=4) of resting naive T 
cells (CD4+, CD62L high, CD44- /low, CD25-) cells, T effector-like (CD4+, CD44+, CD62L low, 
CD25-)  and memory T cells ( CD4+, CD44+, CD62L+, CD25-) frequencies in VavBcl2 and Suv420h2 
ko; VavBcl2 spleens. NS, not significant and *P < 0.05 (unpaired two-tailed Student‟s t-test).
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2.2 Discussion (I) 
 
Antigen presentation to naive T cells by APCs triggers a number of differentiation events 
which initiate the immune response to pathogens. Germinal center formation is one of the 
most elaborated immune answers which results from antigen presentation and mediates 
production of highly specific antibodies. Failure to induce proper immune responses results in 
immunodeficiency; while, at the opposite, aberrant activation of the immune system is the 
primary source for inflammatory diseases, autoimmune disorders and lymphoma.  
Although the signalling pathways which trigger and modulate the immune response are 
abundantly explained, we still lack some knowledge regarding the functional role that histone 
modifications exert in this context. An effort in this direction has been recently made by 
Beguelin and colleagues demonstrated that EZH2, the enzyme responsible for H3K27me3 
establishment, is required for germinal center formation. In fact, it seems that the repressive 
H3K27me3 is necessary to keep silent genes involved in plasma cell differentiation, as their 
derepression antagonizes and bypasses the germinal center reaction (Beguelin et al., 2013).  
Additional evidences which underlined the importance of repressive histone marks during 
mature T cell differentiation have been collected in the Almouzni laboratory. This group 
demonstrated that maintenance of the SUV39H1–H3K9me3–HP1α pathway is critical to 
ensure TH2 cell stability by inhibiting TH1 cell-associated genes, indicating that H3K9me3 
repressive mark is essential to silence inappropriate transcriptional programs (Allan et al., 
2012).  
The role of the repressive mark H4K20me3 during hematopoietic development has been 
already demonstrated by Schotta et al. In this paper, loss of Suv420h1 and Suv420h2 during 
haematopoiesis impaired lymphoid differentiation and resulted in ineffective B cell class 
switch recombination. Up to the present, this publication remains the only descriptive study 
which established an in vivo link between SUV420H-mediated H4K20me3 and hematopoietic 
development. Interestingly, in this thesis we described that the sole loss of Suv420h2 did not 
impair lymphoid development, but instead resulted in spontaneous germinal center B cell 
activation. In homeostatic condition germinal center B cells are not present; therefore loss of 
Suv420h2 and its associated H4K20me3 must generate positive signals to initiate the germinal 
center reaction. In this regard the work published by Stender and colleagues, encouraged us to 
believe that H4K20me3 represent a suppressive signal for several immune-related genes and 
its removal is required to initiate their expression. Since these results were obtained from in 
vitro derived macrophages and the histone methyltransferase which mediates H4K20me3 
silencing of pro inflammatory genes is SMYD5 and not SUV420H2, we cannot decipher our 
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phenotype in the light of these findings; however it is exciting to observe the presence of 
H4K20me3 outside its conventional heterochromatic location (Stender et al., 2012).  
In the first place, we connected the production of Suv420h2 ko germinal center B cells mice to 
the B cell defects observed in Suv420h conditional knockout animals, implying a major role of 
SUV420h enzymes during B cell differentiation. For this reason we assumed that the observed 
defects were B cell intrinsic. However; in vitro experiments demonstrated that Suv420h2 ko B 
cells activated by different stimuli behaved comparably to wild type cells, suggesting that 
aberrant Suv420h2 ko B cell activation is not cell autonomous.  
Making a step backwards in the germinal center formation timeline, we encounter a very 
specialized T helper cell population, known as TFH. TFHs differentiate from resting CD4+ T 
cells and gradually spread into follicular areas where they start to interact with B cells, 
initiating germinal center reaction. Notably, increased germinal centers nicely correlated with 
presence of TFHs in the absence of Suv420h2. Furthermore, effector T cells were also 
increased in the absence of Suv420h2 (Fig. 2.5 d and e), confirming signs of activation within 
CD4+ T cell population. Recent work demonstrated that TFHs survive in the blood as memory 
T cells (Schmitt et al., 2014). Nicely, we found that also this population was increased 
compared to wild type mice, reinforcing the idea that Suv420h2 ko mice are able to 
differentiate more TFHs in the absence of immune stimuli.  
Because germinal center B cells undergo massive apoptosis due to removal of potential self-
reactive-antibody-producing cells, we verified whether releasing apoptotic check point had 
any impact on the observed phenotype. To do this we generated Suv420h2 ko; VavBcl2 
transgenic mice and checked how germinal center B and TFH cells behaved in young mice. 
Importantly, young VavBcl2 animal‟s germinal centers were not significantly increased and 
TFHs were comparable to wild type mice. Differently, Suv420h2 loss in the VavBcl2 
background showed a significant increase in the germinal center B cell population 
accompanied by a 3 fold increase of TFHs. These observations consistently confirmed what 
we already observed in Suv420h2 ko mice.  
Because Suv420h2 ko mice are full knockout animals, we could not attribute the origin of the 
phenotype to any specific cell type, however we planned to perform bone marrow 
transplantation with Suv420h2 ko; VavBcl2 B cells or naive T cells to reveal which of these 
populations is the actual inducer of spontaneous germinal center formation. Also, Suv420h2 
ko; VavBcl2 mice represent a promising tool to better investigate the molecular details of the 
described phenotype. In fact, we are going to test whether in vitro stimulation of Suv420h2 ko; 
VavBcl2 B or/and T cells will show different behaviour compared to control cells. 
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VavBcl2 mice are prone to get follicular lymphoma after 1 year of age. Interestingly, 
preliminary data showed that Suv420h2 ko; VavBcl2 mice die earlier compared to VavBcl2 
(data not shown). This phenotype needs to be further investigated, since we do not really know 
at the moment why loss of Suv420h2 would further compromise VavBcl2 mice viability. One 
hypothesis could be related to the onset of a more aggressive form of follicular lymphoma or a 
combination of tumour onset and persistent inflammation. To better address this question we 
set up an aging experiment were a cohort of mice is monitored for the appearance of any 
obvious disease.  
In the near future we aim to identify genome wide H4K20me3 and SUV420H2 binding 
sites, in B and T cells. So far, ChIP-Seq analysis has been performed in our laboratory in MEF 
cells and revealed that SUV420H2-mediated H4K20me3 mainly covers retrotransposable 
elements and constitutive heterochromatic regions (telomeres, centromeres). However, the 
genomic distribution of this mark might change according to the cellular context we take in 
account. Once these target regions will be identified, we are going to analyse whether loss of 
H4K20me3 also results in gene activation which might promote terminal differentiation of 
mature immune cells. 
Noteworthy, stacks of confocal images showed that only a very small percentage of CD4+ T 
cells carried a clear H4K20me3 methylation pattern, while the others seemed to be totally 
refractory to the establishment of this repressive mark (Fig. 2.8). To better elucidate this point, 
we will sort CD4+ T cell subpopulations to verify whether there is a preferential accumulation 
of H4K20me3 in a certain cell type. Moreover, we also noticed that the H4K20me3 signal not 
always overlapped with DAPI dense regions, suggesting that the H4K20me3 methylation 
pattern might be slightly different from the one observed in MEFs.  
Although the limited amounts of data which have been collected so far leave little room for 
speculations and conclusions, we are pretty confident that H4K20me3 plays a role during 
germinal center formation. As yet, how this happens is unclear; however additional 
experiments will hopefully reveal more about the molecular basis of this phenotype. 
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Figure 2.8 Heterogeneous H4K20me3 mark distribution within CD4+ T cell population 
a) Confocal picture showing CD4+ T cells stained with H4K20me3 primary antibody detected with 
Alexa488 secondary staining. 
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 Results (II) 3
 
3.1 SETDB1-mediated silencing of MuLVs is essential for B cell 
development 
3.1.1 Loss of Setdb1 impairs B cell development  
 
To investigate the role of Setdb1 during B cells development, we generated Setdb1
p/Δ
Mb1cre 
mice, hereafter referred as Setdb1
Mb1 
(Fig. 3.1 a).
 
These conditional knockout mice (cKO) 
carried an engineered Setdb1 floxed allele which loxP sites flanked exon 4; a Stedb1 deleted 
allele and the cre recombinase. The expression of the recombinase was driven by the Mb1 
(CD79α) promoter, which starts to be active at early stages of B cell development. As soon as 
Mb1cre starts to be expressed, the Setdb1
flox 
allele is recognized and excised from the DNA, 
resulting in complete deletion of Setdb1
 
starting from the pro B cell stage (Fig. 3.1 b and c).  
B cells are produced and develop in the bone marrow through a series of well-defined 
differentiation stages and then relocate in peripheral organs. CLPs are the earliest B cells 
progenitors which gradually become pro B cells passing through the pre-pro B cell stage. Pro 
B cells start to rearrange DNA in order to produce the heavy immunoglobulin chain. This 
chain will be expressed on the pro B cells surface inducing a burst of proliferation which will 
direct cells to the pre B cell stage. At this point, light immunoglobulin chains will start to be 
rearranged to form functional immunoglobulins. Next, B cells will reach the immature B stage 
which is marked by surface expression of the immunoglobulins M (IgM). Some of these cells 
will become immature, immunoglobulin D (IgD) expressing B cells in the bones; while others 
will leave the bones to terminate their differentiation at other sites (Fig. 3.1 c). After 
maturation, the main organs which are populated by B cells are the spleen, the lymph nodes 
and the Peyer´s patches. Anomalies in the size of these organs are already suggestive of 
aberrant B cell development. 
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Figure 3.1  Generation of Setdb1
Mb1 
conditional knockout mice 
a) Breeding scheme adopted to obtain control and Setdb1
Mb1
 cko mice. b) Setdb1 deletion rate 
measured via PCR on genomic DNA from pro B cells sorted with FACSAria. c) Graphic representation 
of B cell development and Mb1cre induced deletion. 
 
Interestingly, the first macroscopic difference we could appreciate when we analysed 
Setdb1
Mb1
 mice was a twofold reduction of the spleen size. This observation was followed by 
microscopic analysis of spleen architecture which revealed a significant decrease of the 
follicular areas, splenic regions where B cells typically collect (Fig. 3.2 a and b).  
To investigate whether Setdb1
Mb1 
B cells were impaired, bone marrow and splenic B cells 
were first stained with α-CD19 and α-B220 antibodies. CD19+ B220+ cell population was 
drastically reduced in Setdb1
Mb1 
bone marrow and completely absent in the spleen, suggesting 
that loss of Setdb1 significantly affects B cell development (Fig. 3.2 d and e).  
 
 
Figure 3.2 Setdb1
Mb1 
mice show severely reduced B cell population in the bone marrow and lack 
mature B cells 
a) Spleens from control and Setdb1
Mb1 
mice. b) Spleen sections stained with haematoxylin/eosin. c) 
Cellularity of bone marrow (BM), spleen (SP) and thymus (TH) in control (con) and and Setdb1
Mb1 
(cko) mice (n=6). **P < 0.01 and ***P < 0.001 (unpaired two-tailed Student‟s t-test). d) Flow 
cytometry of bone marrow and splenic B cells (B220+, CD19+). e) Statistics from d) shown as 
percentage of living cells (n=6). **P < 0.01 and ***P < 0.001 (unpaired two-tailed Student‟s t-test). 
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To better understand which stage of B cell differentiation was impaired in Setdb1
Mb1 
mice, we 
analysed via multicolour flow cytometry all B cell compartments.  
Mb1 promoter reaches its peak of activation at pro B cell stage; however it starts to transcribe 
already in pre-pro B cells. Setdb1
Mb1
 pre-pro B cells were reduced by nearly 2 fold (Fig. 3.3 a 
and b); nevertheless they could still generate a largely normal pro B cell population, 
indicating that partial expression of the cre recombinase did not irreversibly affect pre-pro B to 
pro B cell transition (Fig. 3.4 a left panel).  
 
 
Figure 3.3   Setdb1
Mb1 
pre-pro B cells are reduced 
a) Flow cytometry analysis of pre-pro B cells (Lin-, CD93+, B220+, CD43-/low; c-kit-/low, IL-7Rα+). 
b) Statistics from a) shown as percentage of living cells (n=3). 
 
Pro B stage represent a critical step during B cell development, because at this point the heavy 
chain of the immunoglobulin starts to rearrange, addressing cells to a permanent B cell fate. 
Successful rearrangements result in the expression of the pre-BCR which induces a burst of 
cell proliferation, marking the entrance into the pre B stage. 
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Figure 3.4 Impaired pro B to pre B cell transition in Setdb1
Mb1
 mice 
a) FACS analysis of the main B cell populations in the bone marrow: pro B  (CD19+, IgM-, IgD-, 
CD25-, c-kit+), pre B (CD19+, IgM-, IgD-, CD25+, c-kit-), immature B (B220+, IgD-,IgM+), mature 
B (B220+, IgD+,IgM-). b) Statistics from a) shown as percentage of living cells (n=6).  
*P < 0.05, **P < 0.01, ***P < 0.001 (unpaired two-tailed Student‟s t-test). 
 
As shown in Fig. 3.4 Setdb1
Mb1 
mice generated normal pro B cells numbers; however only few 
of them passed the checkpoint to the pre B stage, as they were reduced by 30 fold compared to 
control mice. Moreover, Setdb1
Mb1
 pre B cells did not proceed to subsequent step of B cell 
commitment, demonstrating that loss of Setdb1 sharply abrogates B cell development at the 
pre B cell stage (Fig. 3.4 a and b).  
To look with better resolution at the pro B to pre B cell switch in Setdb1
Mb1
 mice we used 
Hardy´s marker scheme (CD43, B220, HSA/CD24, BP1) for B cell fractionation (Hardy et al., 
1991). 
 
 
Figure 3.5 Loss of Setdb1
Mb1
 B cell occurs at late pro B cell stage 
a) FACS plots showing pro B to pre B cell transition according to the Hardy scheme. B220+, CD43+ 
population encompasses early and late pro B cells together with small pre B cells. These 3 
subpopulations are discriminated in fraction A, B and C according to the expression level of HSA and 
BP1 markers. b) Statistics from a) shown as percentage of living cells (n=6). **P < 0.01 and ***P < 
0.001 (unpaired two-tailed Student‟s t-test). 
 
This marker combination allows discriminating different populations within the CD43+ 
B220+ cells: fraction A (pre-pro B and early pro B; HSA low/+ BP1-), fraction B (late pro B; 
HSA+/+ BP1-) and fraction C (large pre B; HSA++ BP1+).  Coherently with the data shown 
above, early pro B cells were not affected in the absence of Setdb1 (Fr.A). However, as soon 
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as B cells progressed towards the late pro B cell stage, they started to decrease (Fr.B) till 
disappearing in the large pre B cell fraction (Fr.C) (Fig. 3.5 a and b).   
To exclude that the observed B cell defects could be caused by ectopic expression of the cre 
recombinase, we also analysed hematopoietic progenitor populations. Importantly, all 
hematopoietic precursors were not affected in Setdb1
Mb1
 mice (Fig. 3.6 a-c).  
Collectively, these data demonstrated that Setdb1 is essential for B cell development. 
 
 
 
Figure 3.6 Normal frequencies of Setdb1
Mb1
 hematopoietic progenitors  
a) LSKs (Lin-, Sca+, c-kit+) hematopoietic stem cells. b) CLPs (Lin-, IL7Rα+, Sca low, c-kit low) and 
c) myeloid progenitors: CMPs (Lin-; IL7Rα-;c-kit high, Sca-; CD34+ and CD16/32-);  GMPs (Lin-; 
IL7Rα-,c-kit high, Sca-; CD34+ and CD16/32+) and MEPs (Lin-; IL7Rα-,c-kit high, Sca-; CD34- and 
CD16/32-). To each FACS plot are associated statistics shown as percentage of living cells (n=5). 
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3.1.2 Intrinsic role of Setdb1 during B cell development  
 
To test whether B cell developmental arrest in Setdb1
Mb1 mice was due to B cell intrinsic 
defects, we first performed in vitro pre B cell colony assay using MethoCult M3630 
supplemented with IL-7.  As shown in Fig. 3.7 c after 10 days of culture, Setdb1
Mb1
 bone 
marrow failed to generate pre B cell colonies. Additionally, while control cells were mostly 
negative to the viability dye 7AAD and were expressing high level of B220 and CD19; nearly 
all Setdb1
Mb1
 cells were positive to 7AAD and B cell markers were hardly expressed on their 
surface (Fig. 3.7 d). Because Setdb1
Mb1
 B cells are already compromised and are overall 
underrepresented in the bone marrow, we repeated the assay using MACS sorted progenitor 
cells where Setdb1 deletion hasn´t occurred yet. Even in this case, Setdb1
Mb1
 progenitors did 
not form any colony (data not shown).  
 
 
Figure 3.7 Intrinsic role of Setdb1 during B cell development   
a) Pre B cell differentiation assay. Lineage negative progenitors were co-cultured with OP9 stromal 
cells in the presence of IL-7 for 8 days and then analysed by FACS using Hardy´s scheme. b) Statistics 
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from a). *P < 0.05 (unpaired two-tailed Student‟s t-test). c)  pre B cell colony assay. Control and 
Setdb1
Mb1
 bone marrow cells were grown on methylcellulose medium for 10-14 days. Colony number 
represents the average of 3 biological replicates. ***P < 0.001 (unpaired two-tailed Student‟s t-test). d) 
Colonies were harvested after 10 days of culture and analysed by FACS for viability (7AAD) and 
expression of B cell markers. On the right FACS histogram shows B220 surface expression on control 
(black line) and Setdb1
Mb1 
(red line) cells, both gated on 7AAD- fraction. 
 
Additionally, we also set up OP9 coculture which allows pre B cell differentiation. Progenitor 
cells were seeded on OP9 stromal cells in the presence of IL-7 and the coculture was refreshed 
every other day. After 8 days cells were analysed by FACS and their ability to differentiate in 
pre B cells was monitored using the Hardy´s scheme. Control CD43+ B220+ population 
distributed 80% of the cells in Fr.C and the 20% in Fr.B. Setdb1
Mb1
 progenitors, instead, 
exhibited a drastic reduction of CD43+ B220+ cells which contained few pro B cells (Fr.B) 
and nearly no pre B cells (Fr.C) (Fig. 3.7 a and b).  
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Figure 3.8 Intrinsic role of Setdb1 during B cell development   
a) Competitive bone marrow transplantation. Bone marrow cells derived from 5-FU injected mice were 
mixed 1:1 and transplanted in sublethally irradiated mice. 1x10
6
 wild type (CD45.1) donor cells were 
mixed with equal amount of control or Setdb1
Mb1
 competitor cells (CD45.2). Mice were analysed 6-9 
weeks after transplantation. b) Statistics showing the relative contribution to the B cell populations 
depicted in a). **P < 0.01 (unpaired two-tailed Student‟s t-test). c) pro B to pre B cell transition in 
transplanted mice. d) Statistics showing the relative contribution to pro B and pre B cell stages 
depicted in c). Bargraphs depict average and standard deviation from at least 5 biological replicates. 
***P < 0.001 (unpaired two-tailed Student‟s t-test). 
Transplantation experiments were performed in collaboration with Klein laboratory (Institute of 
Immunology, LMU Munich) 
 
All these in vitro experiments already provided strong evidence that Setdb1 loss intrinsically 
affect B cell development; however we also performed additional analysis to confirm in vivo 
the cell intrinsic nature of the observed phenotype. To address this point, competitive bone 
marrow transplantations were performed using 1:1 mixture of wild type (CD45.1) and 
Setdb1
Mb1
 (CD45.2) progenitors or wild type (CD45.1) and Mb1cre (CD45.2) progenitors. 6-9 
weeks after transplantation mice were analysed to check B cell development. Mb1cre 
transgenic bone marrow showed a largely normal B cell development, producing pro B and 
pre B cells in a similar fashion to the cotransplanted wild type cells. Then we tested B cell 
population in Setdb1
Mb1
 transplanted animals. Consistently with what happens in non-
transplanted mice, Setdb1
Mb1
 donor cells produced significantly less amount of B cells in the 
bone marrow and showed almost complete absence of splenic B cells (Fig. 3.8 a and b). 
Analysis of B cells differentiation in the bone marrow displayed that pro B cell population 
were present with normal frequencies, while Setdb1
Mb1
 pre B cell population was 
compromised (Fig. 3.8 c and d). To demonstrate that other lineages were not impaired, 
Setdb1
Mb1
 transplanted cells were also checked myeloid cells. Importantly, Gr+ Mac+ 
population resulted to be comparable to the cotransplanted wild type cells (data not shown). 
Taken together these data demonstrate that Setdb1 controls B cell development in a cell-
intrinsic manner. 
3.1.3 Setdb1Mb1 B cells ectopically transcribe murine retrotransposable elements 
 
To learn more about the molecular mechanism which cause B cell failure in the absence of 
Setdb1, we performed RNA-Seq analysis on sorted pro B cells. Overall, we found that 260 
genes were deregulated more than 2 folds in Setdb1
Mb1
 pro B cells (Fig. 3.9 a). Considering 
the repressive function which has been continuously attributed to Setdb1 in the last years, we 
expected to observe a clear bias towards gene upregulation. Surprisingly, within the cohort of 
deregulated genes, the number of down and upregulated transcripts was nearly the same, 
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suggesting that loss of Setdb1 does not result mainly in gene derepression (Fig. 3.9 a; 
Appendix, Table 5.2). 
To reveal whether the group of deregulated genes was part of a specific regulatory pathway, 
we performed gene ontology (GO) analysis with the intent to group them according to their 
function and/or the biological processes they are involved in. As a result, we found that 
Setdb1
Mb1
 pro B cells deregulated genes involved in immune regulation, as well as 
developmental and differentiation processes, reflecting the strong developmental block we 
observed during B cell differentiation (Fig. 3.9 c). Although GO analysis nicely confirmed 
that immune regulation was impaired; it was really challenging to guess which genes were 
directly responsible for B cell developmental arrest in Setdb1
Mb1
 pro B cells, as none of them 
was a master regulator of B cell development.  
 
 
 
Figure 3.9 Gene expression analyses in Setdb1
Mb1
 pro B cells 
a) RNA-Seq performed on sorted pro B cells. Dot plot showing the number of up (red) and down 
(blue) regulated genes. b) Gene set enrichment analysis performed over all deregulated genes. 
Setdb1
Mb1
 B cells exhibited enrichment for early pro B cells signature (Fr.A) and poorly expressed late 
pro B cells transcripts (Fr.B/C). c) GO analysis of >2 fold deregulated genes in Setdb1
Mb1
 pro B cells.  
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In the first place, we carefully examined the function of all deregulated genes found in our list 
and checked whether they could be connected to the pro B cell developmental block. Analysis 
of the most deregulated transcripts revealed that any of them could be directly responsible for 
the B cell developmental failure since (1) many of these genes were already transcribed at 
such low level in control mice that further downregulation could not have any impact on 
transcriptional networks, (2) full or conditional knockout mouse model have been previously 
described for some of the analysed genes, but none of them showed B cell developmental 
arrest at the pro B cells stage, (3) genes modestly upregulated, for which no mouse model was 
available, were poorly transcribed in wild type pro B cells and (4) no B cell master regulator 
was found to be transcriptionally altered. All this led us to think that maybe gene deregulation 
was not the cause but rather the consequence of B cell failure upon Setdb1 loss. We then 
compared all Setdb1
Mb1
 pro B cells deregulated genes with the wild type Hardy´s Fr.A and 
Fr.B signatures available at immgen.org. Notably, we found that Setdb1
Mb1
 pro B cells 
accumulated early pro B cell transcripts, while late pro B cells related genes were poorly 
represented compared to control cells (Fig. 3.9 b), possibly reflecting the more immature stage 
already evident in the Hardy staining. Indeed, RNA-Seq was performed on sorted pro B cells 
(CD19+, IgM-, IgD-, CD25-, c-kit+) which corresponded to Hardy´s FrA and Fr.B. Within 
these fractions we could notice a clear enrichment of Setdb1Mb1cells in Fr.A, while Fr.B 
contained significantly less events compared to control (Fig. 3.5 a). This bias was indicative 
for an evident retention of Setdb1 deficient pro B cells in a more immature stage, as confirmed 
by the gene expression profile.  All these observations suggested that gene deregulation might 
not be the direct cause for B cell failure and that some other events must interfere with the 
establishment of the B cell program in the absence of Setdb1. 
Recent literature demonstrated that SETDB1 induces retrotransposons silencing via 
establishment of the repressive mark H3K9me3 (Karimi et al., 2011). Because analysis of 
deregulated coding transcripts seemed not to be the direct cause of the phenotype, we started 
investigating the non-coding part the genome. At first, we checked whether non-coding 
elements were expressed in Setdb1
Mb1 
pro B cells. Interestingly, among all families of 
endogenous retroviruses, two classes of retrotransposons were prominently transcribed. These 
elements are known as murine leukaemia viruses (MuLVs) and mouse VL30 retroelements 
(MMVL30) (Fig. 3.10 a and b; Appendix, Table 5.3), and they are able to cause cancer when 
ectopically expressed in the host (Herquel et al., 2013; Young et al., 2012).  
To substantiate the transcriptional changes observed in our RNA-Seq profile, we designed a 
set of primers which amplified several regions of the MuLV elements and performed qRT-
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PCR on pro B cells cDNA derived from 6 biological replicates. Importantly, MuLV transcripts 
were not detectable in control pro B cells, while they were abundantly expressed in the 
absence of Setdb1 (Fig. 3.10 c). Interestingly, MuLVs regions were not only transcribed but 
also translated, producing viral proteins. Bone marrow cells were incubated with 83A25, an 
antibody which recognizes viral envelope protein (MLV SU).  83A25 was then secondary 
labelled with Alexa647 to test its expression on the pro B cell surface. Consistently with the 
high level of retroviral transcripts, we also detected significant amount of the envelope viral 
protein on Setdb1
Mb1
 pro B cells surface (Fig. 3.10 d and e). 
 Identification of MuLVs derepression, confirmed the recent findings which described 
SETDB1 as main silencer of endogenous retroviruses; however so far nobody has ever 
provided a comprehensive explanation of how overexpression of retrotransposons might 
interfere with developmental processes.  
 
 
Figure 3.10 Ectopic expression of retrotransposons in Setdb1
Mb1
pro B cells  
a) Number of reads across one representative MuLV elements in control and Setdb1
Mb1
 pro B cells. b) 
Dot plot showing expression of endogenous retroviruses in control and Setdb1
Mb1
 pro B cells. c) 
MuLVs transcription confirmed via q-RT-PCR (n=6). Several primer pairs were used to detect 
transcription of MuLV genes (gag, pol and env). Here we show transcription level of the gag 
transcripts from the highest upregulated MuLVs. **P < 0.01 and ***P < 0.001 (unpaired two-tailed 
Student‟s t-test). d) Expression of envelop viral protein on the pro B cells surface detected by FACS 
analysis. Bone marrow cells were incubated with α-env (83A25) antibody followed by secondary 
detection with Alexa647. e) Bar graph showing env protein expression level calculated as average of 
the mean fluorescence intensity (n=6). ***P < 0.001 (unpaired two-tailed Student‟s t-test). 
 
In summary, we conclude that aberrant gene expression in Setdb1
Mb1
 pro B cells is not a direct 
consequence of Setdb1 depletion, but rather results from other events which managed to retain 
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cells in the early pro B stage. Because gene deregulation could not explain B cells 
developmental arrest in Setdb1
Mb1 
mice; we propose that massive transcription of endogenous 
retroviral elements can be a direct consequence of Stedb1 depletion. To corroborate this 
hypothesis we next performed ChIP-Seq experiments. 
3.1.4 SETDB1 represses retrotransposons in pro B cells  
 
To learn more about SETDB1 binding sites and to understand whether MuLVs silencing was 
due to SETDB1 mediated H3K9me3, we performed ChIP-Seq using short-term cultured 
Rag2ko pro-B cells. Chromatin from these cells was immunoprecipitated using α-SETDB1, α-
H3K9me3 and α-H3K9ac antibodies and analysed via high-throughput sequencing. 
 
 
Figure 3.11 SETDB1 and H3K9me3 enrichment across repetitive elements.  
a) ChIP-Seq analysis of in vitro expanded pro B cells performed with α-SETDB1 α-H3K9me3 and α-
H3K9ac antibodies. This experiment was performed in collaboration with Busslinger laboratory (IMP, 
Vienna). b) Correlation analysis of SETDB1 and H3K9me3 across retrotransposable elements. The 
highest association was found over MuLV elements. c) Dot plot showing expression of endogenous 
retroviruses in control and Setdb1
Mb1
 pro B cells. 
 
Bioinformatic analysis of SETDB1 and H3K9me3 peaks showed that SETDB1 covered many 
more regions in the genome compared to H3K9me3. Unexpectedly, SETDB1 binding sites 
were rarely overlapping with H3K9me3 peaks, suggesting that this histone methyltransferase 
does not establishes H3K9me3 at all its binding sites. 
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Subsequently, we started investigating SETDB1, H3K9me3 and H3K9ac binding sites 
genome-wide. SETDB1 and H3K9me3 peak colocalization excluded the presence of the active 
mark H3K9ac and, vice versa, H3K9me3 repressive mark was missing at loci where SETDB1 
and H3K9ac gathered (Fig. 3.11 a). Next, we tried to unravel which genomic areas underlaid 
SETDB1/H3K9me3 and SETDB1/H3K9ac binding sites. Notably, SETDB1/H3K9me3 mostly 
covered repetitive elements, while SETDB1/H3K9ac peaks were found at promoter regions 
(Fig. 3.11 a).  
Because MuLVs and MMLV30 expression in pro B cells might be a direct consequence of 
Setdb1 depletion, we checked SETDB1 coverage across these elements.  Remarkably, we 
found that SETDB1 clearly occupied these regions together with H3K9me3; strongly 
supporting the idea that ectopic transcription of these elements in pro B cells is directly 
connected to Setdb1 loss (Fig. 3.11 b). 
To test how repressive chromatin behaved upon Setdb1 depletion, we sorted CD43+ CD19+ 
cells from control and Setdb1
Mb1
 bone marrow and performed ChIP-qPCR for the repressive 
H3K9me3 and the active H3K4me3 chromatin marks. Because MuLV elements showed the 
highest transcription levels (Fig. 3.10 b), we choose these regions to test whether the 
distribution of the histone marks was changed in upon Setdb1 depletion.  H3K9me3 broadly 
covered MuLV elements in control cells, confirming what we observed in our ChIP-Seq 
profile. Unexpectedly, sorted Setdb1
Mb1
 pro B cells displayed a reduction but not a complete 
loss of H3K9me3, indicating that MuLVs can be activated even if the repressive mark 
H3K9me3 is still present on the sequence (Fig. 3.12 a).  
Because MuLVs are massively transcribed in Setdb1
Mb1
 pro B cells we also performed ChIP-
qPCR on sorted cells to test whether they gained H4K3me3 across their sequences. Setdb1
Mb1
 
cells showed a significant increase of H3K4me3 across MuLVs compared to control mice, 
which showed almost no enrichment of this mark across MuLVs (Fig. 3.12 b). Additionally, 
we also tested whether MuLVs derepression influenced the chromatin environment in 
neighbouring genes (Tubb3 and Def8 are shown as an example in Fig. 3.12). Interestingly, 
some of the MuLVs flanking genes were minimally covered by H3K9me3 in control and 
mutant cells; however we could appreciate a significant increase of the active H3K4me3 mark 
in Setdb1
Mb1
pro B cells also across these regions (Fig. 3.12 b). 
All together these data demonstrated that SETDB1 binds to MuLV elements and that these 
elements are covered with H3K9me3 in control pro B cells. Nevertheless, it remains unclear 
whether MuLVs silencing is mediated via establishment of H3K9me3 or if this mark is just a 
consequence of SETDB1mediated silencing. Notably, we observed that Setdb1 depletion 
results in a decrease but not a complete loss of H3K9me3 across MuLV elements. Presence of 
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H3K9me3, however, does not seem to be a hindrance for H3K4me3 establishment, which 
clearly occurs through all MuLV regions and; notably, also spread across their neighbouring 
genes such as Tubb3 and Def8 (Fig. 3.12 b). 
 
 
Figure 3.12 MuLVs partially lost the repressive H3K9me3 while gaining the H3K4me3 
transcriptional mark in Setdb1
Mb1
 pro B cells    
a) ChIP analysis performed on CD43+ CD19+ sorted pro B cells. α-H3K9me3 and b) α-H3K4me3 
were used to identify loss or gain of these marks over MuLV elements and neighbouring regions.  
 
3.1.5 MuLVs derepression results in activation of neighbouring genes 
 
Because it is known that, beyond starting transcription of the proviral genome, LTRs 
promoters are able to enhance the transcription of genes which are located in their vicinity (Lu 
et al., 2014; van de Lagemaat et al., 2003); we verified whether transcription of MuLVs 
neighbouring genes was also affected in the absence of Setdb1. Plus, ChIP-qPCR analysis 
displayed a substantial gain of the active mark H3K4me3 over MuLV proximal genes, which 
might indicate the presence of a transcriptionally active environment also in the vicinity of 
MuLVs genomic regions (Fig. 3.12 b). 
At first, we looked in our RNA-Seq profile at genes located at MuLVs 5´and 3´end. 
Interestingly, we found that all MuLVs flanking genes were highly transcribed, although 
neither SETDB1 nor H3K9me3 occupied their genomic sequence (Fig. 3.13 a; 3.10 a). 
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Significantly, transactivation of MuLVs flanking genes was also confirmed via qRT-PCR in 6 
biological replicates (Fig. 3.13 b).  
 
 
Figure 3.13 Transactivating functions of retrotransposons on neighbouring genes  
a) SETDB1 and H3K9me3 coverage over one representative MuLV region and its flanking gene. b) 
Overexpression of MuLV neighbouring genes in Setdb1
Mb1
 sorted pro B cells (n=6). ***P < 0.001 
(unpaired two-tailed Student‟s t-test). c) Representative FACS histograms showing Fcγr2b protein 
detection on Setdb1
Mb1
  pro B cell surface d) Bar graph displaying Fcγr2b protein expression level 
calculated as average of the mean fluorescence intensity (n=6). 
 
This findings indicate that upregulation of MuLVs neighbouring genes does not directly result 
from loss of SETDB1 repressive function, but rather comes from the enhancing role that LTR 
promoters exert in their proximity.  
Taking advantage of the fact that one of MuLVs neighbouring genes was a cell surface maker, 
we tested by FACS analysis whether these transcripts were also translated. Consistently to 
what we observed for the viral protein env, also transactivated genes were translated into 
proteins, as it shown by Fcγr2b overexpression onto the Setdb1 deficient pro B cell surfaces 
(Fig. 3.13 c and d). 
3.1.6 Setdb1 loss in pro B cells induces apoptosis 
 
It has already been demonstrated that accumulation of viral transcripts induces activation of 
the interferon pathway which triggers apoptosis. This happens because retroviral endogenous 
transcripts are somehow recognized by molecules that specifically detect viral DNA or RNA, 
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inducing programmed cell death (Pichlmair and Reis e Sousa, 2007; Stetson and Medzhitov, 
2006). Other evidences also demonstrated that expression of the viral envelope protein on the 
cell surface can induce programmed cell death via several mechanisms (Biard-Piechaczyk et 
al., 2000; Perfettini et al., 2005; Ullrich et al., 2000).  
In order to understand whether ectopic expression of endogenous retroviruses induces 
apoptosis in pro B cells, we tested Setdb1
Mb1
 pro B cells for apoptotic markers.  Annexin V 
staining revealed that 30% of control pro B cells underwent apoptosis, reflecting the rate of 
aberrant IgH recombination which occurs at this stage of development. Interestingly, when we 
tested Setdb1
Mb1
 pro B cells, we observed enhanced apoptosis: nearly the double compared to 
control cells (Fig. 3.14 a and b).  
 
 
Figure 3.14 Setdb1
Mb1
 pro B cells showed enhanced apoptosis 
a) Apoptosis detected via AnnV staining. b) Statistics from a) (n=6). **P < 0.01 (unpaired two-tailed 
Student‟s t-test). 
 
 
3.1.7 Ovexpression of antiapoptotic Bcl2 partially rescues B cell defects in Setdb1Mb1 
mice 
 
Nearly all Setdb1
Mb1
 pro B cells undergo programmed cell death, as demonstrated by the 
Annexin V staining (Fig. 3.14 a and b). To understand whether this phenotype could be 
rescued by overexpression of antiapoptotic molecules, we generated Setdb1
Mb1
; VavBcl2 mice, 
which overexpress the antiapoptotic Bcl2 throughout all the haematopoiesis. Remarkably, 
MACS sorted lineage negative Setdb1
Mb1
; VavBcl2 progenitors readily formed pre B cell 
colonies in methylcellulose medium supplemented with IL-7, in a comparable fashion to 
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VavBcl2 control (Fig. 3.15 a). Although Setdb1
Mb1
 B cell differentiation defects could be 
rescued in vitro, we also investigated whether in vivo Bcl2 overexpression could bypass 
Setdb1
Mb1
 pro B cell apoptosis. Therefore, we analysed B cell development in Setdb1
Mb1
; 
VavBcl2 bone marrow. We performed immunophenotyping to specifically check all B cell 
developmental stages. As shown in Fig. 3.15 b, pro B cell numbers in Setdb1
Mb1
; VavBcl2 
mice were comparable to VavBcl2 controls and, importantly, pro B cells underwent very little 
apoptosis, proving that Bcl2 overexpression clearly rescues cell death at the pro B cell stage 
(Fig. 3.15 d). 
Although Bcl2 overexpression was obviously not enough to fully restore B cell development 
in Setdb1
Mb1
 mice (Fig. 3.15 c), we observed that Setdb1
Mb1;
 VavBcl2 pre B cells increased 5 
fold compared to Setdb1
Mb1
 mice without VavBcl2 transgene; demonstrating that in the 
absence of Setdb1 pro B to pre B cell transition can be partially restored preventing apoptosis 
(Fig. 3.15 b and c; Appendix Fig. 5.1). Analysis of later stages of B cell development in 
Setdb1
Mb1
; VavBcl2 mice, also showed an increase in immature B and mature B cells 
compared to Setdb1
Mb1
 mice, which completely lacked mature B cells (Fig. 3.15 b and c; 
Fig.3.4 a and b). Notably, these populations were able to migrate to the spleen (Fig. 3.15 e 
and f), demonstrating that even though B cell development has not completely recovered in 
Setdb1
Mb1
; VavBcl2 mice, we can detect differentiated B cells also in the periphery. 
Importantly, we showed that these cells largely deleted Setdb1, indicating that splenic 
Setdb1
Mb1
; VavBcl2 B cells were not deletion escapers (Fig. 3.15 g).   
Altogether these data provide in vitro and in vivo evidences that Bcl2 overexpression in 
Setdb1
Mb1
 mice results in partial rescue of B cell development, indicating that many Setdb1
Mb1
 
B cells undergo apoptosis due to reasons which are not strictly linked to developmental 
defects. Developmental failures, in fact, cannot be rescued by just overexpressing 
antiapoptotic molecules, because cells would be kept anyway in a more immature state 
missing the tools to progress to the next developmental stage. Pro B to pre B cell transition in 
Setdb1
Mb1
; VavBcl2 mice is, however, only moderately resolved; therefore we cannot exclude 
the possibility that Setdb1 plays additional roles during early and/or later stages of B cell 
development. 
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Figure 3.15 Enforced Bcl2 expression partially rescues B cell development in Setdb1
Mb1
 pro B cells  
a) pre B cell colony assay. VavBcl2 and Setdb1
Mb1
; VavBcl2 Lin- bone marrow cells were grown on 
methylcellulose medium containing IL-7 for 10 days. Colony number represents the average of 3 
biological replicates. b) B cell developmental rescue in Setdb1
Mb1
; VavBcl2 mice. FACS analysis of 
the main B cell populations in the bone marrow: pro B (CD19+, IgM-, IgD-, CD25-, c-kit+), pre B 
(CD19+, IgM-, IgD-, CD25+, c-kit-), immature B (B220+, IgD-,IgM+), mature B (B220+, IgD+,IgM-
). c) Statistics from b) calculated as percentage of living cells from 5 biological replicates. d) AnnV 
staining to detect apoptosis in VavBcl2 and Setdb1
Mb1
; VavBcl2 pro B cells (n=7). e) B cell (CD19+, 
B220+) population in the spleen (n=4). f) Statistics from e) calculated as percentage of living cells. g) 
Setdb1 deletion rate in IgM+ IgD + sorted splenocytes. Genomic DNA purified from sorted IgD+IgM+ 
splenic B cells was amplified by PCR to test the presence of the floxed and ∆ Setdb1 alleles. 
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3.2 Discussion (II)  
 
SETDB1 is an essential histone methyltransferase during development. Setdb1 ko mice die at 
the peri-implantation stage and conditional deletion of the enzyme during neuronal and 
mesenchyme development severely impairs cell differentiation programs (Dodge et al., 2004). 
So far, all the efforts to reveal why SETDB1 mediated silencing is so essential during 
developmental transitions have not provided a clear answer. This is due to the main limitations 
which come along in vivo studies, as lack of biological material due to lethal effects of Setdb1 
deletion, together with obvious difficulties to monitor cell behaviour in living organisms.  
The best known developmental context is the haematopoiesis. Over the past years a lot of 
progresses in dissecting all transitions which occur during hematopoietic differentiation have 
been made. In fact, gain and loss of function experiments revealed the essential role of many 
transcription factors at every stage of hematopoietic development, which allowed drawing the 
actual hierarchical model of haematopoiesis (Fig. 1.4). Additionally, the expression of stage 
specific surface markers, represent a big advantage to isolate definite hematopoietic 
subpopulations directly from the bone marrow. Here, we induced Setdb1 conditional deletion 
during B cell differentiation using the stage specific Mb1cre recombinase. Remarkably, this 
resulted in a strong block during pro B to pre B cell transition. Virtually, Setdb1
Mb1
 mice 
produced pro B cells comparably to control mice, while the pre B cell population was reduced 
by 50 fold and none of these cells made it to the next stages of B cell development. Such 
strong blockage is similarly observed in mice lacking B cell master regulators; therefore we 
first thought that loss of Setdb1 resulted in inability to establish the B cell program. This 
assumption was also supported by the fact that SETDB1 has been described as a silencer of 
developmental gene in mES cells (Bilodeau et al., 2009), although it is not yet clear whether 
this is the main silencing activity exerted by the enzyme.  To check how Setdb1 depletion 
affects transcription, we performed RNA-Seq in sorted pro B cells. We found 260 deregulated 
genes which equally divided in downregulated and upregulated. Considering the postulated 
silencing function of SETDB1 this observation was really surprising, as we expected massive 
gene derepression. Even more surprising was the fact that all main factors which are known to 
be essential for B cell development, as Pax5, Ebf1, E2a, Rag1/2 were transcriptionally 
unaltered, indicating that the main transcriptional networks were successfully settled in the 
absence of Setdb1. Although none of these master regulators was affected, GO analysis 
highlighted that many deregulated transcripts clustered with high score in the category of 
immune regulators. To better understand whether gene deregulation was the cause or the 
consequence of the phenotype, we used in vitro expanded pro B cells to perform ChIP-Seq 
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analysis with α-SETDB1 and α-H3K9me3 to find SETDB1 target genes. Peak calling analysis 
revealed that SETDB1 set on many promoters; however at nearly all these sites H3K9me3 was 
absent. Importantly, we observed that exclusive presence of SETDB1 over TSSs did not affect 
gene regulation, as demonstrated by the minimal transcriptional changes which occurred at 
these sites in Setdb1
Mb1
 pro B cells (Fig. 3.16).  
 
 
Figure 3.16 Exclusive SETDB1 occupancy over TSSs does not affect gene regulation  
Gene set enrichment analysis performed on genes sitting within cluster A and cluster B genomic areas 
derived from the ChIP-Seq profile (see Fig. 3.11 a). 
 
Then, we asked our profile which genomic regions were co-occupied by SETDB1 and 
H3K9me3. Repetitive elements and intergenic regions resulted to be the areas where SETDB1 
and H3K9me3 showed the strongest correlation, possibly indicating that SETDB1 repressive 
function are exerted at these sites. To verify this, we checked in our RNA-Seq profile whether 
these regions were derepressed in Setdb1
Mb1
 pro B cells. Importantly, we found that two 
classes of endogenous retroviruses, known as murine leukaemia viruses (MuLVs) and mouse 
VL30 retroelements (MMVL30), were significantly transcribed. Noteworthy, in mES cells 
loss of Setdb1 resulted in specific upregulation of another class of element known as internal 
A-particles (IAPs) but not MMVL30 and MuLVs. The specific activation of certain classes of 
retroviruses in different Setdb1 deficient cell types, clearly indicated that although SETDB1 
covers these elements, their transcription is not simply a function of Setdb1 depletion but also 
requires the presence of tissue specific transcription factors which are able to start their 
transcription. For example, it has been shown that in certain kind of lymphoid neoplasms the B 
cell factor E2A binds to MuLVs elements influencing their transcription (Lawrenz-Smith and 
Thomas, 1995). In this regard, further experiments could be performed to investigate which 
cell specific transcription factors are required to selectively activate transcription of distinct 
class of retrotransposons. Moreover, it would be interesting to verify whether ectopic 
expression of E2a in Setdb1ko ESCs or MEFs is able to induce MuLV transcription. 
Another interesting aspect about transcription of endogenous elements regards the chromatin 
environment which needs to be established to allow their activation. In fact, we observed in 
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our ChIP-qPCR experiment that upon Setdb1 depletion H3K9me3 marks were only reduced, 
but not completely lost. This can be explained by the fact that this methyl mark is removed by 
passive demethylation, a process which requires cell cycle to occur. Because pro B cell 
population contains slow-cycling cells due to the VDJ recombination, it is reasonable to think 
that a complete loss of the H3K9me3 is not achievable due to the low number of cell divisions 
occurring at this stage.  Interestingly, despite the presence of residual H3K9me3, the active 
H3K4me3 mark could be established, therefore complete removal of H3K9me3 is not required 
for H3K4me3 installation. This finding questions the role of chromatin modifications as sole 
regulators of transcription. In fact, it would be interesting to verify whether reintroducing a 
catalytically inactive form of SETDB1 inside Setdb1
Mb1
 pro B cells would rescue the B cell 
developmental blockage.  
Retroviral elements, together with other silenced genomic regions, were depicted in 
former times as non-coding or `junk´ DNA.  With these terms biologists indicated genomic 
areas that could never be linked with any function in cell physiology. However, in the light of 
the most recent discoveries this concept needs to be reconsidered. Indeed, contemporary 
studies demonstrated that endogenous retroviral elements enhanced the expression of key 
developmental genes in embryonic stem cells (ESCs), suggesting a clear physiological role of 
these sequences in transcriptional regulation (Lu et al., 2014; Ryan, 2004). In our work, we 
also observed that derepression of endogenous retroviruses upon Setdb1 loss resulted in 
transactivation of neighbouring genes. In fact, Setdb1
Mb1 
pro B cells transcribed genomic areas 
which were located next to the retroelements; although in wild type these regions were not 
covered by SETDB1 or H3K9me3. Importantly, some of them showed opposite transcriptional 
orientation in respect to their associated repetitive elements, excluding the possibility that 
fusion proteins could originate from reading-through effects of the polymerase.      
Ectopic expression of MuLVs has been associated with programmed cell death due to 
cytotoxicity induced by ER stress (Nanua and Yoshimura, 2004; Yoshimura et al., 2001; Zhao 
and Yoshimura, 2008). Additionally, expression of the env protein in peripheral human B cells 
has been found to interfere with cell proliferation (Jelicic et al., 2013). These evidences 
indicate that derepression of endogenous elements damages cell metabolism. Therefore we 
checked whether Setdb1
Mb1 
pro B cells underwent apoptosis, independently from physiological 
cell death associated to the VDJ combinatorial events. Setdb1 deficient pro B cells showed 2 
fold more apoptosis compared to control cells, which exhibited a physiological 30%. Notably, 
if B cell apoptosis due to Setdb1 depletion originated form developmental defects (such as 
impaired immunoglobulin rearrangement), it would not be possible to rescue differentiation 
via enforced expression of antiapoptotic due to the fact that B cell development impose 
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obligated checkpoints which cannot be bypassed.  To address this point, we generated 
Setdb1
Mb1
; VavBcl2 mice, which overexpressed antiapoptotic Bcl2 during haematopoiesis. 
These animals showed a partial but substantial rescue of B cell development, as they produced 
5 fold more pre B cells compared to Setdb1
Mb1
 mice. Importantly, Setdb1
Mb1
; VavBcl2 pre B 
cells were also able to proceed further during B cell development and relocate in peripheral 
organs. Indeed, these cells populated the spleen and, notably, they were all Setdb1 deficient. 
The partial rescue observed in vivo was a clear demonstration that part of Setdb1
Mb1
 deficient 
pro B cells could bypass apoptosis upon Bcl2 overexpression, continuing their path though B 
cell development. However, the fact that some cells still struggled to proceed to next 
developmental stages strongly suggests that of SETDB1 might have additional roles which 
cannot be resolved by Bcl2 overexpression or that these cells follow a different pathway which 
leads to death.  
Recently, it has been observed that mice lacking antibody producing B cells, such as 
Rag deficient mice, significantly transcribed retroviral elements in macrophages. In this study 
Young et al. showed that immune stimuli trigger expression of retroviral element which 
randomly reintegrated in the genome, generating instability and ultimately leukaemia. 
Interestingly, expression of these elements in mature differentiated cells as macrophage 
seemed not to affect cell viability, while in our study pro B cells were dramatically affected by 
the presence of retroviral transcripts. This might indicate that developing cells cannot tolerate 
ectopic expression of retroviruses, differently from mature cells. 
In this regards, it would be intriguing to generate conditional knockout mice which delete 
Setdb1 in later stages of B cell development to understand (1) whether this also induces 
derepression of repetitive elements, (2) if mature B cells can cope with their presence. 
 
 
 
Figure 3.17 Model  
 
In summary our data support the role of SETDB1 as main silencer of retroviral elements in the 
pro B cells genome. We observed that loss of Setdb1 results in derepression of retroviruses 
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without affecting the establishment of B cell transcriptional networks. Therefore, we assume 
that ectopic transcription of MuLVs and MMVL30 strongly interferes with B cell 
development inducing cellular stress which ultimately results in apoptosis (Fig. 3.17). Our 
results propose the first molecular link between Setdb1 depletion and developmental defects, 
highlighting the importance of silencing endogenous retrovirus during B cell development.   
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 Results (III) 4
4.1 The role of the histone methyltransferase SETDB1 during 
haematopoiesis 
 
4.1.1 Setdb1Vav mice are underdeveloped and show impaired hematopoietic organs  
 
To assess the role that SETDB1 plays during early stages of haematopoiesis, we generated 
conditional knockout mice (Setdb1
Vav
). These animals were obtained by crossing Setdb1p/p 
mice, which carried two Setdb1 floxed alleles with VavCre mice, accomplishing tissue specific 
Setdb1 depletion in all hematopoietic cells (Fig. 4.1 a). 
 
 
 
Figure 4.1 Setdb1
Vav 
mice were underdeveloped and show hematopoietic defects 
a) Breeding scheme adopted to obtain control and Setdb1
Mb1
 cko mice.  b) Underdeveloped Setdb1
Vav 
mice. All analysed animals weighted 2-3 folds less than controls and died within 4
th
 week of age c). d) 
Hematopoietic organs cellularity calculated from at least 6 biological replicates. 
 
Setdb1
Vav
 4 weeks old mice were 3 fold smaller compared to littermate controls (Fig. 4.1 b) 
and they showed clear developmental defects. In facts, in addition to reduced body size, 
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mutant mice exhibited streaked tails, showed a sparse hair coat, lack of down teeth and twisted 
upper teeth. To make up for the lack of down teeth, mice were provided with wet diet soon 
after weaning or they were kept in the mating cages for a longer time. Also, we verified that 
weaned mice could chew and eat properly, to avoid further complication which might have 
interfered with the already existing developmental defects. Unfortunately, even though 
Setdb1
Vav 
mice could be regularly fed and behaved normally, they died within the first 4-5 
weeks after birth (Fig. 4.1 c). At first, we associated early postnatal lethality to lack of 
erythrocyte. However, this hypothesis was excluded when we analysed Setdb1
Vav 
blood smear 
and observed that red blood cells were regularly produced and that their morphology was 
unchanged compared to control (Fig. 4.2). 
 
 
 
Figure 4.2 Setdb1
Vav 
erythrocytes are morphologically unaltered 
Blood smears from control and Setdb1
Vav 
mice stained May-Grünwald GIEMSA. 
 
Due to short survival time, we carefully monitored all littermates in this colony to identify 
mutant mice even before weaning.  As soon as Setdb1
Vav 
mice could be identified and weaned, 
they were immediately scarified and prepared for analysis of all hematopoietic organs. 
The strong developmental defects shown by Setdb1
Vav 
mice already heralded the possibility of 
a severe impairment of the hematopoietic system. Indeed, when we started analysing the 
hematopoietic organs, we first noticed that Setdb1
Vav
 mice exhibited a rudimental thymus 
which was hardly visible with naked eyes. Similar size reduction was observed in other 
lymphoid organs, like mesenteric lymph nodes and Peyer‟s patches, which could be hardly 
identified in the abdomen of these animals. Surprisingly, Setdb1
Vav 
spleens were comparable in 
weight to control spleens and they were enlarged 2-3 folds in proportion to body size. Bone 
marrow cellularity in Setdb1
Vav 
mice was reduced by 3 fold (Fig. 4.1 d). Yet, this could just 
reflect the smaller size of the mice.  
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Altogether these developmental defects showed that tissue specific depletion of SETDB1 
using the VavCre recombinase, resulted in severe underdevelopment and impairment of the 
hematopoietic compartment. 
4.1.2 Lack of Setdb1 during hematopoietic development results in complete loss of 
lymphocytes and expansion of myeloid-erythroid lineage in the periphery 
 
To further understand which steps of hematopoietic development broke down in the absence of 
Setdb1, we started analysing all terminally differentiated cell of the immune system.  
Thymus is the central hematopoietic organs where T cells develop before migrating to the 
periphery. Young mice count approximately two million thymocytes, most of which are 
developing T cells.  Setdb1
Vav
 thymus size was reduced 100 folds compared to controls (Fig. 
4.1 d), indicating that this organ could not really sustain proper T cell development (Fig. 4.3 b). 
On the other hand, spleen size was unaffected; therefore we asked which kind of cells 
populated Setdb1
Vav 
spleens. Consistently with what we observed in the thymus, we could 
detect no splenic T cells, demonstrating that the few T cells produced are not able to reach 
peripheral organs (data not shown). Next, to test if also B cells were affected in the lymphoid 
compartment, we stained Setdb1
Vav
 splenocytes with B cells markers. Notably, CD19+, B220+ 
cells were completely missing in Setdb1
Vav 
spleens, showing that this organ was totally 
deprived of lymphoid cells (Fig. 4.3 a bottom panel). Excluding the presence of lymphoid 
cells in Setdb1
Vav
 spleen, we checked for myeloid-erythroid populations, the other cell types 
that normally resides into the spleen. Setdb1
Vav 
Gr+ Mac+ cells, which represent the myeloid 
fraction, were overrepresented and the macrophage (Mac+, Gr-) population was increased more 
than 3 fold (Fig. 4.3 c bottom panel). Additionally, we tested erythroid cells, which can be 
distinguished according to the developmental stage they are going through. Although we 
detected mild differences in each developmental steps, terminally differentiated erythrocytes 
were normally produced and looked morphologically unaltered (Fig. 4.3 d), as we could also 
appreciate in the GIEMSA staining performed on blood smears from Setdb1
Vav
 mice (Fig. 4.2).  
In summary, we conclude that Setdb1
Vav
 mice completely lack terminally differentiated B and T 
cells but overexpand myeloid-erythroid populations in the periphery. 
4.1.3 Setdb1Vav bone marrow completely abolishes B cell development in favour of 
myeloid-erythroid expansion 
 
Because we observed a total loss of lymphoid cells and a gain of myeloid population in the 
periphery, we also analysed how the myeloid and lymphoid compartment behaved in the bone 
marrow, headquarter of the haematopoiesis. Analysis of Setdb1
Vav 
B cell population in the 
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bone marrow confirmed what we have already observed in the spleen. In fact, also here 
CD19+, B220+ cells were missing (Fig. 4.3 a top panel). Because of complete lack of B cell 
markers, we could not detect any population in all B cell differentiation steps, confirming that 
loss of Setdb1 in early haematopoiesis completely abrogates B cells development. Because we 
observed an increase in Gr-1+ Mac-1+ cells and erythroblasts in the periphery, we also tested 
these populations in the bone marrow, which is the main myeloid organ.  
Coherently to what we found in the spleen, myeloid cells and erythroblasts were 
overrepresented. In particular, we also noticed the presence of an unusually abundant Mac-1 
only positive cell population which is produced in very low amount in the bone marrow (Fig. 
4.3 c bottom panel).  
 
 
 
Figure 4.3 Hematopoietic development is severely compromised in Setdb1
Vav 
mice  
a-d) Flow cytometry analysis of bone marrow and splenic B cells (B220+ ,CD19+) and bargraph 
depicting average and standard deviation of  8 biological replicates a); main T cell populations in the 
thymus b); myeloid (Gr+ Mac+) cell population together with bargraph depicting average and standard 
deviation of  8 biological replicates c) and erythroid cells d) in bone marrow and spleen.  
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4.1.4 Common lymphoid progenitors (CLPs) are not altered in Setdb1Vav mice while 
granulocytes macrophage progenitors (GMPs) are overrepresented 
 
In order to understand whether B cell failure and overexpansion of myeloid population in 
Setdb1
Vav 
  mice was due to aberrant production of hematopoietic progenitors, we performed 
FACS analysis to test lymphoid and myeloid precursors. 
Common lymphoid progenitors (CLPs) give rise to B and T cells and some natural killer cells 
(NKs). Aberrant production of these cells would explain absence of lymphoid cells in 
Setdb1
Vav
 mice. Surprisingly, Setdb1
Vav
 CLPs were produced in a similar fashion to control 
mice (Fig. 4.4 a top panel and b), suggesting that this population was virtually present, but 
not able to further differentiate.  
 
 
Figure 4.4 Lymphoid progenitors are unaltered in Setdb1
Vav 
bone marrow while myeloid 
progenitors show a bias towards GMPs differentiation 
a) Flow cytometry analysis of hematopoietic multipotent progenitors. Top panel shows CLPs (Lin-, 
IL7Rα+, Sca low, c-kit low). Bottom panel depicts myeloid-erythroid progenitors: CMPs (Lin-, IL7Rα-
, c-kit high, Sca-; CD34+ and CD16/32- ); GMPs (Lin-, IL7Rα-, c-kit high, Sca-, CD34+ and 
CD16/32+); MEPs (Lin-, IL7Rα-, c-kit high, Sca-; CD34- and CD16/32-). b) Bargraphs depicting 
average and standard deviation of 6 biological replicates. c) Cytospin preparation of bone marrow cells 
stained with May-Grünwald Giemsa. d) Myeloid and lymphoid cell colony assay. Control and 
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Setdb1
Vav
 bone marrow progenitors were grown on methylcellulose medium enriched either with Stem 
Cell Factor IL-3 and IL-6 and Erythropoietin or IL-7 to promote myeloid-erythroid and lymphoid 
differentiation, respectively. Colony number represents the average of 3 biological replicates.  
 
The overrepresentation of differentiated Gr+ Mac+ cells in the bone marrow and in the spleen 
for Setdb1
Vav
 mice led us to investigate also myeloid progenitors. Myeloid precursors start to 
differentiate from the less mature common myeloid progenitors (CMPs), which then give rise 
to either megakaryocytes-erythrocytes progenitors (MEPs) or granulocyte macrophage 
progenitors (CMPs).  
Percentages of Setdb1
Vav 
CMPs were normal; however we appreciated a significant loss of 
MEPs and a substantial gain in GMPs (Fig. 4.4 a bottom panel and b). Although this clear 
bias towards GMPs production would nicely explain the overrepresentation of mature Gr+ 
Mac+ cells, loss of MEPs conflicts with the existence of normally shaped erythrocytes and 
normal amounts of erythroid precursors. 
According to these data, we conclude that Setdb1 depletion blocks lymphoid differentiation at 
the CLPs stage and generates a strong bias towards GMPs production. 
4.1.5 HSCs compartment collapses 4 weeks after birth in Setdb1Vav mice 
 
Hematopoietic stem cells are the starting point of all hematopoietic development, as they can 
initiate the specification of lymphoid and myeloid-erythroid lineage. To complete our view on 
hematopoietic development in Setdb1
Vav 
mice we checked whether HSC population (Lin- Sca+ 
c-kit+ or LSK) was affected.  Surprisingly, HSCs were not detectable in 4 weeks old bone 
marrow, indicating that 4 weeks old Setdb1
Vav 
  mice completely miss the cells which give rise 
to the entire hematopoietic compartment.  
Because Setdb1
Vav 
mice produced significant amounts of myeloid cells, we were wondering 
whether they differentiated from LSKs previously generated. To verify this hypothesis, we 
tested foetal liver from E18.5 embryos and bone marrow from 2-3 weeks old mice for the 
presence of hematopoietic stem cells. Interestingly, LSK population was increased 2 fold in 
both Setdb1
Vav 
foetal liver cells and 2-3 weeks old bone marrow (Fig. 4.5 a and b). This 
finding demonstrate that Setdb1
Vav 
mice produce enough LSKs in the foetal liver and during 
the first 3 weeks of life, while after the 4
th
 week of age they manifest a full collapse of the 
HSCs compartment.  
Importantly, comparably to what we observed in 4 weeks old Setdb1
Vav 
mice, we could 
confirm lack of lymphoid cells and overexpansion of mature and immature myeloid cells in 
Setdb1
Vav
 foetal liver and 2-3 weeks old bone marrow (data not shown); although at this stage 
the HSCs compartment was virtually not affected. 
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These data suggest that loss of Setdb1 might either induce HSCs exhaustion or, alternatively, 
impaired maintenance of the HSCs.  
 
 
 
Figure 4.5 HSCs compartment collapses in Setdb1
Vav 
mice 4 weeks after birth 
a) Flow cytometry analysis of hematopoietic stem cell population in E18.5 foetal liver (left), 2 weeks 
(middle) and 4 weeks old bone marrow (right). Hematopoietic stem cells were identified by FACS 
analysis as Lin-, Sca+, c-kit+ (LSK). b) Bargraphs depicting average and standard deviation of 6 
biological replicates. 
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4.2 Discussion (III) 
 
In the previous discussion part we have already spoken about the importance of the histone 
methyltransferase Setdb1 during development. Moreover we described how loss of Setdb1 
interferes during B cell differentiation due to aberrant expression of retrotransposable 
elements. These data strongly supported the idea that developmental defects observed in 
Setdb1
Mb1
 mice are linked to retrotransposons induced toxicity. If this was always the case, 
broad deletion of Setdb1 throughout all hematopoietic development would have completely 
abolished the hematopoietic system due to global apoptosis. To address this point and to 
generally investigated Setdb1 functions during all haematopoiesis, we generated Setdb1
Vav
 
mice. These animals induced excision of Setdb1 floxed alleles already during foetal 
haematopoiesis when the recombinase starts to be expressed under the control of Vav 
promoter. Setdb1
Vav
 mutant mice were not produced according to Mendelian ratio, but they 
were underrepresented compared to the other genotypes. This could be either due to (1) low 
penetrance of the Vavcre recombinase in our mouse colony; (2) to the fact that Vav promoter 
is also active in trophoblast cells, therefore interfering with embryo development (3) to high 
level of postnatal death. Although Setdb1
Vav
 mice were produced with low frequencies, we 
managed to accumulate some interesting data about their phenotype.  
Setdb1
Vav
 mice were severely underdeveloped as they weighed 3 folds less than their 
littermate controls. Curiously, before weaning they had no problem in ambulation and ate 
normally, although their upper teeth were twisted and the lower ones were missing. After 
weaning, these mice needed a daily checking since they exhibited clear signs of weakness. For 
these reasons all mice used for analysis were taken before or soon after weaning to avoid that 
the hematopoietic phenotype was affected by other developmental problems. Noteworthy, 
Setdb1
Vav 
mice died within 5 weeks after birth, as a result of a strong developmental phenotype 
(Fig. 4.1 a). If early death was the results of hematopoietic defects or the consequence of 
expression leakage of the recombinase in other tissue, it still has to be determined.  
The essential role of Setdb1 during haematopoiesis became immediately evident when we 
examined at the main hematopoietic organs. In fact, curiously, these mice completely lacked 
the thymus while spleen size was comparable to the controls. Bone marrow cellularity was 
also significantly decreased; however this effect was imputable to the fact that mice were 
smaller. 
These macroscopic evidences were already suggestive of the pivotal role that Setdb1 exerts 
during hematopoietic development.  
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To better understand which subpopulations were affected in the absence of Setdb1 we 
analysed all main hematopoietic lineages by FACS analysis. Remarkably, Setdb1
Vav 
mice 
completely abrogated production of lymphoid cells, as demonstrated by total loss of T cells in 
thymus and missing B lymphocytes from bone marrow and spleen. Differently from the 
lymphoid lineage, the myeloid counterpart was overexpanded. In fact, either the bone marrow 
or the spleen were fully populated by myeloid-erythroid cells, indicating that Setdb1 depletion 
induce a clear bias towards myeloid differentiation at the expenses of the lymphoid lineage. 
Notably, these observations led us to think that if loss of Setdb1 induced toxicity due to 
aberrant expression of ERVs, all hematopoietic lineages should have been affected. However, 
this was not the case as myeloid-erythroid cells could tolerate Setdb1 depletion. Moreover, 
GMPs overexpansion also suggested that Setdb1 deficiency might push myeloid progenitor 
differentiation towards this direction.  
Although Setdb1
Vav 
haematopoiesis have pretty unique features, several mouse models which 
showed impaired lymphopoiesis, have a bias towards the myeloid lineage. For example, mice 
carrying Dnmt1 hypomorphic alleles also show myeloid-erythroid restriction and aberrant 
lymphopoiesis (Broske et al., 2009). Also, absence of Mef2c hijacked haematopoiesis to the 
myeloid fate, severely impairing development of B, T and NK cells. In both papers, the 
molecular reasons which caused the phenotype were both found in the aberrant expression of 
master regulators which drive hematopoietic lineage decision. Indeed, Mef2c is the upstream 
transcription factor which regulates the myeloid factor PU.1 while DNA hypomethylation 
leads to myeloid-erythroid genes derepression in HSCs (Stehling-Sun et al., 2009). 
Unfortunately, we are not yet aware about molecular details which could explain the myeloid-
erythroid expansion in Setdb1
Vav
 mice; however ongoing experiments will hopefully clarify 
soon why Setdb1 is so essential during haematopoiesis. 
Because defects in mature blood cells might results from aberrant differentiation of progenitor 
cells, we started tracking back all hematopoietic development to check earlier developmental 
stages. Because Setdb1
Vav 
mice did not generate any lymphoid cells we stained their direct 
precursor, the common lymphoid progenitors (CLPs). Surprisingly, these cells were regularly 
produced in Setdb1
Vav
 bone marrow, indicating that at this stage Setdb1 depletion abolished the 
establishment of B and T cell program.  
Next, we also analysed myeloid progenitor population in Setdb1
Vav 
bone marrow. Interestingly, 
common myeloid progenitors (CMPs), which can differentiate GMPs and MEPs, exhibited a 
clear preference towards GMPs differentiation, revealing that there is an evident trend to 
produce more Gr+ Mac+ cells already at the progenitor stage (Fig. 4.4 a bottom panel).  
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Next, we verified whether LSK hematopoietic stem cells population was affected. 
Remarkably, we found that already after weaning these cells were severely underrepresented 
within the lineage negative progenitors and that c-KIT expression was markedly decreased 
(Fig. 4.5). Disappearance of LSK indicates an evident collapse of the haematopoietic system 
as from this population all blood cells originate; however we still do not know whether this 
phenotype can be lethal for the mouse or if additional developmental defects impaired LSKs 
maintenance in the hematopoietic stem cell niches. Because Setdb1
Vav 
embryos or newly born 
Setdb1
Vav 
mice did not show detectable developmental defects, we also analysed 
haematopoiesis in younger mice and in the foetus. This analysis was also performed because 
we could not explain the presence of mature hematopoietic cells in 4 weeks old mice while 
LSKs were missing. In fact, since all hematopoietic system originate from these cells their 
complete absence in younger mice or in the foetus would have resulted in global 
hematopoietic failure. As shown in Fig. 4.5, LSKs were regularly produced in the foetal liver 
or in 2-3 weeks old bone marrow, indicating that somehow Setdb1 deficient LSKs can held 
hematopoietic development till the 4
th
 week of age. Importantly, also CLPs, CMPs, MEPs and 
GMPs were checked in younger mice and all phenotype observed in 4 weeks old mice were 
confirmed as any B or T cell population was detectable and mature and progenitor myeloid 
cells were overrepresented (data not shown). Preliminary analyses to prove the cell intrinsic 
nature of the phenotype have been done in vitro using MethoCult 3630 and 3434 which 
promote lymphoid and myeloid differentiation, respectively. Setdb1
Vav
 lineage negative 
progenitor cells failed to produce pre B cell colonies while they managed to produce some 
myeloid colonies (Fig. 4.4 d). This experiment suggested that the inability to generate 
lymphoid cells in the absence of Setdb1 might be due to cell-intrinsic defects, however the 
myeloid overexpansion which characterize Setdb1
Vav 
mice was not reproducible in vitro, since 
low amount of myeloid colonies were detectable. This effect could be attributed to the fact that 
we used progenitors from 4 weeks old mice; therefore LSKs function could have been already 
compromised. Colony formation assay for both myeloid and lymphoid potential will be 
repeated using Lin- progenitors derived from younger bone marrows where LSK population is 
still present. More importantly, we will also perform bone marrow transplantation experiments 
to test in vivo whether SETDB1 is intrinsically required for hematopoietic development.  
Unfortunately, the implementation of this experiment it will be particularly challenging since 
the number of CD4 CD8 depleted bone marrow cells that we can get from young Setdb1
Vav
 
mice is very limited. Alternatively, we could also inject mice with 5-FU to get progenitors out 
of Setdb1
Vav 
bone marrows. This approach enriches for multipotent cells and gives the 
advantage to use lower amount cells for reconstitution. However, injection of Setdb1
Vav
 mice, 
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even at young age might be really harmful considering the strong developmental defects that 
these animals exhibit. Nevertheless, we hope to perform bone marrow transplantation as soon 
as enough biological material will be available. Meanwhile, we crossed Setdb1
Vav
 mice with 
VavBcl2 transgenic mice with the intent to rescue eventual apoptosis occurring in upon Setdb1 
depletion.  Thus far, we managed to analyse only one Setdb1
Vav
;
 
VavBcl2 mouse. Interestingly, 
this animal clearly recovered the developmental weaknesses characteristic of Setdb1
Vav 
mice, 
indicating that apoptotic rescue can improve Setdb1
Vav 
  mouse fitness. Additionally, we were 
able to age this mouse for 3 months and, during this period, no evident signs of weakness were 
detectable. To verify whether we could confirm the Setdb1
Vav
 hematopoietic phenotypes we 
also analysed Setdb1
Vav
;
 
VavBcl2 by FACS. Remarkably, all defects detected in Setdb1
Vav
 mice 
were reproduced in Setdb1
Vav
;
 
VavBcl2 animals. Indeed, lymphoid lineage differentiation was 
still not occurring and myeloid cells were clearly overexpanded. However; differently from 
Setdb1
Vav 
mice, Setdb1
Vav
;
 
VavBcl2 transgenic LSKs were still present in 3 months old animals 
although, as shown in the FACS plot in Fig. 4.6, the marker distribution on the cell surface 
was clearly perturbed.  
 
 
Figure 4.6 LSK population from 3 months old Setdb1Vav; VavBcl2 mice 
Hematopoietic stem cells were identified by FACS analysis as Lin-, Sca+, c-kit+ (LSK).  
 
Significantly, more Setdb1
Vav
;
 
VavBcl2 mice have to be produced to confirm our preliminary 
data; yet these first observations encouraged us to believe that Setdb1 is strongly required to 
balance lineage decision during hematopoietic development.   
All data discussed so far are purely descriptive and all the assumptions we can make about the 
molecular mechanism which hides behind these phenotypes, remain merely speculative. 
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Therefore, to elucidate the origin of all these defects, we planned to perform RNA-Seq 
analysis on sorted hematopoietic progenitors to check transcriptional changes occurring upon 
Setdb1 depletion. Moreover, we could take advantage of the increased viability of Setdb1
Vav
;
 
VavBcl2 mice to perform aging experiment which will allow observing possible tumour onset 
due to persistent production of myeloid cells.  
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 Appendix 5
5.1 Appendix (Results I) 
 
Table 5.1 Deregulated genes in Suv420h2 ko splenic B cells (collaboration with Patrick Kremer 
laboratory; Gene Center, Munich) 
 
AffyID SYMBOL Fold change Deregulation 
10607950 NA 3.136436667 up 
10340272 NA 1.614476667 up 
10576807 Cd209d 1.437966667 up 
10403006 NA 1.434246667 up 
10549635 Lilra5 1.405286667 up 
10474419 Lgr4 1.32121 up 
10407387 Gm7120 1.302866667 up 
10608711 Erdr1 1.293216667 up 
10489721 IAP 1.28211 up 
10528205 IAP 1.28211 up 
10484355 IAP 1.28211 up 
10363005 IAP 1.28211 up 
10582983 IAP 1.28211 up 
10512463 IAP 1.28211 up 
10543029 IAP 1.28211 up 
10528165 IAP 1.28211 up 
10422247 IAP 1.28211 up 
10345436 IAP 1.28211 up 
10589974 IAP 1.28211 up 
10527425 IAP 1.28211 up 
10522742 IAP 1.28211 up 
10500527 IAP 1.28211 up 
10581009 IAP 1.28211 up 
10568534 NA 1.28211 up 
10496336 IAP 1.28211 up 
10356762 IAP 1.28211 up 
10476399 NA 1.28211 up 
10607429 IAP 1.28211 up 
10410927 IAP 1.28211 up 
10374352 NA 1.28211 up 
10457667 Gm4638 1.28211 up 
10586863 IAP 1.28211 up 
10416698 NA 1.28211 up 
10468487 IAP 1.28211 up 
10483161 NA 1.28211 up 
10469127 IAP 1.28211 up 
10603803 IAP 1.28211 up 
10541129 IAP 1.28211 up 
10574434 IAP 1.28211 up 
10485355 Gm4638 1.28211 up 
10346222 IAP 1.28211 up 
10497327 IAP 1.28211 up 
10374183 Gm4638 1.28211 up 
10565598 IAP 1.28211 up 
10395275 IAP 1.28211 up 
10416696 NA 1.28211 up 
10427389 IAP 1.28211 up 
10603549 IAP 1.28211 up 
10478746 IAP 1.28211 up 
10496167 IAP 1.28211 up 
10448230 IAP 1.28211 up 
10540531 IAP 1.28211 up 
10375324 IAP 1.28211 up 
10363561 IAP 1.28211 up 
10357298 IAP 1.28211 up 
10359642 IAP 1.28211 up 
10424377 Gm4638 1.28211 up 
10574432 Gm4638 1.28211 up 
10423971 Pkhd1l1 1.046233333 down 
10338989 NA 1.059156667 down 
10542172 Clec1b 1.059886667 down 
10338966 NA 1.06161 down 
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10344207 NA 1.063043333 down 
10342917 NA 1.063793333 down 
10375055 F830116E18Rik 1.06413 down 
10570894 Ank1 1.065766667 down 
10338577 NA 1.070986667 down 
10344331 NA 1.07137 down 
10339167 NA 1.072073333 down 
10507500 Slc6a9 1.07515 down 
10560624 Apoe 1.07903 down 
10343453 NA 1.080766667 down 
10339089 NA 1.08169 down 
10545086 Snca 1.084823333 down 
10344100 NA 1.089166667 down 
10341384 NA 1.091923333 down 
10342786 NA 1.102373333 down 
10342114 NA 1.104233333 down 
10341669 NA 1.108736667 down 
10362428 Trdn 1.110586667 down 
10344113 NA 1.111903333 down 
10459391 Fech 1.119923333 down 
10473356 Ube2l6 1.126663333 down 
10342748 NA 1.130133333 down 
10538459 Aqp1 1.140773333 down 
10481627 Lcn2 1.147273333 down 
10504692 Tmod1 1.14755 down 
10339273 NA 1.148993333 down 
10473349 Ypel4 1.150043333 down 
10342475 NA 1.166316667 down 
10342827 NA 1.16659 down 
10391649 Slc4a1 1.167036667 down 
10400483 Slc25a21 1.201346667 down 
10339166 NA 1.21424 down 
10338617 NA 1.21689 down 
10338332 NA 1.227113333 down 
10466659 Gda 1.229463333 down 
10567564 Cdr2 1.236206667 down 
10515848 Ermap 1.239373333 down 
10539080 St3gal5 1.240966667 down 
10461979 Aldh1a1 1.24488 down 
10339567 NA 1.252913333 down 
10338462 NA 1.258173333 down 
10602372 Alas2 1.262343333 down 
10338546 NA 1.27335 down 
10344068 NA 1.27363 down 
10340865 NA 1.27596 down 
10341388 NA 1.279896667 down 
10537179 Bpgm 1.293256667 down 
10429968 NA 1.29663 down 
10344233 NA 1.30486 down 
10474229 Cd59a 1.310603333 down 
10341472 NA 1.33807 down 
10342272 NA 1.339823333 down 
10340845 NA 1.362546667 down 
10338377 NA 1.36328 down 
10549700 Suv420h2 1.369103333 down 
10490923 Car2 1.370346667 down 
10341301 NA 1.38235 down 
10351905 Spna1 1.3849 down 
10342791 NA 1.407726667 down 
10339230 NA 1.415156667 down 
10342166 NA 1.42899 down 
10589535 Ngp 1.430423333 down 
10607972 Kdm5d 1.430866667 down 
10608001 Eif2s3y 1.431806667 down 
10399710 Rsad2 1.43485 down 
10340162 NA 1.44882 down 
10344372 NA 1.450243333 down 
10445046 Trim10 1.460053333 down 
10544383 Kel 1.470013333 down 
10534389 Cldn13 1.480493333 down 
10608710 Ahsp 1.48214 down 
10509002 Rhd 1.48334 down 
10419151 Ear1 1.483993333 down 
10608138 Ddx3y 1.52976 down 
Appendix 
 
88 
10338428 NA 1.534223333 down 
10499062 Fhdc1 1.56721 down 
10342665 NA 1.58273 down 
10343713 NA 1.59116 down 
10445192 Rhag 1.61186 down 
10486664 Epb4.2 1.63213 down 
10451670 Tspo2 1.633906667 down 
10338259 NA 1.64597 down 
10550332 Slc1a5 1.694356667 down 
10573054 Gypa 1.7213 down 
10338649 NA 1.776523333 down 
10608107 Uty 1.779483333 down 
10549655 Eps8l1 1.803306667 down 
10561055 Ceacam2 3.841073333 down 
                  
5.2 Appendix (Results II) 
 
Table 5.2 Deregulated genes in Setdb1
Mb1 pro B cells 
 
Gene Control cko Ratio Regulated 
Stfa1 0.0 3.2 3234.8 up 
Amd2 0.0 9.9 3049.8 up 
2410003L11Rik 0.0 2.5 2480.2 up 
St6galnac5 0.0 3.9 191.7 up 
Tubb3 2.0 211.7 106.4 up 
Tdrd9 0.0 4.3 93.1 up 
Mc1r 0.2 3.8 24.1 up 
Acoxl 0.2 3.4 20.0 up 
Cbr3 0.4 6.6 18.4 up 
Nrg4 0.9 13.4 15.2 up 
Gm5483 0.2 2.3 13.9 up 
Def8 4.5 53.0 11.9 up 
Lalba 8.2 85.7 10.4 up 
Stfa3 0.5 5.1 10.3 up 
BC100530 0.6 5.6 9.7 up 
AI506816 63.3 599.7 9.5 up 
Fcgr2b 12.4 95.4 7.7 up 
Fbln1 0.3 2.6 7.4 up 
Bglap 0.5 3.2 7.0 up 
4921508A21Rik 3.4 23.1 6.8 up 
Stfa2 0.5 3.2 6.7 up 
Stag3 2.7 17.0 6.4 up 
Rps4y2 19.9 120.3 6.1 up 
Dmc1 0.6 3.3 6.0 up 
Rims3 0.8 4.5 5.9 up 
Lrrc32 0.5 3.0 5.9 up 
2810474O19Rik 6.5 37.2 5.7 up 
1700030C10Rik 1.3 7.4 5.6 up 
Rpl39l 3.4 18.8 5.5 up 
Akap5 1.0 5.3 5.5 up 
Cd209c 1.3 7.1 5.4 up 
Ly6k 5.2 27.9 5.3 up 
Clec2g 0.6 2.9 5.2 up 
Thy1 15.0 76.9 5.1 up 
Cldn4 7.0 35.8 5.1 up 
Tmem40 0.5 2.6 5.1 up 
1700097N02Rik 20.8 90.9 4.4 up 
Pnp2 5.7 24.2 4.3 up 
Gstp2 1.4 5.8 4.2 up 
Tmem90a 1.5 6.4 4.1 up 
Apoc2 0.9 3.5 3.9 up 
Csf1r 0.7 2.9 3.9 up 
Fbxo17 2.4 9.3 3.8 up 
H19 0.8 2.9 3.8 up 
Myl9 1.1 3.9 3.7 up 
Olfr1033 2.3 8.5 3.7 up 
Rffl 7.3 26.8 3.7 up 
2310039L15Rik 1.8 6.6 3.6 up 
Gm12505 2.9 10.1 3.5 up 
Trim24 10.4 36.4 3.5 up 
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Rbm44 0.9 3.1 3.5 up 
BC048943 1.9 6.6 3.5 up 
Gm5111 6.1 20.6 3.4 up 
Serpina3f 5.3 17.5 3.3 up 
A130040M12Rik 201.2 649.6 3.2 up 
Apoe 19.3 62.2 3.2 up 
Tnf 2.0 6.5 3.2 up 
Lta 2.9 9.1 3.1 up 
Vpreb2 242.1 729.5 3.0 up 
Ephb2 2.6 7.9 3.0 up 
Rnf187 228.3 665.5 2.9 up 
Pglyrp2 1.8 5.3 2.9 up 
Ckap4 7.0 20.3 2.9 up 
S100a4 7.2 20.8 2.9 up 
Cd244 2.3 6.4 2.8 up 
Wdr92 8.7 23.9 2.8 up 
Stfa2l1 1.3 3.5 2.7 up 
Padi3 7.5 20.0 2.7 up 
Ccl6 1.4 3.7 2.7 up 
Prnp 4.5 12.0 2.7 up 
3300005D01Rik 3.2 8.5 2.6 up 
Snhg9 184.9 487.5 2.6 up 
1700102H20Rik 2.3 5.9 2.6 up 
Clcn5 2.0 5.4 2.6 up 
Derl3 3.5 9.1 2.6 up 
Ncs1 1.6 4.1 2.6 up 
D10Wsu102e 12.3 31.4 2.6 up 
Fcrla 65.2 166.2 2.5 up 
BC024386 2.0 5.0 2.5 up 
Cacna1h 1.4 3.6 2.5 up 
Atp1b3 207.9 523.6 2.5 up 
Cst7 3.6 9.1 2.5 up 
Nr1d1 6.6 16.6 2.5 up 
Flt3 6.6 16.6 2.5 up 
Pde8a 1.9 4.7 2.5 up 
Fgd2 6.9 17.3 2.5 up 
Sema3g 2.9 7.3 2.5 up 
Padi2 4.0 9.9 2.5 up 
Socs2 16.4 40.1 2.5 up 
Zcwpw1 6.4 15.6 2.4 up 
Lst1 10.2 24.6 2.4 up 
Sh2b2 2.5 6.0 2.4 up 
Prr5 18.1 42.5 2.3 up 
Fam69b 6.0 14.0 2.3 up 
C030037D09Rik 2.9 6.7 2.3 up 
0610010F05Rik 1.7 4.0 2.3 up 
Gm16062 1.7 4.0 2.3 up 
5730469M10Rik 3.5 7.9 2.3 up 
Bcl2l11 6.6 15.3 2.3 up 
Cyp4f18 55.6 126.5 2.3 up 
Cebpb 3.1 7.1 2.3 up 
Hcst 12.0 26.6 2.2 up 
Pilra 2.0 4.3 2.2 up 
Aig1 1.9 4.2 2.2 up 
Ptk7 1.7 3.7 2.2 up 
I730030J21Rik 3.0 6.5 2.2 up 
Alyref2 22.4 49.0 2.2 up 
Poli 3.4 7.4 2.2 up 
Ston1 2.8 6.1 2.2 up 
Vill 5.2 11.2 2.2 up 
Fads3 2.3 5.0 2.1 up 
Fanca 7.4 15.5 2.1 up 
Tdrkh 2.6 5.6 2.1 up 
Relt 6.0 12.5 2.1 up 
1810044D09Rik 10.7 22.3 2.1 up 
Dnahc8 3.1 6.4 2.1 up 
Pnp 54.8 113.8 2.1 up 
Ebpl 6.8 14.1 2.1 up 
Iqcg 2.2 4.5 2.1 up 
Cish 14.3 29.5 2.1 up 
Aipl1 2.5 5.1 2.1 up 
Deptor 2.1 4.3 2.1 up 
Ahsa2 6.4 13.1 2.0 up 
Ifitm6 4.5 9.2 2.0 up 
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Csf2rb 5.4 11.1 2.0 up 
Grap2 4.4 8.9 2.0 up 
Apobec2 3.8 7.8 2.0 up 
2610524H06Rik 17.4 35.4 2.0 up 
Bok 29.4 59.3 2.0 up 
Myo10 2.7 5.4 2.0 up 
Phlda3 4.6 2.3 0.5 down 
Tcn2 17.3 8.6 0.5 down 
Sik1 27.0 13.4 0.5 down 
H2-T24 4.4 2.2 0.5 down 
Rpl3l 10.6 5.2 0.5 down 
Hspa12b 8.4 4.1 0.5 down 
Tctn1 14.6 7.2 0.5 down 
Calcoco1 20.6 10.1 0.5 down 
4930562F07Rik 18.7 9.1 0.5 down 
Irf7 9.2 4.5 0.5 down 
Rtp4 8.3 4.0 0.5 down 
Comt 99.4 48.2 0.5 down 
Tubb2b 12.5 6.0 0.5 down 
Btg1 52.5 25.4 0.5 down 
Slc7a7 10.4 5.0 0.5 down 
Hlx 8.2 3.9 0.5 down 
2200002D01Rik 17.6 8.3 0.5 down 
Hvcn1 41.9 19.7 0.5 down 
Relb 9.5 4.4 0.5 down 
Samhd1 14.3 6.6 0.5 down 
2410066E13Rik 6.3 2.9 0.5 down 
Bmf 23.6 10.9 0.5 down 
Rapgefl1 5.3 2.4 0.5 down 
Nuak1 4.8 2.2 0.5 down 
Arntl 63.5 29.0 0.5 down 
Tcf7 10.1 4.6 0.5 down 
Malat1 42.5 19.1 0.4 down 
Tnk2 12.0 5.4 0.4 down 
E230016M11Rik 5.1 2.3 0.4 down 
Tbx6 10.2 4.5 0.4 down 
Camk2b 15.6 6.9 0.4 down 
Rab6b 4.7 2.1 0.4 down 
Lmo4 65.9 29.1 0.4 down 
1700027J07Rik 12.0 5.3 0.4 down 
Zfp296 10.6 4.7 0.4 down 
Ets2 4.9 2.1 0.4 down 
Tcp11l2 15.6 6.8 0.4 down 
Eya2 8.2 3.6 0.4 down 
Otud1 8.5 3.7 0.4 down 
Bcl6 4.6 2.0 0.4 down 
Slit1 6.4 2.8 0.4 down 
Crip2 14.7 6.3 0.4 down 
Gchfr 4.1 1.8 0.4 down 
Steap4 13.7 5.7 0.4 down 
Apbb1 12.1 5.0 0.4 down 
Chrnb1 5.8 2.4 0.4 down 
Cmtm8 6.1 2.5 0.4 down 
Plekhg5 4.4 1.8 0.4 down 
Emid1 14.9 6.1 0.4 down 
Parvb 10.6 4.3 0.4 down 
Stxbp1 5.7 2.3 0.4 down 
Ankrd33b 14.9 6.0 0.4 down 
Phlda1 3.4 1.4 0.4 down 
Cass4 4.5 1.8 0.4 down 
Capsl 7.3 2.9 0.4 down 
Col27a1 11.1 4.3 0.4 down 
Rab19 5.2 2.0 0.4 down 
Slc2a8 4.3 1.6 0.4 down 
Clec2i 3.3 1.2 0.4 down 
Egr1 9.1 3.4 0.4 down 
Mt1 34.2 12.8 0.4 down 
Usp18 3.3 1.2 0.4 down 
Mgst1 31.7 11.7 0.4 down 
Cd55 3.7 1.4 0.4 down 
Zbp1 7.7 2.8 0.4 down 
Socs1 10.8 3.9 0.4 down 
Neurl3 6.8 2.5 0.4 down 
Ly6d 222.9 80.7 0.4 down 
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Rnase6 6.5 2.3 0.4 down 
Ephx1 8.4 3.0 0.4 down 
Kdm5b 6.7 2.3 0.4 down 
Ccr7 9.2 3.2 0.3 down 
Klrb1c 3.6 1.2 0.3 down 
Hdac11 11.5 3.9 0.3 down 
Gm16386 4.1 1.4 0.3 down 
Neat1 21.4 7.2 0.3 down 
Gpr155 3.4 1.1 0.3 down 
Asb2 11.3 3.7 0.3 down 
Rgs2 20.9 6.7 0.3 down 
Amd1 10.2 3.3 0.3 down 
Bcl3 4.6 1.5 0.3 down 
Maf 10.4 3.3 0.3 down 
Mt2 7.9 2.4 0.3 down 
Enpep 5.3 1.6 0.3 down 
H2-Q8 27.0 7.8 0.3 down 
Klf2 47.7 13.8 0.3 down 
Efhd1 3.2 0.9 0.3 down 
Dtx1 3.1 0.9 0.3 down 
2010300C02Rik 15.6 4.4 0.3 down 
H2-Eb1 11.7 3.2 0.3 down 
Gh 3.5 1.0 0.3 down 
Trib2 6.8 1.8 0.3 down 
Cd72 133.3 34.6 0.3 down 
Apobec1 16.6 4.2 0.3 down 
Glcci1 7.7 1.9 0.2 down 
Ntng2 3.3 0.8 0.2 down 
Tmem163 3.7 0.9 0.2 down 
Aim1 2.7 0.6 0.2 down 
H2-Aa 16.0 3.5 0.2 down 
Zap70 6.0 1.3 0.2 down 
Kcna5 2.6 0.5 0.2 down 
Rgs10 5.6 1.1 0.2 down 
Nrgn 70.4 13.8 0.2 down 
Srpk3 5.9 1.1 0.2 down 
Inppl1 3.4 0.6 0.2 down 
Hck 8.2 1.3 0.2 down 
H2-Q9 3.3 0.5 0.2 down 
Scd1 6.3 1.0 0.2 down 
Cpm 9.7 1.5 0.2 down 
Cd74 123.7 18.2 0.1 down 
Cd38 5.3 0.8 0.1 down 
Slc45a3 2.6 0.4 0.1 down 
Heyl 16.8 2.2 0.1 down 
Cd40 4.0 0.5 0.1 down 
Sertad4 10.0 1.2 0.1 down 
Speer2 7.1 0.9 0.1 down 
Il2ra 2.5 0.3 0.1 down 
H2-Q6 26.9 3.2 0.1 down 
H2-Q7 20.9 2.3 0.1 down 
Gas7 9.9 1.1 0.1 down 
Serpina3n 2.3 0.2 0.1 down 
Dlx1 3.0 0.3 0.1 down 
Cacna1e 3.7 0.4 0.1 down 
Fcrl6 10.0 0.9 0.1 down 
Egr3 2.4 0.2 0.1 down 
Ms4a1 7.5 0.7 0.1 down 
Adam19 9.0 0.8 0.1 down 
Reln 2.7 0.2 0.1 down 
Faim3 17.8 1.1 0.1 down 
Ikzf3 16.7 1.0 0.1 down 
Polm 15.6 0.9 0.1 down 
Col5a3 7.7 0.3 0.0 down 
Fcer2a 2.8 0.1 0.0 down 
Grb7 19.1 0.6 0.0 down 
Cd2 10.0 0.3 0.0 down 
Dlx1as 2.4 0.0 0.0 down 
 
 
Table 5.3 Deregulated repetitive elements in Setdb1
Mb1 pro B cells 
 
Appendix 
 
92 
Repeat Family Average 
Length 
Copie
s 
control 
reads 
ko reads control 
RPKM 
ko 
RPKM 
ratio 
MuLV-int|LTR|ERV1 779.9 392 5333.621 82922.696 0.0184 0.2722 14.7585 
RLTR3_Mm|LTR|ERVK 382.3 31 227.593 1691.392 0.0202 0.1437 7.1133 
MMTV-int|LTR|ERVK 980.5 35 275.819 1939.206 0.0090 0.0575 6.3634 
RLTR6C_Mm|LTR|ERV1 411.7 102 156.523 970.806 0.0047 0.0241 5.1018 
MER49|LTR|ERV1 84.6 7 0 2.406 0.0010 0.0051 5.0628 
MMVL30-int|LTR|ERV1 720.5 956 4071.286 13848.719 0.0069 0.0211 3.0540 
LTRIS4B|LTR|ERV1 317.5 71 0 45.713 0.0010 0.0030 3.0279 
MER66-int|LTR|ERV1 117.7 23 5.076 16.842 0.0029 0.0072 2.5117 
RLTR50A|LTR|ERVK 291.9 85 1.692 37.292 0.0011 0.0025 2.3432 
RLTR4_Mm|LTR|ERV1 466.6 239 3497.651 8070.801 0.0324 0.0734 2.2671 
RLTR6_Mm|LTR|ERV1 540 237 439.956 1049 0.0044 0.0092 2.0724 
RNLTR23|LTR|ERVK 99.4 5 1.692 3.609 0.0044 0.0083 1.8757 
MER50|LTR|ERV1 85.2 13 1.692 3.609 0.0025 0.0043 1.6847 
Charlie17|DNA|hAT-Charlie 233.2 134 16.921 40.901 0.0015 0.0023 1.4978 
RLTR30D_RN|LTR|ERV1 278.3 64 285.125 434.276 0.0170 0.0254 1.4924 
RLTR6-int|LTR|ERV1 1871.2 1220 1302.101 2929.259 0.0016 0.0023 1.4539 
IAPLTR4|LTR|ERVK 322.3 663 68.532 196.086 0.0013 0.0019 1.4520 
MER95|LTR|ERV1 204.5 54 0 4.812 0.0010 0.0014 1.4358 
MADE2|DNA|TcMar-Mariner 71.1 208 2.538 9.624 0.0012 0.0017 1.4090 
ERVB4_2-I_MM-int|LTR|ERVK 1530.8 313 28.766 233.378 0.0011 0.0015 1.4029 
Eulor2A|DNA?|DNA? 149.2 41 0 2.406 0.0010 0.0014 1.3933 
LTR86B2|LTR|ERVL 184.8 36 1.692 4.812 0.0013 0.0017 1.3739 
RNERVK23-int|LTR|ERVK 180.7 45 180.213 250.22 0.0232 0.0318 1.3717 
MamRep1894|DNA|hAT 92.2 36 0 1.203 0.0010 0.0014 1.3624 
L1ME3D|LINE|L1 234.3 323 27.074 63.758 0.0014 0.0018 1.3570 
IAPEY4_I-int|LTR|ERVK 808.6 521 178.521 388.563 0.0014 0.0019 1.3502 
UCON12A|Unknown|Unknown 150 23 0 1.203 0.0010 0.0013 1.3487 
RLTR4_MM-int|LTR|ERV1 1328.6 432 25123.183 34078.051 0.0448 0.0604 1.3485 
X9_LINE|LINE|L1? 74.3 52 37.227 50.525 0.0106 0.0141 1.3236 
Charlie16a|DNA|hAT-Charlie 163.2 197 20.306 32.48 0.0016 0.0020 1.2321 
RMER16B3|LTR|ERVK 260.8 101 0 6.015 0.0010 0.0012 1.2284 
Charlie6|DNA|hAT-Charlie 262.6 148 26.228 39.698 0.0017 0.0020 1.2069 
RLTR45|LTR|ERVK 451.2 1557 665.011 925.093 0.0019 0.0023 1.1902 
MER136|DNA|DNA 185.5 23 8.461 10.827 0.0030 0.0035 1.1859 
MMERGLN-int|LTR|ERV1 1477.2 856 1192.112 1643.272 0.0019 0.0023 1.1837 
MER106B|DNA|hAT-Charlie 183.4 242 13.537 24.06 0.0013 0.0015 1.1817 
RLTR48B|LTR|ERV1 295.4 110 21.152 30.075 0.0017 0.0019 1.1663 
Tigger8|DNA|TcMar-Tigger 229 121 177.675 211.725 0.0074 0.0086 1.1658 
RLTR31_Mm|LTR|ERVK 377.4 145 21.152 33.683 0.0014 0.0016 1.1652 
RLTR8|LTR|ERVK 311 241 10.153 24.06 0.0011 0.0013 1.1634 
MMETn-int|LTR|ERVK 1515.5 980 550.791 879.379 0.0014 0.0016 1.1614 
Charlie18a|DNA|hAT-Charlie 153.7 242 41.457 54.134 0.0021 0.0025 1.1612 
Chap1_Mam|DNA|hAT-Charlie 149.8 153 32.151 40.901 0.0024 0.0028 1.1589 
LTR86B1|LTR|ERVL 174.8 49 5.076 7.218 0.0016 0.0018 1.1570 
Kanga1b|DNA|TcMar-Tc2 203.1 121 0.846 4.812 0.0010 0.0012 1.1560 
LTR16D2|LTR|ERVL 166.2 65 1.692 3.609 0.0012 0.0013 1.1534 
RLTR19-int|LTR|ERVK 335.5 2407 1195.496 1502.523 0.0025 0.0029 1.1533 
LTRIS5|LTR|ERV1 317.3 85 1.692 6.015 0.0011 0.0012 1.1508 
RLTR20D|LTR|ERVK 265.4 777 65.147 105.862 0.0013 0.0015 1.1500 
MER4B-int|LTR|ERV1 184.9 52 0.846 2.406 0.0011 0.0013 1.1491 
UCON5|Unknown|Unknown 144.7 56 0 1.203 0.0010 0.0011 1.1485 
L1M2b|LINE|L1 127 16 18.614 21.654 0.0102 0.0117 1.1472 
MER91C|DNA|hAT-Tip100 89.4 110 0.846 2.406 0.0011 0.0012 1.1461 
ERVB7_1-LTR_MM|LTR|ERVK 304.8 770 57.533 99.847 0.0012 0.0014 1.1448 
Helitron3Na_Mam|RC|Helitron 179.9 191 7.615 13.233 0.0012 0.0014 1.1338 
L1M3f|LINE|L1 259.4 100 3.384 7.218 0.0011 0.0013 1.1307 
IAPEY4_LTR|LTR|ERVK 313.8 95 5.076 9.624 0.0012 0.0013 1.1304 
MER112|DNA|hAT-Charlie 139.2 358 26.228 36.089 0.0015 0.0017 1.1296 
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MER97c|DNA|hAT-Tip100 297.8 64 0 2.406 0.0010 0.0011 1.1262 
MMERGLN_LTR|LTR|ERV1 384 435 48.226 74.585 0.0013 0.0014 1.1224 
RMER16C|LTR|ERVK 288.6 190 29.612 39.698 0.0015 0.0017 1.1194 
MLTR18_MM|LTR|ERVK 348.2 427 18.614 38.495 0.0011 0.0013 1.1188 
Tigger9b|DNA|TcMar-Tigger 217.9 360 6.769 16.842 0.0011 0.0012 1.1182 
IAPLTR2a|LTR|ERVK 386.8 627 49.918 84.209 0.0012 0.0013 1.1173 
LTR85c|LTR|Gypsy? 175.3 119 0 2.406 0.0010 0.0011 1.1153 
ERVB4_1-I_MM-int|LTR|ERVK 1351.9 296 8.461 55.337 0.0010 0.0011 1.1147 
LTR90B|LTR|LTR 151.6 91 0.846 2.406 0.0011 0.0012 1.1065 
MER113B|DNA|hAT-Charlie 158.7 72 0 1.203 0.0010 0.0011 1.1053 
Tigger9a|DNA|TcMar-Tigger 181.1 200 4.23 8.421 0.0011 0.0012 1.1036 
MER54A|LTR|ERVL 272.9 273 5.076 13.233 0.0011 0.0012 1.1025 
ERVB2_1-I_MM-int|LTR|ERVK 541.3 83 14.383 20.451 0.0013 0.0015 1.1023 
RLTR31_Mur|LTR|ERVK 391.1 354 27.92 44.51 0.0012 0.0013 1.0997 
MTB-int|LTR|ERVL-MaLR 698.8 592 204.749 265.859 0.0015 0.0016 1.0988 
RLTR26C_MM|LTR|ERVK 364.8 454 61.763 84.209 0.0014 0.0015 1.0987 
L1ME5|LINE|L1 271 146 0.846 4.812 0.0010 0.0011 1.0981 
LTR85a|LTR|Gypsy? 160 234 0 3.609 0.0010 0.0011 1.0964 
RLTRETN_Mm|LTR|ERVK 310 1355 118.45 169.62 0.0013 0.0014 1.0950 
MamGyp-int|LTR|Gypsy 415.8 28 25.382 28.872 0.0032 0.0035 1.0943 
MURVY-int|LTR|ERV1 3584.3 544 8.461 186.462 0.0010 0.0011 1.0909 
Tigger16a|DNA|TcMar-Tigger 169.2 290 5.922 10.827 0.0011 0.0012 1.0892 
MER90a|LTR|ERV1 229 581 10.153 22.857 0.0011 0.0012 1.0887 
RLTR10F|LTR|ERVK 282.2 482 17.767 31.278 0.0011 0.0012 1.0879 
L1MCa|LINE|L1 276.3 3565 346.042 458.336 0.0014 0.0015 1.0844 
RLTR13F|LTR|ERVK 602.6 98 10.999 16.842 0.0012 0.0013 1.0834 
MER73|LTR|ERVL 239.5 135 0.846 3.609 0.0010 0.0011 1.0833 
RLTR1C|LTR|ERV1 447.1 697 19.46 46.916 0.0011 0.0012 1.0829 
RLTR9A2|LTR|ERVK 313.6 227 6.769 13.233 0.0011 0.0012 1.0829 
MER126|DNA|DNA 155.2 118 0.846 2.406 0.0010 0.0011 1.0814 
RLTR46B|LTR|ERVK 337 73 9.307 12.03 0.0014 0.0015 1.0803 
RLTR35B_MM|LTR|ERVL 262.2 492 16.075 27.669 0.0011 0.0012 1.0799 
LTR87|LTR|ERVL? 191.6 214 2.538 6.015 0.0011 0.0011 1.0799 
Tigger17|DNA|TcMar-Tigger 169.5 315 22.844 28.872 0.0014 0.0015 1.0791 
RLTR20A1|LTR|ERVK 238.3 98 5.076 7.218 0.0012 0.0013 1.0753 
MER45R|DNA|hAT-Tip100 180.3 375 4.23 9.624 0.0011 0.0011 1.0751 
RLTR30D_MM|LTR|ERV1 344.4 268 5.922 13.233 0.0011 0.0011 1.0744 
RLTR1B|LTR|ERV1 418.2 893 34.689 64.961 0.0011 0.0012 1.0742 
RLTR12H|LTR|ERVK 341.4 188 6.769 12.03 0.0011 0.0012 1.0741 
Tigger18a|DNA|TcMar-Tigger 241.1 240 1.692 6.015 0.0010 0.0011 1.0726 
RMER17A-int|LTR|ERVK 365.7 409 13.537 25.263 0.0011 0.0012 1.0719 
MER44A|DNA|TcMar-Tigger 211.7 661 52.456 66.164 0.0014 0.0015 1.0713 
ERVB4_2-LTR_MM|LTR|ERVK 468.8 144 13.537 19.248 0.0012 0.0013 1.0705 
MER88|LTR|ERVL 219 58 2.538 3.609 0.0012 0.0013 1.0703 
RLTR1A2_MM|LTR|ERV1 422.1 406 20.306 33.683 0.0011 0.0012 1.0698 
MER102a|DNA|hAT-Charlie 173.9 386 71.07 80.6 0.0021 0.0022 1.0690 
Charlie21a|DNA|hAT-Charlie 250.5 174 1.692 4.812 0.0010 0.0011 1.0689 
MER77B|LTR|ERVL 247.5 505 10.153 19.248 0.0011 0.0012 1.0673 
LTR77|LTR|ERV1 117.8 38 0.846 1.203 0.0012 0.0013 1.0671 
RLTR12BD_Mm|LTR|ERVK 293.5 883 96.452 120.298 0.0014 0.0015 1.0671 
MMERVK10C-int|LTR|ERVK 879.3 3230 153.139 350.068 0.0011 0.0011 1.0658 
L4_A_Mam|LINE|RTE-X 186.8 630 17.767 26.466 0.0012 0.0012 1.0642 
LTR78B|LTR|ERV1 175.7 405 22.844 28.872 0.0013 0.0014 1.0641 
RLTR43C|LTR|ERVK 273.9 264 16.075 21.654 0.0012 0.0013 1.0631 
ERVB4_3-LTR_MM|LTR|ERVK 424.9 137 0 3.609 0.0010 0.0011 1.0620 
RLTR19A|LTR|ERVK 292 153 10.999 14.436 0.0012 0.0013 1.0617 
AmnSINE1|SINE|Deu 96.2 1311 111.681 126.313 0.0019 0.0020 1.0615 
RLTR30E_MM|LTR|ERV1 364.4 320 16.075 24.06 0.0011 0.0012 1.0602 
L1M8|LINE|L1 251.3 201 1.692 4.812 0.0010 0.0011 1.0598 
MLT1M|LTR|ERVL-MaLR 183.8 212 29.612 33.683 0.0018 0.0019 1.0594 
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RMER16B2|LTR|ERVK 282.4 329 8.461 14.436 0.0011 0.0012 1.0589 
MER102b|DNA|hAT-Charlie 179.2 507 27.92 34.886 0.0013 0.0014 1.0586 
ETnERV-int|LTR|ERVK 1280.3 906 226.747 307.963 0.0012 0.0013 1.0586 
RLTR23|LTR|ERV1 323 1524 69.378 102.253 0.0011 0.0012 1.0585 
MER58C|DNA|hAT-Charlie 111.4 436 14.383 18.045 0.0013 0.0014 1.0582 
RLTR13A2|LTR|ERVK 865.6 151 0.846 8.421 0.0010 0.0011 1.0576 
RMER17A|LTR|ERVK 479.3 1819 54.995 108.268 0.0011 0.0011 1.0575 
MLT1G1|LTR|ERVL-MaLR 215.4 1080 47.38 62.555 0.0012 0.0013 1.0542 
RLTR30|LTR|ERV1 258.6 390 1.692 7.218 0.0010 0.0011 1.0539 
IAPLTR2_Mm|LTR|ERVK 450.4 1388 478.029 536.53 0.0018 0.0019 1.0530 
MamTip2|DNA|hAT-Tip100 98.8 892 32.151 38.495 0.0014 0.0014 1.0527 
MLTR18C_MM|LTR|ERVK 437.5 468 19.46 31.278 0.0011 0.0012 1.0527 
RLTR12G|LTR|ERVK 386.4 238 16.075 21.654 0.0012 0.0012 1.0516 
RLTR9E|LTR|ERVK 353.5 1318 16.075 40.901 0.0010 0.0011 1.0515 
L1M3d|LINE|L1 248.1 171 2.538 4.812 0.0011 0.0011 1.0506 
MER96B|DNA|hAT-Tip100 151.3 410 5.076 8.421 0.0011 0.0011 1.0498 
MER91B|DNA|hAT-Tip100 96.6 229 25.382 27.669 0.0021 0.0023 1.0481 
ERV3-16A3_LTR|LTR|ERVL 205.8 279 0.846 3.609 0.0010 0.0011 1.0474 
MLT1K|LTR|ERVL-MaLR 181.5 2759 744.541 803.591 0.0025 0.0026 1.0474 
MLT1-int|LTR|ERVL-MaLR 234.6 285 8.461 12.03 0.0011 0.0012 1.0474 
LTRIS4A|LTR|ERV1 347 228 6.769 10.827 0.0011 0.0011 1.0472 
MamRep1527|LTR|LTR 157.9 372 0.846 3.609 0.0010 0.0011 1.0464 
ERVB4_1C-LTR_Mm|LTR|ERVK 224.9 961 45.688 57.743 0.0012 0.0013 1.0460 
RLTR1F_Mm|LTR|ERVK 412.1 83 0.846 2.406 0.0010 0.0011 1.0445 
L1MC4a|LINE|L1 232.4 3077 245.36 287.513 0.0013 0.0014 1.0439 
MER34A|LTR|ERV1 199 694 18.614 25.263 0.0011 0.0012 1.0424 
MER119|DNA|hAT-Charlie 212.2 404 12.691 16.842 0.0011 0.0012 1.0422 
RLTR1B-int|LTR|ERV1 707.3 798 65.147 91.427 0.0011 0.0012 1.0417 
BGLII_A|LTR|ERVK 316.7 292 10.153 14.436 0.0011 0.0012 1.0417 
L1M3de|LINE|L1 282.8 157 1.692 3.609 0.0010 0.0011 1.0416 
RLTR20B1|LTR|ERVK 310.9 668 32.151 42.104 0.0012 0.0012 1.0415 
UCON29|DNA|PiggyBac? 166.9 141 2.538 3.609 0.0011 0.0012 1.0411 
RLTR28B|LTR|ERVL 279.5 428 25.382 31.278 0.0012 0.0013 1.0407 
LTR16B1|LTR|ERVL 231.7 299 4.23 7.218 0.0011 0.0011 1.0406 
MER52-int|LTR|ERV1 233.9 206 5.076 7.218 0.0011 0.0011 1.0402 
BGLII_Mur|LTR|ERVK 340.8 611 18.614 27.669 0.0011 0.0011 1.0399 
LTR37B|LTR|ERV1 199.9 386 1.692 4.812 0.0010 0.0011 1.0396 
RLTR19C|LTR|ERVK 333.4 248 17.767 21.654 0.0012 0.0013 1.0387 
RLTR13D2|LTR|ERVK 730.5 270 10.153 18.045 0.0011 0.0011 1.0381 
MLT1A1|LTR|ERVL-MaLR 154.3 9015 143.832 200.898 0.0011 0.0011 1.0372 
Tigger16b|DNA|TcMar-Tigger 132.5 197 43.15 45.713 0.0027 0.0028 1.0370 
ORR1D1-int|LTR|ERVL-MaLR 466 1715 108.297 140.749 0.0011 0.0012 1.0358 
MamRep564|Unknown|Unknown 147 125 1.692 2.406 0.0011 0.0011 1.0356 
MT-int|LTR|ERVL-MaLR 401.5 438 25.382 32.48 0.0011 0.0012 1.0353 
RLTR10D|LTR|ERVK 342 491 11.845 18.045 0.0011 0.0011 1.0345 
MER74A|LTR|ERVL 244.2 731 21.998 28.872 0.0011 0.0012 1.0343 
RLTR51B_Mm|LTR|ERVK? 242 662 10.999 16.842 0.0011 0.0011 1.0341 
IAPLTR1_Mm|LTR|ERVK 368.5 1492 268.204 295.933 0.0015 0.0015 1.0339 
Charlie24|DNA|hAT-Charlie 213.1 374 43.996 48.119 0.0016 0.0016 1.0333 
MER67B|LTR|ERV1 224.5 220 4.23 6.015 0.0011 0.0011 1.0333 
MLT2B4|LTR|ERVL 220.8 1871 13.537 27.669 0.0010 0.0011 1.0331 
LTR79|LTR|ERVL 165.8 380 8.461 10.827 0.0011 0.0012 1.0331 
RLTR27|LTR|ERVK 168.8 1621 13.537 22.857 0.0010 0.0011 1.0325 
L1M3b|LINE|L1 286.2 169 0.846 2.406 0.0010 0.0010 1.0317 
MER58B|DNA|hAT-Charlie 164.3 2843 87.991 104.659 0.0012 0.0012 1.0300 
MER99|DNA|hAT? 224.7 198 3.384 4.812 0.0011 0.0011 1.0298 
RLTR22_Mus|LTR|ERVK 448.8 1191 73.608 91.427 0.0011 0.0012 1.0293 
MER68B|LTR|ERVL 220.5 237 16.075 18.045 0.0013 0.0013 1.0288 
LTR16B|LTR|ERVL 213.7 260 10.153 12.03 0.0012 0.0012 1.0286 
LTR55|LTR|ERVL? 265.5 160 0 1.203 0.0010 0.0010 1.0283 
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L1M3c|LINE|L1 288.7 337 0.846 3.609 0.0010 0.0010 1.0282 
RMER6-int|LTR|ERVK 425.5 607 11.845 19.248 0.0010 0.0011 1.0274 
LTR72_RN|LTR|ERV1 219.6 1000 60.917 68.57 0.0013 0.0013 1.0273 
IAPLTR3-int|LTR|ERVK 966.3 1773 63.455 111.877 0.0010 0.0011 1.0273 
Arthur1|DNA|hAT-Tip100 273.1 920 28.766 36.089 0.0011 0.0011 1.0262 
RMER16A2|LTR|ERVK 264.4 273 16.921 19.248 0.0012 0.0013 1.0261 
Charlie2a|DNA|hAT-Charlie 266.9 505 11.845 15.639 0.0011 0.0011 1.0259 
LTR75B|LTR|ERVL 195.6 69 0.846 1.203 0.0011 0.0011 1.0249 
L1MEa|LINE|L1 241.7 169 2.538 3.609 0.0011 0.0011 1.0247 
MLTR11A|LTR|ERVK 327.5 2124 60.071 78.194 0.0011 0.0011 1.0240 
RLTR15|LTR|ERVK 274.5 2437 124.372 143.155 0.0012 0.0012 1.0237 
L1MDb|LINE|L1 241.3 583 35.535 39.698 0.0013 0.0013 1.0236 
Plat_L3|LINE|CR1 153.2 579 20.306 22.857 0.0012 0.0013 1.0234 
MLTR18A_MM|LTR|ERVK 365.8 299 9.307 12.03 0.0011 0.0011 1.0229 
MER5B|DNA|hAT-Charlie 107.3 5140 106.605 121.501 0.0012 0.0012 1.0226 
ERVB4_3-I_MM-int|LTR|ERVK 1534.1 99 2.538 6.015 0.0010 0.0010 1.0225 
RLTR41|LTR|ERV1 339 1121 15.229 24.06 0.0010 0.0011 1.0223 
MLT2B2|LTR|ERVL 226.3 1351 16.921 24.06 0.0011 0.0011 1.0221 
MLT1A0-int|LTR|ERVL-MaLR 340.2 206 0.846 2.406 0.0010 0.0010 1.0220 
L1ME4a|LINE|L1 207.1 1560 104.913 114.283 0.0013 0.0014 1.0219 
MamGypLTR2b|LTR|Gypsy 142.8 109 0.846 1.203 0.0011 0.0011 1.0218 
MER70B|LTR|ERVL 229.4 254 0 1.203 0.0010 0.0010 1.0206 
ORR1A1-int|LTR|ERVL-MaLR 919.5 859 73.608 91.427 0.0011 0.0011 1.0206 
Charlie2b|DNA|hAT-Charlie 236.1 884 34.689 39.698 0.0012 0.0012 1.0206 
MLT1H1-int|LTR|ERVL-MaLR 341.4 49 0.846 1.203 0.0011 0.0011 1.0203 
RLTR10B2|LTR|ERVK 332.5 854 26.228 32.48 0.0011 0.0011 1.0202 
RLTR9D2|LTR|ERVK 321.8 194 27.074 28.872 0.0014 0.0015 1.0201 
MER44C|DNA|TcMar-Tigger 275.3 185 8.461 9.624 0.0012 0.0012 1.0196 
RLTR31A_Mm|LTR|ERVK 369 209 12.691 14.436 0.0012 0.0012 1.0194 
MERVK26-int|LTR|ERVK 628.1 1001 17.767 30.075 0.0010 0.0010 1.0190 
RMER6D|LTR|ERVK 332.6 2411 79.531 96.238 0.0011 0.0011 1.0190 
X7B_LINE|LINE|CR1 104.7 162 6.769 7.218 0.0014 0.0014 1.0189 
RMER21A|LTR|ERV1 355.5 622 150.6 157.591 0.0017 0.0017 1.0188 
MuRRS4-int|LTR|ERV1 881.3 2735 109.989 156.388 0.0010 0.0011 1.0184 
RMER20C_Mm|LTR|ERVK 327.1 1595 53.302 63.758 0.0011 0.0011 1.0182 
L1ME3C|LINE|L1 235.3 326 3.384 4.812 0.0010 0.0011 1.0178 
MER76|LTR|ERVL 228.4 247 20.306 21.654 0.0014 0.0014 1.0176 
RLTR26D_MM|LTR|ERVK 395.2 247 4.23 6.015 0.0010 0.0011 1.0175 
RLTR11B|LTR|ERVK 317.1 1049 260.589 270.671 0.0018 0.0018 1.0170 
RMER17D|LTR|ERVK 400 1166 49.072 57.743 0.0011 0.0011 1.0168 
LTR40b|LTR|ERVL 217.7 577 5.076 7.218 0.0010 0.0011 1.0164 
Tigger19a|DNA|TcMar-Tigger 125.3 771 24.536 26.466 0.0013 0.0013 1.0159 
RLTR11A|LTR|ERVK 353.7 2655 350.273 370.518 0.0014 0.0014 1.0157 
RLTR19|LTR|ERVK 303.2 944 28.766 33.683 0.0011 0.0011 1.0156 
Charlie29a|DNA|hAT-Charlie 211.1 324 8.461 9.624 0.0011 0.0011 1.0151 
Kanga1c|DNA|TcMar-Tc2 193.9 184 4.23 4.812 0.0011 0.0011 1.0146 
MER74C|LTR|ERVL 215 114 0.846 1.203 0.0010 0.0010 1.0141 
RLTR13B2|LTR|ERVK 716 314 7.615 10.827 0.0010 0.0010 1.0138 
ERVB5_1-I_MM-int|LTR|ERVK 699.1 292 6.769 9.624 0.0010 0.0010 1.0135 
MERV1_LTR|LTR|ERV1 321.2 615 32.997 36.089 0.0012 0.0012 1.0134 
MLT1H-int|LTR|ERVL-MaLR 243.7 379 11.845 13.233 0.0011 0.0011 1.0133 
RLTR6B_Mm|LTR|ERV1 541.9 646 82.069 87.818 0.0012 0.0013 1.0133 
RLTR34B_MM|LTR|ERVK 366.6 527 35.535 38.495 0.0012 0.0012 1.0129 
RLTR44-int|LTR|ERVK 804.6 653 63.455 70.976 0.0011 0.0011 1.0128 
ORR1A4-int|LTR|ERVL-MaLR 773 1326 120.142 134.734 0.0011 0.0011 1.0127 
IAPEY3C_LTR|LTR|ERVK 288.9 475 10.153 12.03 0.0011 0.0011 1.0127 
MamGypLTR3a|LTR|Gypsy 170.6 161 0.846 1.203 0.0010 0.0010 1.0126 
RLTR9D|LTR|ERVK 328.5 803 16.921 20.451 0.0011 0.0011 1.0126 
ORR1D2|LTR|ERVL-MaLR 241.9 15061 440.802 492.019 0.0011 0.0011 1.0125 
MLT2B5|LTR|ERVL 191 442 8.461 9.624 0.0011 0.0011 1.0125 
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MER20B|DNA|hAT-Charlie 202.2 831 93.068 96.238 0.0016 0.0016 1.0121 
L4_C_Mam|LINE|RTE-X 173.9 590 5.922 7.218 0.0011 0.0011 1.0119 
L1M4a2|LINE|L1 242.4 736 10.999 13.233 0.0011 0.0011 1.0118 
ERVL-int|LTR|ERVL 316.7 721 3.384 6.015 0.0010 0.0010 1.0114 
MLT1H1|LTR|ERVL-MaLR 209.7 1001 8.461 10.827 0.0010 0.0011 1.0108 
MER67D|LTR|ERV1 238.6 468 0 1.203 0.0010 0.0010 1.0108 
IAPEY_LTR|LTR|ERVK 337.1 1410 27.074 32.48 0.0011 0.0011 1.0108 
RLTR10C|LTR|ERVK 414.6 1779 142.14 151.576 0.0012 0.0012 1.0107 
L1_Mus2|LINE|L1 756.3 21079 2400.299 2592.424 0.0012 0.0012 1.0105 
HAL1|LINE|L1 225.9 3550 121.834 131.125 0.0012 0.0012 1.0101 
RLTR33|LTR|ERVK 469.5 1336 58.379 64.961 0.0011 0.0011 1.0096 
L1MB1|LINE|L1 268 2524 32.997 39.698 0.0010 0.0011 1.0094 
RLTR13A3|LTR|ERVK 847.3 243 7.615 9.624 0.0010 0.0010 1.0094 
RLTR44C|LTR|ERVK 395.6 198 54.148 55.337 0.0017 0.0017 1.0090 
L1VL1|LINE|L1 1106.4 1797 33.843 51.728 0.0010 0.0010 1.0088 
RLTR19A2|LTR|ERVK 235.4 94 3.384 3.609 0.0012 0.0012 1.0088 
ERVL-E-int|LTR|ERVL 255.1 1044 28.766 31.278 0.0011 0.0011 1.0085 
LTR102_Mam|LTR|ERVL 217.3 215 0.846 1.203 0.0010 0.0010 1.0075 
RMER16-int|LTR|ERVK 653.8 2599 56.687 69.773 0.0010 0.0010 1.0075 
MLT1A1-int|LTR|ERVL-MaLR 362.1 130 0.846 1.203 0.0010 0.0010 1.0075 
L1_Mus1|LINE|L1 807.3 27252 2248.852 2415.586 0.0011 0.0011 1.0069 
CR1_Mam|LINE|CR1 177.1 257 15.229 15.639 0.0013 0.0013 1.0067 
RLTR13E|LTR|ERVK 616.5 603 26.228 28.872 0.0011 0.0011 1.0066 
RLTR20B5_MM|LTR|ERVK 327.8 868 36.381 38.495 0.0011 0.0011 1.0066 
IAP-d-int|LTR|ERVK 486.1 1323 12.691 16.842 0.0010 0.0010 1.0063 
IAPLTR1a_Mm|LTR|ERVK 337.4 1786 72.762 76.991 0.0011 0.0011 1.0063 
ERVB4_1B-I_MM-int|LTR|ERVK 549.8 1368 10.999 15.639 0.0010 0.0010 1.0061 
MERV1_I-int|LTR|ERV1 701 1365 91.375 97.441 0.0011 0.0011 1.0058 
MLT2D|LTR|ERVL 213.9 1567 16.075 18.045 0.0010 0.0011 1.0056 
L1_Rod|LINE|L1 372.8 11315 134.525 158.794 0.0010 0.0010 1.0056 
HAL1ME|LINE|L1 197.9 900 10.999 12.03 0.0011 0.0011 1.0055 
Tigger5|DNA|TcMar-Tigger 183.4 1975 85.453 87.818 0.0012 0.0012 1.0053 
RLTR53_Mm|LTR|ERVK 285.5 481 120.142 121.501 0.0019 0.0019 1.0053 
ETnERV3-int|LTR|ERVK 1382.9 560 12.691 16.842 0.0010 0.0010 1.0053 
MER121|DNA|TcMar? 195.7 588 4.23 4.812 0.0010 0.0010 1.0049 
RLTR14-int|LTR|ERV1 440.6 1816 101.528 105.862 0.0011 0.0011 1.0048 
MER58A|DNA|hAT-Charlie 155.4 3714 93.068 96.238 0.0012 0.0012 1.0047 
MER34|LTR|ERV1 164 737 4.23 4.812 0.0010 0.0010 1.0047 
BGLII_Mus|LTR|ERVK 298.7 615 13.537 14.436 0.0011 0.0011 1.0046 
L1Md_F|LINE|L1 1472.9 4016 119.296 146.764 0.0010 0.0010 1.0046 
MER115|DNA|hAT-Tip100 193.9 521 84.607 85.412 0.0018 0.0018 1.0043 
MLT1D-int|LTR|ERVL-MaLR 302.1 176 3.384 3.609 0.0011 0.0011 1.0040 
MLTR31D_MM|LTR|ERVK 418.4 318 12.691 13.233 0.0011 0.0011 1.0037 
Charlie5|DNA|hAT-Charlie 178.3 1547 313.046 315.181 0.0021 0.0021 1.0036 
IAPLTR4_I|LTR|ERVK 557.9 183 0.846 1.203 0.0010 0.0010 1.0035 
L1M6|LINE|L1 189.9 329 3.384 3.609 0.0011 0.0011 1.0034 
MLT1A|LTR|ERVL-MaLR 190 4950 66.839 69.773 0.0011 0.0011 1.0029 
MYSERV6-int|LTR|ERVK 549 3183 112.527 117.892 0.0011 0.0011 1.0029 
Lx2A|LINE|L1 601.5 1364 10.999 13.233 0.0010 0.0010 1.0027 
MER92-int|LTR|ERV1 256.1 324 3.384 3.609 0.0010 0.0010 1.0026 
L1MDa|LINE|L1 271.4 3451 68.532 70.976 0.0011 0.0011 1.0024 
MMERVK10D3_I-int|LTR|ERVK 1077.1 458 10.999 12.03 0.0010 0.0010 1.0020 
MamRep1879|DNA|hAT-Tip100? 125.8 105 14.383 14.436 0.0021 0.0021 1.0019 
ORSL-2b|DNA|hAT-Tip100 222.8 210 5.922 6.015 0.0011 0.0011 1.0018 
MuRRS-int|LTR|ERV1 1307.4 996 39.765 42.104 0.0010 0.0010 1.0017 
L1MCb|LINE|L1 287.1 713 0.846 1.203 0.0010 0.0010 1.0017 
Lx2A1|LINE|L1 480.8 2739 25.382 27.669 0.0010 0.0010 1.0017 
Looper|DNA|PiggyBac 238.6 209 5.922 6.015 0.0011 0.0011 1.0017 
RLTR44A|LTR|ERVK 296.3 259 20.306 20.451 0.0013 0.0013 1.0015 
Kanga2_a|DNA|TcMar-Tc2 226.8 356 20.306 20.451 0.0013 0.0013 1.0014 
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RMER1A|Other|Other 542.9 3854 458.57 461.945 0.0012 0.0012 1.0013 
MMERVK9E_I-int|LTR|ERVK 918.9 1568 84.607 86.615 0.0011 0.0011 1.0013 
RMER17C-int|LTR|ERVK 381.9 1940 79.531 80.6 0.0011 0.0011 1.0013 
RLTR5_Mm|LTR|ERV1 605.8 601 6.769 7.218 0.0010 0.0010 1.0012 
L1MA4A|LINE|L1 293.2 2709 50.764 51.728 0.0011 0.0011 1.0011 
AmnSINE2|SINE|Deu 89.3 391 14.383 14.436 0.0014 0.0014 1.0011 
MLT1F1|LTR|ERVL-MaLR 212 1608 32.151 32.48 0.0011 0.0011 1.0009 
ERVB7_3-LTR_MM|LTR|ERVK 334.8 319 5.922 6.015 0.0011 0.0011 1.0008 
RMER16A3|LTR|ERVK 154.9 699 5.922 6.015 0.0011 0.0011 1.0008 
MLT1J-int|LTR|ERVL-MaLR 233.7 506 5.922 6.015 0.0011 0.0011 1.0007 
MLT2B1|LTR|ERVL 245.2 1637 17.767 18.045 0.0010 0.0010 1.0007 
RLTR50B|LTR|ERVK 438.6 334 5.922 6.015 0.0010 0.0010 1.0006 
RLTR31M|LTR|ERVK 376.9 264 60.071 60.149 0.0016 0.0016 1.0005 
MusHAL1|LINE|L1 587.9 3890 56.687 57.743 0.0010 0.0010 1.0005 
IAPEY3-int|LTR|ERVK 892 2345 32.997 33.683 0.0010 0.0010 1.0003 
L1VL2|LINE|L1 1127.6 4697 152.292 153.982 0.0010 0.0010 1.0003 
MER92D|LTR|ERV1 178.7 70 0 0 0.0010 0.0010 1.0000 
LTR90A|LTR|LTR 150.3 99 0 0 0.0010 0.0010 1.0000 
UCON1|Unknown|Unknown 128.5 15 0 0 0.0010 0.0010 1.0000 
C573_MM|Other|Other 299.2 1738 0 0 0.0010 0.0010 1.0000 
RLTR47_MM|LTR|ERV1 308 45 0 0 0.0010 0.0010 1.0000 
MARINER1_EC|DNA|TcMar-
Tigger 
76.5 2 0 0 0.0010 0.0010 1.0000 
MLT1E2-int|LTR|ERVL-MaLR 292.4 35 0 0 0.0010 0.0010 1.0000 
HY5|scRNA|scRNA 74 1 0 0 0.0010 0.0010 1.0000 
ORSL-2a|DNA|hAT-Tip100 194.4 69 0 0 0.0010 0.0010 1.0000 
nhAT5a_ML|DNA|hAT-Charlie 100 4 0 0 0.0010 0.0010 1.0000 
Tigger17b|DNA|TcMar-Tigger 213.5 72 0 0 0.0010 0.0010 1.0000 
L1P5|LINE|L1 135.6 166 0 0 0.0010 0.0010 1.0000 
Ricksha_a|DNA|MULE-MuDR 265.7 30 0 0 0.0010 0.0010 1.0000 
Eulor10|DNA?|DNA? 134.4 29 0 0 0.0010 0.0010 1.0000 
MamGypLTR1d|LTR|Gypsy 168 116 0 0 0.0010 0.0010 1.0000 
MER133B|DNA?|DNA? 92.3 22 0 0 0.0010 0.0010 1.0000 
Helitron1Nb_Mam|RC|Helitron 194.2 92 0 0 0.0010 0.0010 1.0000 
LTR16D|LTR|ERVL 196.8 185 0 0 0.0010 0.0010 1.0000 
UCON28a|Unknown|Unknown 177.9 87 0 0 0.0010 0.0010 1.0000 
MER72|LTR|ERV1 100.4 9 0 0 0.0010 0.0010 1.0000 
MER66A|LTR|ERV1 87.6 5 0 0 0.0010 0.0010 1.0000 
UCON12|Unknown|Unknown 136 25 0 0 0.0010 0.0010 1.0000 
Cheshire_Mars_|DNA|hAT-Charlie 249.3 6 0 0 0.0010 0.0010 1.0000 
MER47C|DNA|TcMar-Tigger 76.5 14 0 0 0.0010 0.0010 1.0000 
Eulor3|DNA?|DNA? 161.6 28 0 0 0.0010 0.0010 1.0000 
UCON25|Unknown|Unknown 91.4 23 0 0 0.0010 0.0010 1.0000 
L1M6B|LINE|L1 140 43 0 0 0.0010 0.0010 1.0000 
UCON28b|Unknown|Unknown 213.2 49 0 0 0.0010 0.0010 1.0000 
MER57-int|LTR|ERV1 135.7 202 0 0 0.0010 0.0010 1.0000 
LTR27C|LTR|ERV1 119.9 7 0 0 0.0010 0.0010 1.0000 
LTR45C|LTR|ERV1 115.2 24 0 0 0.0010 0.0010 1.0000 
LTR39|LTR|ERV1 87.5 11 0 0 0.0010 0.0010 1.0000 
X1_LINE|LINE|CR1 234.9 40 0 0 0.0010 0.0010 1.0000 
RLTR1|LTR|ERV1 227.6 62 0 0 0.0010 0.0010 1.0000 
LTR108c_Mam|LTR|ERVL 232.5 15 0 0 0.0010 0.0010 1.0000 
MER94B|DNA|hAT-Blackjack 94 86 0 0 0.0010 0.0010 1.0000 
LTR9D|LTR|ERV1 77.2 11 0 0 0.0010 0.0010 1.0000 
Eulor11|DNA|DNA 171.8 49 0 0 0.0010 0.0010 1.0000 
Charlie1b_Mars|DNA|hAT-Charlie 359.5 2 0 0 0.0010 0.0010 1.0000 
MER110-int|LTR|ERV1 233.5 38 0 0 0.0010 0.0010 1.0000 
UCON10|Unknown|Unknown 178 49 0 0 0.0010 0.0010 1.0000 
X5A_LINE|LINE|CR1 106.6 69 0 0 0.0010 0.0010 1.0000 
RMER3D2|LTR|ERVK 82.3 3 0 0 0.0010 0.0010 1.0000 
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MER133A|DNA?|DNA? 78.5 35 0 0 0.0010 0.0010 1.0000 
LTR75_1|LTR|ERV1 89.2 9 0 0 0.0010 0.0010 1.0000 
MLT1K-int|LTR|ERVL-MaLR 269.2 8 0 0 0.0010 0.0010 1.0000 
L5|LINE|RTE-X 180.4 122 0 0 0.0010 0.0010 1.0000 
UCON17|Unknown|Unknown 198 23 0 0 0.0010 0.0010 1.0000 
Eulor9C|DNA|DNA 96.9 71 0 0 0.0010 0.0010 1.0000 
UCON7|DNA?|DNA? 166.4 99 0 0 0.0010 0.0010 1.0000 
Charlie22a|DNA|hAT-Charlie 175.3 163 0 0 0.0010 0.0010 1.0000 
HERVL32-int|LTR|ERVL 124 1 0 0 0.0010 0.0010 1.0000 
LTR9A1|LTR|ERV1 114.6 11 0 0 0.0010 0.0010 1.0000 
L1MEg1|LINE|L1 206.1 92 0 0 0.0010 0.0010 1.0000 
X2_LINE|LINE|CR1 141.4 32 0 0 0.0010 0.0010 1.0000 
MER57E3|LTR|ERV1 187.5 4 0 0 0.0010 0.0010 1.0000 
MLT1L-int|LTR|ERVL-MaLR 211 13 0 0 0.0010 0.0010 1.0000 
MER132|DNA|TcMar-Pogo 127.6 21 0 0 0.0010 0.0010 1.0000 
RLTR46|LTR|ERVK 256.2 46 0 0 0.0010 0.0010 1.0000 
LTR68|LTR|ERV1 168.5 106 0 0 0.0010 0.0010 1.0000 
Eulor6A|DNA?|DNA? 122.6 21 0 0 0.0010 0.0010 1.0000 
Helitron2Na_Mam|RC?|Helitron? 147.4 74 0 0 0.0010 0.0010 1.0000 
UCON19|Unknown|Unknown 153.8 24 0 0 0.0010 0.0010 1.0000 
MER83A-int|LTR|ERV1 119 1 0 0 0.0010 0.0010 1.0000 
MLT1H2-int|LTR|ERVL-MaLR 342.6 53 0 0 0.0010 0.0010 1.0000 
Ricksha|DNA|MULE-MuDR 288.3 60 0 0 0.0010 0.0010 1.0000 
LTR52-int|LTR|ERVL 317 50 0 0 0.0010 0.0010 1.0000 
MamRep488|DNA|hAT-Tip100 121 29 0 0 0.0010 0.0010 1.0000 
MLT1J1-int|LTR|ERVL-MaLR 258.1 67 0 0 0.0010 0.0010 1.0000 
LTR106_Mam|LTR|LTR 229.5 164 0 0 0.0010 0.0010 1.0000 
RMER3D3|LTR|ERVK 95.6 8 0 0 0.0010 0.0010 1.0000 
Eulor6B|DNA?|DNA? 162.8 56 0 0 0.0010 0.0010 1.0000 
MLT1F1-int|LTR|ERVL-MaLR 265.9 89 0 0 0.0010 0.0010 1.0000 
Tigger11a|DNA|TcMar-Tigger 211.1 75 0 0 0.0010 0.0010 1.0000 
Charlie7a|DNA|hAT-Charlie 145.5 102 0 0 0.0010 0.0010 1.0000 
LTR34|LTR|ERV1 115.5 8 0 0 0.0010 0.0010 1.0000 
UCON15|Unknown|Unknown 160.8 32 0 0 0.0010 0.0010 1.0000 
MamGypLTR1a|LTR|Gypsy 170.2 137 0 0 0.0010 0.0010 1.0000 
UCON11|Unknown|Unknown 184.7 45 0 0 0.0010 0.0010 1.0000 
UCON27|Unknown|Unknown 221 64 0 0 0.0010 0.0010 1.0000 
LTR23-int|LTR|ERV1 81.6 11 0 0 0.0010 0.0010 1.0000 
Eulor4|Unknown|Unknown 209.8 24 0 0 0.0010 0.0010 1.0000 
LTR29|LTR|ERV1 164.5 34 0 0 0.0010 0.0010 1.0000 
LTR86A2|LTR|ERVL 154.7 79 0 0 0.0010 0.0010 1.0000 
MER83B-int|LTR|ERV1 113.8 9 0 0 0.0010 0.0010 1.0000 
RMER3D1|LTR|ERVK 90 1 0 0 0.0010 0.0010 1.0000 
RLTR43A|LTR|ERVK 92.7 3 0 0 0.0010 0.0010 1.0000 
MER134|DNA?|DNA? 131.7 53 0 0 0.0010 0.0010 1.0000 
UCON22|Unknown|Unknown 115.1 27 0 0 0.0010 0.0010 1.0000 
MLT1E3-int|LTR|ERVL-MaLR 257.2 12 0 0 0.0010 0.0010 1.0000 
MER127|DNA|TcMar-Tigger 180.3 119 0 0 0.0010 0.0010 1.0000 
L1PB4|LINE|L1 335.7 144 0 0 0.0010 0.0010 1.0000 
MER125|DNA|DNA 123.8 111 0 0 0.0010 0.0010 1.0000 
Ricksha_c|DNA|MuDR 173.7 26 0 0 0.0010 0.0010 1.0000 
HY1|scRNA|scRNA 90.6 38 0 0 0.0010 0.0010 1.0000 
MER34-int|LTR|ERV1 263.1 66 0 0 0.0010 0.0010 1.0000 
LTR36|LTR|ERV1 99.2 5 0 0 0.0010 0.0010 1.0000 
Ricksha_0|DNA|MuDR 197.4 29 0 0 0.0010 0.0010 1.0000 
MER68C|LTR|ERVL 158.8 60 0 0 0.0010 0.0010 1.0000 
MLT1E1-int|LTR|ERVL-MaLR 413.6 8 0 0 0.0010 0.0010 1.0000 
Eulor1|DNA|DNA 169.2 56 0 0 0.0010 0.0010 1.0000 
Ricksha_a|DNA|MuDR 132 11 0 0 0.0010 0.0010 1.0000 
LTR91|LTR|ERVL 134.7 57 0 0 0.0010 0.0010 1.0000 
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UCON20|Unknown|Unknown 208.6 37 0 0 0.0010 0.0010 1.0000 
MLT1I-int|LTR|ERVL-MaLR 265 57 0 0 0.0010 0.0010 1.0000 
Eulor9B|DNA|DNA 147.1 14 0 0 0.0010 0.0010 1.0000 
MER92C|LTR|ERV1 191.7 72 0 0 0.0010 0.0010 1.0000 
LTR73|LTR|ERV1 236.2 137 0 0 0.0010 0.0010 1.0000 
LTR52|LTR|ERVL 198.1 230 0 0 0.0010 0.0010 1.0000 
Charlie10a|DNA|hAT-Charlie 139.7 61 0 0 0.0010 0.0010 1.0000 
HERVL74-int|LTR|ERVL 290.6 149 0 0 0.0010 0.0010 1.0000 
HY4|scRNA|scRNA 82.7 3 0 0 0.0010 0.0010 1.0000 
LTR32|LTR|ERVL 115.8 9 0 0 0.0010 0.0010 1.0000 
LTR64|LTR|ERV1 105.2 8 0 0 0.0010 0.0010 1.0000 
MER65-int|LTR|ERV1 167.1 49 0 0 0.0010 0.0010 1.0000 
MER110|LTR|ERV1 195.8 147 0 0 0.0010 0.0010 1.0000 
Eulor8|DNA|TcMar? 200.2 110 0 0 0.0010 0.0010 1.0000 
UCON21|DNA?|DNA? 128.3 23 0 0 0.0010 0.0010 1.0000 
MER4CL34|LTR|ERV1 68.8 6 0 0 0.0010 0.0010 1.0000 
LTR108e_Mam|LTR|ERVL 210 36 0 0 0.0010 0.0010 1.0000 
RLTR46A2|LTR|ERVK 290.7 58 0 0 0.0010 0.0010 1.0000 
MER70-int|LTR|ERVL 282.4 56 0 0 0.0010 0.0010 1.0000 
Helitron1Na_Mam|RC|Helitron 229.8 62 0 0 0.0010 0.0010 1.0000 
MER92A|LTR|ERV1 209.5 37 0 0 0.0010 0.0010 1.0000 
MamRep1151|LTR?|LTR? 271.9 249 0 0 0.0010 0.0010 1.0000 
MamGypLTR3|LTR|Gypsy 155.1 105 0 0 0.0010 0.0010 1.0000 
Eulor5B|DNA?|DNA? 114.3 37 0 0 0.0010 0.0010 1.0000 
RLTR9A4|LTR|ERVK 246.4 35 0 0 0.0010 0.0010 1.0000 
MER76-int|LTR|ERVL 250.6 16 0 0 0.0010 0.0010 1.0000 
RLTR43B|LTR|ERVK 126 1 0 0 0.0010 0.0010 1.0000 
UCON18|Unknown|Unknown 174.2 17 0 0 0.0010 0.0010 1.0000 
Eulor6D|DNA?|DNA? 151.1 47 0 0 0.0010 0.0010 1.0000 
MER89-int|LTR|ERV1 263.6 98 0 0 0.0010 0.0010 1.0000 
L1M2a1|LINE|L1 63 11 0 0 0.0010 0.0010 1.0000 
MLT1A-int|LTR|ERVL-MaLR 286.3 123 0 0 0.0010 0.0010 1.0000 
MER57E2|LTR|ERV1 190.1 62 0 0 0.0010 0.0010 1.0000 
Charlie20a|DNA|hAT-Charlie 223.7 161 0 0 0.0010 0.0010 1.0000 
UCON24|Unknown|Unknown 131.3 18 0 0 0.0010 0.0010 1.0000 
LTR103_Mam|LTR|ERV1? 183.6 58 0 0 0.0010 0.0010 1.0000 
Eulor7|DNA?|DNA? 142.8 4 0 0 0.0010 0.0010 1.0000 
Charlie17a|DNA|hAT-Charlie 136.1 63 0 0 0.0010 0.0010 1.0000 
UCON8|Unknown|Unknown 164 55 0 0 0.0010 0.0010 1.0000 
L1M3a|LINE|L1 257.7 120 0 0 0.0010 0.0010 1.0000 
Eulor2C|DNA?|DNA? 120.6 24 0 0 0.0010 0.0010 1.0000 
MLT1E-int|LTR|ERVL-MaLR 266.2 9 0 0 0.0010 0.0010 1.0000 
Eulor12|DNA?|DNA? 117.8 35 0 0 0.0010 0.0010 1.0000 
LTR75|LTR|ERVL 211.9 94 0 0 0.0010 0.0010 1.0000 
MER72B|LTR|ERV1 111.5 74 0 0 0.0010 0.0010 1.0000 
MamRep1161|DNA|TcMar 170.4 7 0 0 0.0010 0.0010 1.0000 
MER101B|LTR|ERV1 133.3 21 0 0 0.0010 0.0010 1.0000 
MamRep137|DNA|TcMar? 115.5 4 0 0 0.0010 0.0010 1.0000 
MLT1G3-int|LTR|ERVL-MaLR 366.2 58 0 0 0.0010 0.0010 1.0000 
UCON9|Unknown|Unknown 184.7 28 0 0 0.0010 0.0010 1.0000 
Eulor6C|DNA?|DNA? 116.6 15 0 0 0.0010 0.0010 1.0000 
MLT1O-int|LTR|ERVL-MaLR 174 2 0 0 0.0010 0.0010 1.0000 
RLTR1E_MM|LTR|ERV1 223.7 86 0 0 0.0010 0.0010 1.0000 
LTR86C|LTR|ERVL 204.2 75 0 0 0.0010 0.0010 1.0000 
LTR103b_Mam|LTR|ERV1? 159.7 57 0 0 0.0010 0.0010 1.0000 
MLT1N2-int|LTR|ERVL-MaLR 339.7 3 0 0 0.0010 0.0010 1.0000 
RMER3D4|LTR|ERVK 63 2 0 0 0.0010 0.0010 1.0000 
UCON16|Unknown|Unknown 136.7 23 0 0 0.0010 0.0010 1.0000 
X7D_LINE|LINE|CR1 61.5 10 0 0 0.0010 0.0010 1.0000 
MER51-int|LTR|ERV1 173.1 7 0 0 0.0010 0.0010 1.0000 
Appendix 
 
100 
Cheshire_Mars|DNA|hAT-Charlie 202.7 3 0 0 0.0010 0.0010 1.0000 
Tigger1a_Mars|DNA|TcMar-Tigger 253 2 0 0 0.0010 0.0010 1.0000 
MLT1J2-int|LTR|ERVL-MaLR 302.7 27 0 0 0.0010 0.0010 1.0000 
ERVB4_1-LTR_MM|LTR|ERVK 150.9 21 0 0 0.0010 0.0010 1.0000 
MER96B|DNA|hAT 119.1 8 0 0 0.0010 0.0010 1.0000 
LTR85b|LTR|Gypsy? 191.6 106 0 0 0.0010 0.0010 1.0000 
MER66B|LTR|ERV1 81.7 7 0 0 0.0010 0.0010 1.0000 
Ricksha_b|DNA|MULE-MuDR 262.3 6 0 0 0.0010 0.0010 1.0000 
HUERS-P3b-int|LTR|ERV1 88.3 3 0 0 0.0010 0.0010 1.0000 
Charlie11|DNA|hAT-Charlie 205.5 52 0 0 0.0010 0.0010 1.0000 
LTR82B|LTR|ERVL 210.8 290 0 0 0.0010 0.0010 1.0000 
LTR59|LTR|ERV1 88.5 8 0 0 0.0010 0.0010 1.0000 
ORR1C2|LTR|ERVL-MaLR 238.7 12473 404.421 402.999 0.0011 0.0011 0.9996 
L1MEd|LINE|L1 217 3245 263.128 262.25 0.0014 0.0014 0.9991 
LTR16A1|LTR|ERVL 198.8 654 33.843 33.683 0.0013 0.0013 0.9990 
IAPEY5_I-int|LTR|ERVK 663 184 2.538 2.406 0.0010 0.0010 0.9989 
RLTR10E|LTR|ERVK 298.2 227 25.382 25.263 0.0014 0.0014 0.9987 
RLTR9C|LTR|ERVK 366.8 477 5.076 4.812 0.0010 0.0010 0.9985 
L1Md_Gf|LINE|L1 2209 1080 42.303 38.495 0.0010 0.0010 0.9984 
L1MA7|LINE|L1 262 3250 50.764 49.322 0.0011 0.0011 0.9984 
MER63D|DNA|hAT-Blackjack 164.9 1034 13.537 13.233 0.0011 0.0011 0.9983 
RLTR17C_Mm|LTR|ERVK 352.2 218 2.538 2.406 0.0010 0.0010 0.9983 
RLTR47|LTR|ERVK 330.6 209 2.538 2.406 0.0010 0.0010 0.9982 
MLTR31A_MM|LTR|ERVK 387.7 352 5.076 4.812 0.0010 0.0010 0.9981 
MMAR1|DNA|TcMar-Mariner 344.2 309 27.92 27.669 0.0013 0.0013 0.9981 
Zaphod|DNA|hAT-Tip100 267.1 728 7.615 7.218 0.0010 0.0010 0.9980 
L1MC1|LINE|L1 299.9 5571 200.518 196.086 0.0011 0.0011 0.9976 
RLTR13D5|LTR|ERVK 758.4 745 10.999 9.624 0.0010 0.0010 0.9976 
MER44D|DNA|TcMar-Tigger 176.7 940 16.075 15.639 0.0011 0.0011 0.9976 
MER70A|LTR|ERVL 282.8 184 2.538 2.406 0.0010 0.0010 0.9976 
RLTR48A|LTR|ERV1 422.9 635 21.152 20.451 0.0011 0.0011 0.9976 
RMER12|LTR|ERVK 297.9 3319 138.755 135.937 0.0011 0.0011 0.9975 
L1Md_A|LINE|L1 1939.8 16844 1047.434 955.167 0.0010 0.0010 0.9973 
MER21C|LTR|ERVL 267.8 2261 126.064 123.907 0.0012 0.0012 0.9971 
RLTR13C3|LTR|ERVK 755.4 538 5.076 3.609 0.0010 0.0010 0.9964 
RLTR44D|LTR|ERVK 343.4 100 2.538 2.406 0.0011 0.0011 0.9964 
MER63C|DNA|hAT-Blackjack 329.2 414 10.153 9.624 0.0011 0.0011 0.9964 
MLT2C2|LTR|ERVL 197.3 651 1.692 1.203 0.0010 0.0010 0.9962 
Lx2|LINE|L1 562.4 18521 472.953 430.667 0.0010 0.0010 0.9961 
L1MEg|LINE|L1 219.3 3797 560.098 554.574 0.0017 0.0017 0.9960 
RLTR10|LTR|ERVK 377.9 2930 201.365 196.086 0.0012 0.0012 0.9960 
MTB_Mm|LTR|ERVL-MaLR 312.8 4963 225.054 217.74 0.0011 0.0011 0.9959 
ORR1C1|LTR|ERVL-MaLR 264.4 7423 269.05 259.844 0.0011 0.0011 0.9959 
B1_Mur1|SINE|Alu 122.9 38058 2493.366 2463.705 0.0015 0.0015 0.9959 
Lx2B|LINE|L1 620.2 6191 115.912 98.644 0.0010 0.0010 0.9956 
MER45B|DNA|hAT-Tip100 237.4 688 6.769 6.015 0.0010 0.0010 0.9956 
L1_Mur1|LINE|L1 581.8 7793 53.302 32.48 0.0010 0.0010 0.9955 
MER103C|DNA|hAT-Charlie 142.3 1072 65.993 64.961 0.0014 0.0014 0.9953 
L1M2|LINE|L1 293.2 18488 336.736 309.166 0.0011 0.0011 0.9952 
MT2B1|LTR|ERVL 270.8 7248 160.753 150.373 0.0011 0.0011 0.9951 
L1Md_F2|LINE|L1 1140.7 64898 1973.034 1598.762 0.0010 0.0010 0.9951 
MamGypLTR1b|LTR|Gypsy 166.8 141 2.538 2.406 0.0011 0.0011 0.9949 
Lx3_Mus|LINE|L1 694.3 12651 250.437 204.507 0.0010 0.0010 0.9949 
LTR33|LTR|ERVL 191.5 1466 13.537 12.03 0.0010 0.0010 0.9949 
L1Md_F3|LINE|L1 920.5 16146 478.875 396.984 0.0010 0.0010 0.9947 
MLTR18D_MM|LTR|ERVK 429.1 620 21.998 20.451 0.0011 0.0011 0.9946 
RLTR25A|LTR|ERVK 295.4 1781 86.299 83.006 0.0012 0.0012 0.9946 
MLTR31FA_MM|LTR|ERVK 417 525 16.921 15.639 0.0011 0.0011 0.9946 
L1MB5|LINE|L1 260.9 3766 192.904 186.462 0.0012 0.0012 0.9945 
MTA_Mm|LTR|ERVL-MaLR 370.3 15623 1053.356 1014.113 0.0012 0.0012 0.9943 
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LTR82A|LTR|ERVL 237.8 341 1.692 1.203 0.0010 0.0010 0.9941 
RLTR13B1|LTR|ERVK 723.4 1029 34.689 30.075 0.0010 0.0010 0.9941 
RLTR25B|LTR|ERVK 237.9 3674 186.981 180.447 0.0012 0.0012 0.9938 
L1_Mur3|LINE|L1 465 27399 434.034 352.473 0.0010 0.0010 0.9938 
LTR88c|LTR|Gypsy? 157.5 118 2.538 2.406 0.0011 0.0011 0.9938 
RLTR45-int|LTR|ERVK 696.6 1317 306.277 298.339 0.0013 0.0013 0.9935 
L1MC4|LINE|L1 228.8 5589 162.445 152.779 0.0011 0.0011 0.9933 
MER63B|DNA|hAT-Blackjack 150.6 701 6.769 6.015 0.0011 0.0011 0.9933 
ORR1A0|LTR|ERVL-MaLR 316.5 2133 137.909 132.328 0.0012 0.0012 0.9931 
LTR16A2|LTR|ERVL 203.8 416 4.23 3.609 0.0010 0.0010 0.9930 
LTR16C|LTR|ERVL 199.4 1352 15.229 13.233 0.0011 0.0010 0.9930 
IAPEY3_LTR|LTR|ERVK 302 553 8.461 7.218 0.0011 0.0010 0.9929 
RMER13B|LTR|ERVK 557.5 2134 120.142 110.674 0.0011 0.0011 0.9928 
L1_Mus4|LINE|L1 738.3 11880 221.67 155.185 0.0010 0.0010 0.9926 
RMER6C|LTR|ERVK 396.5 4887 105.759 90.224 0.0011 0.0010 0.9924 
MLTR73|LTR|ERV1 170.6 956 19.46 18.045 0.0011 0.0011 0.9922 
RCHARR1|DNA|hAT-Charlie 308.8 6811 297.816 279.092 0.0011 0.0011 0.9922 
Tigger12|DNA|TcMar-Tigger 170.2 155 49.918 49.322 0.0029 0.0029 0.9922 
Lx6|LINE|L1 503.8 18164 459.416 383.751 0.0011 0.0010 0.9921 
L1VL4|LINE|L1 1032.4 6091 172.598 121.501 0.0010 0.0010 0.9921 
MURVY-LTR|LTR|ERV1 449.3 1910 39.765 32.48 0.0010 0.0010 0.9919 
RLTR24B_MM|LTR|ERV1 192.2 1018 18.614 16.842 0.0011 0.0011 0.9917 
RLTR13A1|LTR|ERVK 613.1 205 5.922 4.812 0.0010 0.0010 0.9916 
Lx5c|LINE|L1 460.1 16422 405.267 338.038 0.0011 0.0010 0.9916 
RMER2|LTR|ERV1 356.1 2358 53.302 45.713 0.0011 0.0011 0.9915 
L1_Mur2|LINE|L1 537.7 20769 463.646 364.503 0.0010 0.0010 0.9915 
L1MA10|LINE|L1 207.3 866 7.615 6.015 0.0010 0.0010 0.9915 
RLTR22_Mur|LTR|ERVK 445 2503 72.762 62.555 0.0011 0.0011 0.9914 
Lx3A|LINE|L1 660.8 9223 168.368 114.283 0.0010 0.0010 0.9914 
L1MA5|LINE|L1 258.8 4952 108.297 96.238 0.0011 0.0011 0.9913 
L1Md_T|LINE|L1 2054.8 23688 1406.167 970.806 0.0010 0.0010 0.9913 
LTR53|LTR|ERVL 240.4 226 1.692 1.203 0.0010 0.0010 0.9913 
L1MEc|LINE|L1 268.5 5378 124.372 110.674 0.0011 0.0011 0.9913 
L1_Mus3|LINE|L1 757 48489 1099.044 766.299 0.0010 0.0010 0.9912 
RLTR9A3B|LTR|ERVK 271.5 346 0.846 0 0.0010 0.0010 0.9911 
HERV16-int|LTR|ERVL 234.9 277 4.23 3.609 0.0011 0.0011 0.9910 
L1_Mm|LINE|L1 643.3 5429 115.912 83.006 0.0010 0.0010 0.9909 
ORR1D-int|LTR|ERVL-MaLR 457.5 878 10.999 7.218 0.0010 0.0010 0.9908 
MLTR14|LTR|ERV1 251.3 6798 189.52 172.026 0.0011 0.0011 0.9908 
Lx|LINE|L1 658.5 24834 659.934 502.846 0.0010 0.0010 0.9908 
L1MA4|LINE|L1 292.4 7467 219.978 197.289 0.0011 0.0011 0.9906 
MER68|LTR|ERVL 265 637 57.533 55.337 0.0013 0.0013 0.9903 
RLTR17D_Mm|LTR|ERVK 596.4 1225 55.841 48.119 0.0011 0.0011 0.9902 
LTR16E2|LTR|ERVL 198.3 423 0.846 0 0.0010 0.0010 0.9900 
Lx3C|LINE|L1 601.9 6475 170.906 129.922 0.0010 0.0010 0.9899 
Lx4B|LINE|L1 533.1 5680 274.126 240.596 0.0011 0.0011 0.9898 
ERVB7_2B-LTR_MM|LTR|ERVK 328.8 710 27.92 25.263 0.0011 0.0011 0.9898 
L1ME4b|LINE|L1 188.3 1818 111.681 107.065 0.0013 0.0013 0.9898 
Lx9|LINE|L1 323 49160 937.445 762.69 0.0011 0.0010 0.9896 
Lx2B2|LINE|L1 576 11012 174.29 105.862 0.0010 0.0010 0.9895 
MER33|DNA|hAT-Charlie 171.1 2719 88.837 83.006 0.0012 0.0012 0.9895 
LTR16E1|LTR|ERVL 190.5 514 5.922 4.812 0.0011 0.0010 0.9893 
MTEa|LTR|ERVL-MaLR 221.1 20061 518.641 464.351 0.0011 0.0011 0.9890 
LTR67B|LTR|ERVL 168.2 632 19.46 18.045 0.0012 0.0012 0.9887 
RLTR42|LTR|ERVK 157 266 1.692 1.203 0.0010 0.0010 0.9887 
RMER19A|LTR|ERVK 484.8 2095 104.067 91.427 0.0011 0.0011 0.9887 
L1MB8|LINE|L1 263.3 6000 335.89 313.978 0.0012 0.0012 0.9886 
ORR1A2-int|LTR|ERVL-MaLR 828.9 2132 199.672 176.838 0.0011 0.0011 0.9884 
ORR1D1|LTR|ERVL-MaLR 235.8 21507 931.522 861.335 0.0012 0.0012 0.9883 
L3|LINE|CR1 129.6 9732 526.255 505.252 0.0014 0.0014 0.9883 
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RMER19B|LTR|ERVK 543.5 5640 479.721 437.885 0.0012 0.0011 0.9882 
Lx3B|LINE|L1 570.6 5993 243.668 199.695 0.0011 0.0011 0.9880 
RMER12B|LTR|ERVK 414.7 1011 146.37 139.546 0.0013 0.0013 0.9879 
MT2_Mm|LTR|ERVL 450.9 2667 135.371 119.095 0.0011 0.0011 0.9878 
MTE2b-int|LTR|ERVL-MaLR 430 729 35.535 31.278 0.0011 0.0011 0.9878 
Lx7|LINE|L1 404.1 40190 939.983 725.398 0.0011 0.0010 0.9875 
Lx5|LINE|L1 585.9 16339 1370.632 1233.056 0.0011 0.0011 0.9874 
MTC-int|LTR|ERVL-MaLR 424.8 3520 263.974 241.799 0.0012 0.0012 0.9874 
Lx10|LINE|L1 291 10010 170.06 131.125 0.0011 0.0010 0.9874 
RMER1C|Other|Other 312.3 6347 151.446 123.907 0.0011 0.0011 0.9871 
L1MA9|LINE|L1 268.2 4587 51.61 34.886 0.0010 0.0010 0.9870 
RMER20B|LTR|ERVK 310.8 1949 28.766 20.451 0.0010 0.0010 0.9869 
Lx4A|LINE|L1 568.7 10564 379.039 294.73 0.0011 0.0010 0.9868 
PB1|SINE|Alu 97.1 11784 758.078 732.616 0.0017 0.0016 0.9866 
RLTR13D4|LTR|ERVK 595.2 205 1.692 0 0.0010 0.0010 0.9863 
L1ME3A|LINE|L1 237.7 2086 155.677 146.764 0.0013 0.0013 0.9863 
RodERV21-int|LTR|ERV1 577.4 1856 68.532 52.931 0.0011 0.0010 0.9863 
B1_Mm|SINE|Alu 131.1 42910 3303.055 3180.682 0.0016 0.0016 0.9863 
ORR1E-int|LTR|ERVL-MaLR 461.5 1446 31.305 21.654 0.0010 0.0010 0.9862 
Tigger5b|DNA|TcMar-Tigger 142.5 2473 43.996 38.495 0.0011 0.0011 0.9861 
Tigger13a|DNA|TcMar-Tigger 229 645 11.845 9.624 0.0011 0.0011 0.9861 
MTE2a|LTR|ERVL-MaLR 258.8 15148 580.404 517.282 0.0011 0.0011 0.9860 
L1MC3|LINE|L1 291.5 5288 118.45 95.036 0.0011 0.0011 0.9859 
MER89|LTR|ERV1 245.1 614 3.384 1.203 0.0010 0.0010 0.9858 
RLTR11A2|LTR|ERVK 369.8 2676 309.661 291.121 0.0013 0.0013 0.9857 
IAPLTR2b|LTR|ERVK 309.9 1017 44.842 39.698 0.0011 0.0011 0.9857 
RMER21B|LTR|ERV1 230.2 1252 34.689 30.075 0.0011 0.0011 0.9857 
MER104|DNA|TcMar-Tc2 131.2 295 4.23 3.609 0.0011 0.0011 0.9855 
Lx8b|LINE|L1 347.6 24166 707.314 575.025 0.0011 0.0011 0.9855 
MER34A1|LTR|ERV1 201.1 541 21.152 19.248 0.0012 0.0012 0.9853 
Lx5b|LINE|L1 644.7 7975 251.283 172.026 0.0010 0.0010 0.9853 
L1MEf|LINE|L1 256 3127 58.379 45.713 0.0011 0.0011 0.9853 
RLTR13C2|LTR|ERVK 596.7 844 38.073 30.075 0.0011 0.0011 0.9852 
RLTR17|LTR|ERVK 454.7 1758 126.91 113.08 0.0012 0.0011 0.9851 
RMER15-int|LTR|ERVL 365.3 3100 236.053 215.334 0.0012 0.0012 0.9849 
IAPEz-int|LTR|ERVK 1622.6 7319 3006.93 2781.292 0.0013 0.0012 0.9848 
L1MA8|LINE|L1 271.1 3882 83.761 66.164 0.0011 0.0011 0.9845 
RLTR20B3|LTR|ERVK 309.5 974 41.457 36.089 0.0011 0.0011 0.9843 
RLTR1D|LTR|ERV1 478.5 305 41.457 38.495 0.0013 0.0013 0.9842 
RMER17C2|LTR|ERVK 207.2 3413 54.148 42.104 0.0011 0.0011 0.9842 
IAPLTR3|LTR|ERVK 330.8 959 7.615 2.406 0.0010 0.0010 0.9840 
MIRc|SINE|MIR 104.1 23213 1254.721 1195.763 0.0015 0.0015 0.9839 
ORR1F|LTR|ERVL-MaLR 209.1 23086 555.021 467.96 0.0011 0.0011 0.9838 
MLT1C-int|LTR|ERVL-MaLR 279.5 122 4.23 3.609 0.0011 0.0011 0.9838 
MTB|LTR|ERVL-MaLR 333.6 6419 416.266 374.127 0.0012 0.0012 0.9835 
LTR41B|LTR|ERVL 192.4 290 3.384 2.406 0.0011 0.0010 0.9835 
MMERVK10D3_LTR|LTR|ERVK 320.6 174 3.384 2.406 0.0011 0.0010 0.9835 
MER46C|DNA|TcMar-Tigger 162.3 788 14.383 12.03 0.0011 0.0011 0.9835 
RLTR20A2B_MM|LTR|ERVK 299 438 16.921 14.436 0.0011 0.0011 0.9832 
MurERV4_19-int|LTR|ERVK 627.3 969 28.766 18.045 0.0010 0.0010 0.9832 
RMER17B|LTR|ERVK 580.9 2898 221.67 188.868 0.0011 0.0011 0.9828 
LTR41|LTR|ERVL 208.8 506 17.767 15.639 0.0012 0.0011 0.9828 
MLT1L|LTR|ERVL-MaLR 178.3 1535 54.995 49.322 0.0012 0.0012 0.9827 
ORR1A4|LTR|ERVL-MaLR 270.1 7791 856.222 804.794 0.0014 0.0014 0.9826 
B1_Mur3|SINE|Alu 124.1 24632 1858.814 1773.194 0.0016 0.0016 0.9826 
ORR1C2-int|LTR|ERVL-MaLR 534.5 914 62.609 52.931 0.0011 0.0011 0.9824 
LTR40a|LTR|ERVL 234.8 709 4.23 1.203 0.0010 0.0010 0.9823 
IAPEY2_LTR|LTR|ERVK 322.7 1062 13.537 7.218 0.0010 0.0010 0.9823 
ORR1A3|LTR|ERVL-MaLR 259.9 4381 301.201 275.483 0.0013 0.0012 0.9821 
RLTR12E|LTR|ERVK 361.3 615 45.688 40.901 0.0012 0.0012 0.9821 
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L1M2c|LINE|L1 304 321 4.23 2.406 0.0010 0.0010 0.9821 
B2_Mm1a|SINE|B2 168.5 18346 6537.578 6364.973 0.0031 0.0031 0.9821 
ERVB7_4-LTR_MM|LTR|ERVK 335.9 166 5.922 4.812 0.0011 0.0011 0.9820 
RLTR16C_MM|LTR|ERVK 377.4 360 13.537 10.827 0.0011 0.0011 0.9819 
L1M3|LINE|L1 241.7 7043 136.217 102.253 0.0011 0.0011 0.9815 
MER2|DNA|TcMar-Tigger 184.6 10246 302.893 262.25 0.0012 0.0011 0.9815 
LTR16A|LTR|ERVL 209.9 1472 16.921 10.827 0.0011 0.0010 0.9813 
LTR78|LTR|ERV1 200.2 583 5.922 3.609 0.0011 0.0010 0.9811 
MER74B|LTR|ERVL 237.9 324 7.615 6.015 0.0011 0.0011 0.9811 
MER5A|DNA|hAT-Charlie 109.7 8982 222.516 199.695 0.0012 0.0012 0.9811 
MLT1F2|LTR|ERVL-MaLR 243.5 2297 76.992 64.961 0.0011 0.0011 0.9811 
ERVB3_1-LTR_MM|LTR|ERVK 276.3 158 0.846 0 0.0010 0.0010 0.9810 
MER77|LTR|ERVL 246.7 570 21.152 18.045 0.0012 0.0011 0.9808 
L1MC5a|LINE|L1 195.4 2588 76.146 64.961 0.0012 0.0011 0.9808 
B1_Mus2|SINE|Alu 128.1 70891 5892.027 5599.877 0.0016 0.0016 0.9805 
ORR1A1|LTR|ERVL-MaLR 284.5 4414 219.132 190.071 0.0012 0.0012 0.9803 
L1ME2z|LINE|L1 233.6 1533 35.535 27.669 0.0011 0.0011 0.9800 
ORR1B2|LTR|ERVL-MaLR 259 8528 357.041 305.557 0.0012 0.0011 0.9799 
L1MA5A|LINE|L1 335.7 1231 46.534 37.292 0.0011 0.0011 0.9799 
B1_Mus1|SINE|Alu 133.3 95081 7075.678 6676.546 0.0016 0.0015 0.9798 
RMER6A|LTR|ERVK 449.8 3983 369.732 326.008 0.0012 0.0012 0.9798 
LTR37A|LTR|ERV1 189.9 549 3.384 1.203 0.0010 0.0010 0.9797 
IAPEy-int|LTR|ERVK 3099.7 755 69.378 20.451 0.0010 0.0010 0.9797 
MER57C2|LTR|ERV1 193.6 415 1.692 0 0.0010 0.0010 0.9794 
RLTR51A_Mm|LTR|ERVK? 132.7 3523 51.61 40.901 0.0011 0.0011 0.9794 
MERVL-int|LTR|ERVL 1660.9 2600 401.037 303.151 0.0011 0.0011 0.9793 
Tigger17c|DNA|TcMar-Tigger 201.3 649 10.153 7.218 0.0011 0.0011 0.9792 
RLTR1D2_MM|LTR|ERV1 492.8 192 11.845 9.624 0.0011 0.0011 0.9791 
RLTR20B2|LTR|ERVK 301.8 880 49.918 43.307 0.0012 0.0012 0.9790 
RLTR21|LTR|ERVK 355.8 3816 171.752 139.546 0.0011 0.0011 0.9789 
MTE-int|LTR|ERVL-MaLR 348.8 4958 520.333 472.772 0.0013 0.0013 0.9789 
MER57E1|LTR|ERV1 186.2 210 0.846 0 0.0010 0.0010 0.9788 
Kanga1a|DNA|TcMar-Tc2 204.5 191 0.846 0 0.0010 0.0010 0.9788 
MLT1E3|LTR|ERVL-MaLR 227.5 1020 29.612 24.06 0.0011 0.0011 0.9788 
RLTR44B|LTR|ERVK 307.9 275 6.769 4.812 0.0011 0.0011 0.9786 
L2|LINE|L2 196.1 17614 632.86 544.95 0.0012 0.0012 0.9785 
RLTR13B3|LTR|ERVK 816.6 265 8.461 3.609 0.0010 0.0010 0.9784 
RLTR41A2|LTR|ERV1 353.1 440 5.922 2.406 0.0010 0.0010 0.9782 
RMER15|LTR|ERVL 219.7 18077 395.96 300.745 0.0011 0.0011 0.9782 
MARNA|DNA|TcMar-Mariner 179.4 562 32.997 30.075 0.0013 0.0013 0.9782 
RLTR44E|LTR|ERVK 338.3 122 3.384 2.406 0.0011 0.0011 0.9781 
ORR1B2-int|LTR|ERVL-MaLR 564.9 857 62.609 50.525 0.0011 0.0011 0.9779 
RSINE1|SINE|B4 124.1 11580
6 
4907.202 4479.902 0.0013 0.0013 0.9778 
L1MC|LINE|L1 233.3 5426 202.211 169.62 0.0012 0.0011 0.9778 
BLACKJACK|DNA|hAT-
Blackjack 
302.3 716 13.537 8.421 0.0011 0.0010 0.9778 
RLTR24|LTR|ERV1 326.7 1240 36.381 26.466 0.0011 0.0011 0.9775 
MLT2F|LTR|ERVL 219.6 574 55.841 51.728 0.0014 0.0014 0.9774 
L1M3e|LINE|L1 279.8 652 31.305 26.466 0.0012 0.0011 0.9774 
RLTR26|LTR|ERVK 341.6 408 11.845 8.421 0.0011 0.0011 0.9774 
L1M4|LINE|L1 242.6 13935 493.258 405.405 0.0011 0.0011 0.9773 
MTC|LTR|ERVL-MaLR 274 27489 1220.032 1021.331 0.0012 0.0011 0.9773 
RMER4B|LTR|ERVK 303.7 5158 368.886 324.805 0.0012 0.0012 0.9772 
L1M5|LINE|L1 213.7 16596 432.341 340.444 0.0011 0.0011 0.9769 
RLTR13D1|LTR|ERVK 573.1 255 5.922 2.406 0.0010 0.0010 0.9769 
Lx8|LINE|L1 334.1 49141 1907.04 1480.87 0.0011 0.0011 0.9767 
MER68-int|LTR|ERVL 251 77 1.692 1.203 0.0011 0.0011 0.9767 
RMER17A2|LTR|ERVK 459.5 2598 231.823 198.492 0.0012 0.0012 0.9766 
RLTR14_RN|LTR|ERV1 256.5 1148 30.458 22.857 0.0011 0.0011 0.9766 
RMER20A|LTR|ERVK 292.8 1559 54.148 42.104 0.0011 0.0011 0.9764 
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MLT1G3|LTR|ERVL-MaLR 221 1075 27.92 21.654 0.0011 0.0011 0.9764 
RLTR11C_MM|LTR|ERVK 357.4 858 43.15 34.886 0.0011 0.0011 0.9764 
RMER19C|LTR|ERVK 408.6 2729 54.148 26.466 0.0010 0.0010 0.9763 
IAP1-MM_I-int|LTR|ERVK 827 479 21.998 12.03 0.0011 0.0010 0.9762 
RLTR28|LTR|ERVL 372.4 1949 258.051 234.581 0.0014 0.0013 0.9761 
MTE2b|LTR|ERVL-MaLR 232.4 14367 432.341 341.647 0.0011 0.0011 0.9760 
Tigger20a|DNA|TcMar-Tigger 196.1 188 3.384 2.406 0.0011 0.0011 0.9757 
MMERVK9C_I-int|LTR|ERVK 1074.5 1807 332.505 276.686 0.0012 0.0011 0.9755 
RLTR20C|LTR|ERVK 227.8 263 10.153 8.421 0.0012 0.0011 0.9753 
ORR1A3-int|LTR|ERVL-MaLR 320.4 2435 82.915 61.352 0.0011 0.0011 0.9750 
ORR1B1|LTR|ERVL-MaLR 296.4 17313 654.858 510.064 0.0011 0.0011 0.9750 
RMER10B|LTR|ERVL 248 3002 203.057 179.244 0.0013 0.0012 0.9749 
B1F1|SINE|Alu 109 19678 1257.259 1171.704 0.0016 0.0015 0.9749 
ERVL-B4-int|LTR|ERVL 323.1 1384 33.843 21.654 0.0011 0.0010 0.9747 
IAP1-MM_LTR|LTR|ERVK 272.6 420 4.23 1.203 0.0010 0.0010 0.9745 
Tigger14a|DNA|TcMar-Tigger 143.4 225 0.846 0 0.0010 0.0010 0.9744 
ORR1A2|LTR|ERVL-MaLR 279.3 14843 725.081 599.085 0.0012 0.0011 0.9741 
RLTR13C1|LTR|ERVK 712.4 309 19.46 13.233 0.0011 0.0011 0.9740 
ERVB2_1A-I_MM-int|LTR|ERVK 574.7 289 11.845 7.218 0.0011 0.0010 0.9740 
MER63A|DNA|hAT-Blackjack 156.5 635 7.615 4.812 0.0011 0.0010 0.9738 
RLTR13G|LTR|ERVK 347.6 877 62.609 52.931 0.0012 0.0012 0.9737 
L1MA6|LINE|L1 275.5 6985 143.832 89.021 0.0011 0.0010 0.9735 
B4A|SINE|B4 181.7 10707
3 
5533.294 4869.668 0.0013 0.0013 0.9734 
RLTR17B_Mm|LTR|ERVK 136.5 27369 566.02 451.118 0.0012 0.0011 0.9733 
RMER16|LTR|ERVK 348.8 471 46.534 40.901 0.0013 0.0012 0.9733 
CYRA11_Mm|Unknown|Y-
chromosome 
142.8 2869 21.152 9.624 0.0011 0.0010 0.9732 
L1MD2|LINE|L1 261.6 3227 164.137 137.14 0.0012 0.0012 0.9732 
MLT2C1|LTR|ERVL 203.1 872 13.537 8.421 0.0011 0.0010 0.9732 
L1ME1|LINE|L1 279.3 5261 263.128 216.537 0.0012 0.0011 0.9731 
RMER1B|Other|Other 461.4 7511 606.632 496.831 0.0012 0.0011 0.9730 
MamRep4096|DNA|hAT? 169.3 180 0.846 0 0.0010 0.0010 0.9730 
MTD|LTR|ERVL-MaLR 259.8 51544 2064.409 1645.678 0.0012 0.0011 0.9729 
L1MB7|LINE|L1 269.6 6956 390.038 328.414 0.0012 0.0012 0.9728 
Charlie12|DNA|hAT-Charlie 196 902 16.075 10.827 0.0011 0.0011 0.9728 
LTRIS2|LTR|ERV1 458.5 1423 118.45 97.441 0.0012 0.0011 0.9727 
L1M4b|LINE|L1 301.4 2190 216.594 192.477 0.0013 0.0013 0.9725 
L1ME2|LINE|L1 269.3 2633 76.992 55.337 0.0011 0.0011 0.9725 
ORR1B1-int|LTR|ERVL-MaLR 467.8 2965 227.593 182.853 0.0012 0.0011 0.9723 
L2b|LINE|L2 123.7 13720 478.029 417.434 0.0013 0.0012 0.9721 
ORR1C1-int|LTR|ERVL-MaLR 575.8 783 41.457 27.669 0.0011 0.0011 0.9720 
RMER13A1|LTR|ERVK 483.2 1082 76.992 60.149 0.0011 0.0011 0.9719 
MLT1C|LTR|ERVL-MaLR 216.5 7791 297.816 241.799 0.0012 0.0011 0.9718 
MTEb|LTR|ERVL-MaLR 208.3 10811 344.35 270.671 0.0012 0.0011 0.9716 
L1ME3B|LINE|L1 225.5 735 32.151 26.466 0.0012 0.0012 0.9713 
LTR16B2|LTR|ERVL 221.6 384 2.538 0 0.0010 0.0010 0.9710 
L1MD1|LINE|L1 294 2268 125.218 102.253 0.0012 0.0012 0.9710 
RMER6B|LTR|ERVK 297.4 1360 77.838 63.758 0.0012 0.0012 0.9708 
L1MD|LINE|L1 223.3 6361 155.677 109.471 0.0011 0.0011 0.9707 
MLT1H2|LTR|ERVL-MaLR 165.3 1034 10.153 4.812 0.0011 0.0010 0.9705 
MLT1H|LTR|ERVL-MaLR 198.3 2322 33.843 19.248 0.0011 0.0010 0.9705 
MER67C|LTR|ERV1 246.3 620 5.922 1.203 0.0010 0.0010 0.9703 
PB1D9|SINE|Alu 96.9 28939 2270.004 2118.45 0.0018 0.0018 0.9701 
MLT1F-int|LTR|ERVL-MaLR 249.9 417 14.383 10.827 0.0011 0.0011 0.9700 
RLTR10B|LTR|ERVK 201.6 477 22.844 19.248 0.0012 0.0012 0.9698 
MLT1D|LTR|ERVL-MaLR 219.2 8368 246.206 182.853 0.0011 0.0011 0.9695 
Zaphod3|DNA|hAT-Tip100 217.5 454 9.307 6.015 0.0011 0.0011 0.9695 
RMER10A|LTR|ERVL 272.1 4464 239.438 194.883 0.0012 0.0012 0.9694 
RLTR19B|LTR|ERVK 382 224 10.153 7.218 0.0011 0.0011 0.9693 
MERVL_2A-int|LTR|ERVL 528 3899 309.661 236.987 0.0012 0.0011 0.9693 
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LTR80A|LTR|ERVL 236.4 112 0.846 0 0.0010 0.0010 0.9690 
L1MD3|LINE|L1 212.4 2480 82.915 63.758 0.0012 0.0011 0.9686 
MER45C|DNA|hAT-Tip100 185.1 290 4.23 2.406 0.0011 0.0010 0.9685 
RMER6BA|LTR|ERVK 234.3 957 32.151 24.06 0.0011 0.0011 0.9684 
MER21-int|LTR|ERVL 246.2 105 0.846 0 0.0010 0.0010 0.9683 
RLTR26_Mus|LTR|ERVK 480.1 1091 37.227 19.248 0.0011 0.0010 0.9680 
LTR33C|LTR|ERVL 197.9 232 33.843 31.278 0.0017 0.0017 0.9678 
LSU-rRNA_Hsa|rRNA|rRNA 146.1 481 4559.468 4410.129 0.0659 0.0638 0.9677 
L1ME3Cz|LINE|L1 197.5 1051 14.383 7.218 0.0011 0.0010 0.9677 
ORR1F-int|LTR|ERVL-MaLR 394.2 395 15.229 9.624 0.0011 0.0011 0.9672 
RMER19B2|LTR|ERVK 470.6 2296 164.137 122.704 0.0012 0.0011 0.9667 
MER110A|LTR|ERV1 189.6 196 2.538 1.203 0.0011 0.0010 0.9664 
RLTR12B|LTR|ERVK 349.6 909 58.379 45.713 0.0012 0.0011 0.9663 
RLTR20B4_MM|LTR|ERVK 314 416 21.998 16.842 0.0012 0.0011 0.9662 
MLT1J1|LTR|ERVL-MaLR 157.5 1135 23.69 16.842 0.0011 0.0011 0.9662 
MT2A|LTR|ERVL 255.2 10140 351.119 251.423 0.0011 0.0011 0.9661 
MIR|SINE|MIR 127.4 38978 966.211 763.893 0.0012 0.0012 0.9659 
ORR1D2-int|LTR|ERVL-MaLR 421.7 1361 131.141 107.065 0.0012 0.0012 0.9659 
RLTR31C_MM|LTR|ERVK 302.9 726 65.147 55.337 0.0013 0.0013 0.9656 
MTEa-int|LTR|ERVL-MaLR 463.6 1368 78.684 54.134 0.0011 0.0011 0.9656 
RLTR13D|LTR|ERVK 521.9 45 0.846 0 0.0010 0.0010 0.9652 
MLT1E1A|LTR|ERVL-MaLR 221.9 1154 30.458 20.451 0.0011 0.0011 0.9651 
URR1A|DNA|hAT-Charlie 184.5 17621 840.147 696.526 0.0013 0.0012 0.9649 
LTR105_Mam|LTR|ERVL 187.5 124 0.846 0 0.0010 0.0010 0.9649 
Charlie25|DNA|hAT-Charlie 271 301 4.23 1.203 0.0011 0.0010 0.9647 
Arthur1B|DNA|hAT-Tip100 213.9 597 5.922 1.203 0.0010 0.0010 0.9647 
MLTR11B|LTR|ERVK 289.6 2985 101.528 67.367 0.0011 0.0011 0.9646 
LTR37-int|LTR|ERV1 253.3 239 8.461 6.015 0.0011 0.0011 0.9646 
MIRb|SINE|MIR 128.4 42160 1455.239 1211.402 0.0013 0.0012 0.9645 
B4|SINE|B4 167.7 64020 2760.724 2279.649 0.0013 0.0012 0.9644 
ORR1A0-int|LTR|ERVL-MaLR 1238.1 456 97.298 73.382 0.0012 0.0011 0.9639 
L2a|LINE|L2 167.1 24277 988.209 804.794 0.0012 0.0012 0.9636 
L1ME3|LINE|L1 237.1 1527 47.38 32.48 0.0011 0.0011 0.9636 
MLT1E2|LTR|ERVL-MaLR 231.2 1821 82.069 63.758 0.0012 0.0012 0.9636 
L1MB2|LINE|L1 259.4 2927 254.667 217.74 0.0013 0.0013 0.9636 
RMER5|LTR|ERV1 280.2 7418 241.13 156.388 0.0011 0.0011 0.9635 
L1M7|LINE|L1 214.4 207 1.692 0 0.0010 0.0010 0.9633 
UCON2|Unknown|Unknown 141.3 82 1.692 1.203 0.0011 0.0011 0.9632 
RMER13A|LTR|ERVK 518.4 1010 54.995 33.683 0.0011 0.0011 0.9632 
RMER3D-int|LTR|ERVK 449.4 2711 549.945 484.801 0.0015 0.0014 0.9632 
B1_Mur4|SINE|Alu 122.3 41031 2681.194 2396.339 0.0015 0.0015 0.9630 
MYSERV16_I-int|LTR|ERVK 568.4 2516 91.375 34.886 0.0011 0.0010 0.9629 
RLTR13D3A|LTR|ERVK 553.6 162 8.461 4.812 0.0011 0.0011 0.9628 
B3A|SINE|B2 149.4 92925 3842.001 3181.885 0.0013 0.0012 0.9628 
Tigger1|DNA|TcMar-Tigger 345.5 1025 57.533 42.104 0.0012 0.0011 0.9625 
ERVB3_1-I_MM-int|LTR|ERVK 821.9 134 9.307 4.812 0.0011 0.0010 0.9624 
LTR10_RN|LTR|ERVK 250.2 546 56.687 49.322 0.0014 0.0014 0.9619 
RLTR10-int|LTR|ERVK 738.9 2617 241.13 157.591 0.0011 0.0011 0.9616 
MLT1F|LTR|ERVL-MaLR 238.6 1561 28.766 13.233 0.0011 0.0010 0.9613 
MamRep434|DNA|TcMar-Tigger 185 518 38.919 33.683 0.0014 0.0014 0.9611 
RLTR46A|LTR|ERVK 293.5 71 0.846 0 0.0010 0.0010 0.9610 
RLTR31B2|LTR|ERVK 292.2 1192 61.763 45.713 0.0012 0.0011 0.9609 
L1M4a1|LINE|L1 244.2 607 16.075 9.624 0.0011 0.0011 0.9607 
MER124|DNA?|DNA? 164 252 1.692 0 0.0010 0.0010 0.9607 
RMER13A2|LTR|ERVK 460.1 1473 109.143 78.194 0.0012 0.0011 0.9607 
BGLII|LTR|ERVK 348.7 2269 610.016 554.574 0.0018 0.0017 0.9604 
Ricksha_c|DNA|MULE-MuDR 153.6 405 5.076 2.406 0.0011 0.0010 0.9603 
RLTR10D2|LTR|ERVK 317.5 225 4.23 1.203 0.0011 0.0010 0.9600 
B2_Mm1t|SINE|B2 164 23218 3859.768 3552.403 0.0020 0.0019 0.9599 
ID_B1|SINE|B4 130.7 11082 7677.233 6788.423 0.0015 0.0015 0.9599 
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MRLTR33|LTR|ERVK 224.5 624 68.532 60.149 0.0015 0.0014 0.9598 
MER113|DNA|hAT-Charlie 189.5 643 75.3 67.367 0.0016 0.0016 0.9598 
LTR33A_|LTR|ERVL 196.8 474 12.691 8.421 0.0011 0.0011 0.9597 
RMER30|DNA|hAT-Charlie 122.5 3588 143.832 120.298 0.0013 0.0013 0.9597 
BGLII_B2|LTR|ERVK 271.2 359 342.658 324.805 0.0045 0.0043 0.9594 
RLTR19D|LTR|ERVK 312.4 64 0.846 0 0.0010 0.0010 0.9594 
MurERV4-int|LTR|ERVK 571.6 1525 284.279 236.987 0.0013 0.0013 0.9591 
RLTR30C_MM|LTR|ERV1 318.9 124 1.692 0 0.0010 0.0010 0.9590 
RLTR13D6|LTR|ERVK 688.8 805 33.843 9.624 0.0011 0.0010 0.9588 
MLT1I|LTR|ERVL-MaLR 169.3 1777 32.997 19.248 0.0011 0.0011 0.9588 
MER31B|LTR|ERV1 217.5 558 17.767 12.03 0.0011 0.0011 0.9588 
MLT1J2|LTR|ERVL-MaLR 170.3 1110 16.921 8.421 0.0011 0.0010 0.9587 
MTA_Mm-int|LTR|ERVL-MaLR 909.9 3027 667.549 525.703 0.0012 0.0012 0.9585 
MER21B|LTR|ERVL 262.4 1618 125.218 102.253 0.0013 0.0012 0.9582 
ORSL|DNA|hAT-Tip100 138.3 281 4.23 2.406 0.0011 0.0011 0.9577 
RMER4A|LTR|ERVK 242.8 3287 346.888 298.339 0.0014 0.0014 0.9576 
RMER17D2|LTR|ERVK 414.1 1783 90.529 55.337 0.0011 0.0011 0.9575 
RLTR9B2|LTR|ERVK 324 178 5.076 2.406 0.0011 0.0010 0.9574 
L1MB3|LINE|L1 257.4 5343 249.59 180.447 0.0012 0.0011 0.9574 
RLTR42-int|LTR|ERVK 268.6 2473 104.913 72.179 0.0012 0.0011 0.9574 
MLT1B|LTR|ERVL-MaLR 203.4 9316 395.96 298.339 0.0012 0.0012 0.9574 
LTR40A1|LTR|ERVL 166.5 114 0.846 0 0.0010 0.0010 0.9573 
RLTR20B3A_MM|LTR|ERVK 320.5 843 34.689 21.654 0.0011 0.0011 0.9572 
B3|SINE|B2 167.1 14842
7 
8204.335 6790.829 0.0013 0.0013 0.9572 
LTR88b|LTR|Gypsy? 160.5 178 2.538 1.203 0.0011 0.0010 0.9571 
Tigger7|DNA|TcMar-Tigger 209.7 5206 208.979 152.779 0.0012 0.0011 0.9568 
MER31-int|LTR|ERV1 250.8 149 1.692 0 0.0010 0.0010 0.9567 
Charlie4a|DNA|hAT-Charlie 209.2 1121 24.536 13.233 0.0011 0.0011 0.9564 
MER58D|DNA|hAT-Charlie 126.9 292 1.692 0 0.0010 0.0010 0.9563 
RLTR13A|LTR|ERVK 658.4 211 7.615 1.203 0.0011 0.0010 0.9562 
L1M4c|LINE|L1 303.7 2049 104.067 72.179 0.0012 0.0011 0.9561 
LTR69|LTR|ERVL 248.5 74 0.846 0 0.0010 0.0010 0.9560 
B2_Mm2|SINE|B2 153.7 90007 5896.257 5027.258 0.0014 0.0014 0.9560 
L1MCc|LINE|L1 226.7 529 11.845 6.015 0.0011 0.0011 0.9558 
MamRep137|DNA|TcMar-Tigger 162.4 339 5.076 2.406 0.0011 0.0010 0.9556 
MLTR18B_MM|LTR|ERVK 359.5 468 112.527 99.847 0.0017 0.0016 0.9548 
LTR33A|LTR|ERVL 201.4 504 38.919 32.48 0.0014 0.0013 0.9541 
MER47B|DNA|TcMar-Tigger 210.2 509 15.229 9.624 0.0011 0.0011 0.9541 
MT2C_Mm|LTR|ERVL 362.5 1982 88.837 51.728 0.0011 0.0011 0.9540 
RLTR9F|LTR|ERVK 342.7 411 11.845 4.812 0.0011 0.0010 0.9539 
UCON26|Unknown|Unknown 161.9 108 0.846 0 0.0010 0.0010 0.9538 
RLTR20C2_MM|LTR|ERVK 125.8 3620 109.143 83.006 0.0012 0.0012 0.9537 
LTR107_Mam|LTR|LTR 185.9 93 0.846 0 0.0010 0.0010 0.9533 
MT2B|LTR|ERVL 127.4 13977 906.14 780.735 0.0015 0.0014 0.9533 
Charlie13a|DNA|hAT-Charlie 236.4 184 5.922 3.609 0.0011 0.0011 0.9532 
L1MC2|LINE|L1 285.4 2252 84.607 50.525 0.0011 0.0011 0.9531 
BGLII_C|LTR|ERVK 231.5 74 0.846 0 0.0010 0.0010 0.9529 
MLT2B3|LTR|ERVL 242.1 1483 27.92 9.624 0.0011 0.0010 0.9527 
Kanga11a|DNA|TcMar-Tc2 227.7 187 3.384 1.203 0.0011 0.0010 0.9525 
RLTR18B|LTR|ERVK 320.8 989 60.071 42.104 0.0012 0.0011 0.9524 
RLTR13B4|LTR|ERVK 739.7 412 20.306 4.812 0.0011 0.0010 0.9523 
PB1D10|SINE|Alu 95.1 65054 4439.326 3932.545 0.0017 0.0016 0.9523 
LTRIS4|LTR|ERV1 352 147 17.767 14.436 0.0013 0.0013 0.9521 
ERV3-16A3_I-int|LTR|ERVL 261 908 39.765 26.466 0.0012 0.0011 0.9519 
LTR81C|LTR|Gypsy 181 99 16.075 14.436 0.0019 0.0018 0.9518 
B1_Mur2|SINE|Alu 122.1 31869 2621.123 2306.115 0.0017 0.0016 0.9516 
RLTR16|LTR|ERVK 317.2 1350 111.681 85.412 0.0013 0.0012 0.9513 
RLTR9A3A|LTR|ERVK 296.8 222 3.384 0 0.0011 0.0010 0.9512 
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Tigger17a|DNA|TcMar-Tigger 310 908 42.303 26.466 0.0012 0.0011 0.9511 
ID4|SINE|ID 70.8 23970 1264.874 1119.975 0.0017 0.0017 0.9511 
MER94|DNA|hAT-Blackjack 105.5 466 2.538 0 0.0011 0.0010 0.9509 
MamGypLTR2c|LTR|Gypsy 148.8 110 0.846 0 0.0011 0.0010 0.9509 
L1MB4|LINE|L1 251 2690 143.832 103.456 0.0012 0.0012 0.9507 
Mam_R4|LINE|Dong-R4 176.5 138 2.538 1.203 0.0011 0.0010 0.9504 
RLTR30D2_MM|LTR|ERV1 352.6 741 61.763 45.713 0.0012 0.0012 0.9503 
ID4_|SINE|ID 70 26384 1098.198 951.558 0.0016 0.0015 0.9502 
RLTR16B_MM|LTR|ERVK 375.8 635 25.382 12.03 0.0011 0.0011 0.9494 
Cheshire|DNA|hAT-Charlie 195.2 1091 22.844 10.827 0.0011 0.0011 0.9490 
MER90|LTR|ERV1 223.7 245 4.23 1.203 0.0011 0.0010 0.9487 
ORR1E|LTR|ERVL-MaLR 235.1 22742 884.989 564.198 0.0012 0.0011 0.9485 
RLTR13D3|LTR|ERVK 640.5 339 24.536 12.03 0.0011 0.0011 0.9483 
Charlie7|DNA|hAT-Charlie 248 844 43.15 30.075 0.0012 0.0011 0.9482 
MLT1E1|LTR|ERVL-MaLR 214 576 21.998 14.436 0.0012 0.0011 0.9479 
RLTR48C|LTR|ERV1 405.1 149 8.461 4.812 0.0011 0.0011 0.9470 
RLTR18|LTR|ERVK 395.2 610 36.381 21.654 0.0012 0.0011 0.9469 
RLTR20A4|LTR|ERVK 78.7 11527 306.277 241.799 0.0013 0.0013 0.9469 
X3_LINE|LINE|RTE-BovB 85.7 260 10.153 8.421 0.0015 0.0014 0.9466 
L1ME4c|LINE|L1 190.3 968 115.912 99.847 0.0016 0.0015 0.9465 
Tigger12A|DNA|TcMar-Tigger 173.6 86 0.846 0 0.0011 0.0010 0.9464 
ID2|SINE|ID 70.7 5671 293.586 256.235 0.0017 0.0016 0.9462 
URR1B|DNA|hAT-Charlie 173.8 16889 956.058 745.848 0.0013 0.0013 0.9460 
RLTR20A2|LTR|ERVK 280 368 21.152 14.436 0.0012 0.0011 0.9459 
Kanga1|DNA|TcMar-Tc2 206.7 321 5.076 1.203 0.0011 0.0010 0.9458 
Charlie9|DNA|hAT-Charlie 127 232 1.692 0 0.0011 0.0010 0.9457 
RLTR20A3_MM|LTR|ERVK 290.7 880 43.996 27.669 0.0012 0.0011 0.9455 
L1ME3G|LINE|L1 177.6 1161 130.295 111.877 0.0016 0.0015 0.9453 
L1MC5|LINE|L1 227 3476 176.828 123.907 0.0012 0.0012 0.9452 
LTRIS_Mus|LTR|ERV1 508.2 919 170.906 135.937 0.0014 0.0013 0.9452 
LTR84b|LTR|ERVL 192.1 187 3.384 1.203 0.0011 0.0010 0.9445 
MTE2a-int|LTR|ERVL-MaLR 441.9 795 32.151 10.827 0.0011 0.0010 0.9444 
L1ME3E|LINE|L1 238.3 327 21.152 15.639 0.0013 0.0012 0.9444 
MTEb-int|LTR|ERVL-MaLR 458.6 635 46.534 27.669 0.0012 0.0011 0.9441 
B1F|SINE|Alu 109.8 45170 2567.82 2146.118 0.0015 0.0014 0.9440 
RLTR18-int|LTR|ERVK 322.2 506 16.075 6.015 0.0011 0.0010 0.9438 
L2c|LINE|L2 126.5 12298 675.163 549.762 0.0014 0.0014 0.9438 
RLTR9A3|LTR|ERVK 283.2 774 24.536 10.827 0.0011 0.0010 0.9438 
LTR48|LTR|ERV1 163.1 651 10.153 3.609 0.0011 0.0010 0.9437 
MER97b|DNA|hAT-Tip100 247.2 55 8.461 7.218 0.0016 0.0015 0.9436 
LTR33B|LTR|ERVL 180.7 268 16.921 13.233 0.0013 0.0013 0.9436 
Charlie1a|DNA|hAT-Charlie 278 2660 181.059 128.719 0.0012 0.0012 0.9431 
LTRIS6|LTR|ERV1 281.6 149 2.538 0 0.0011 0.0010 0.9430 
L1ME3F|LINE|L1 247.9 308 5.922 1.203 0.0011 0.0010 0.9426 
MER53|DNA|hAT 121.6 1693 32.997 19.248 0.0012 0.0011 0.9424 
RLTR13D3A1|LTR|ERVK 478.7 613 62.609 42.104 0.0012 0.0011 0.9424 
RLTR9B|LTR|ERVK 333 206 9.307 4.812 0.0011 0.0011 0.9423 
RMER17B2|LTR|ERVK 474.3 898 33.843 7.218 0.0011 0.0010 0.9421 
L1M1|LINE|L1 146.5 881 11.845 3.609 0.0011 0.0010 0.9416 
MLT1A0|LTR|ERVL-MaLR 201.8 10413 497.489 344.053 0.0012 0.0012 0.9410 
Charlie15b|DNA|hAT-Charlie 198 272 3.384 0 0.0011 0.0010 0.9409 
LTR65|LTR|ERV1 202.8 162 8.461 6.015 0.0013 0.0012 0.9408 
LTR31|LTR|ERV1 214.2 187 2.538 0 0.0011 0.0010 0.9404 
MTD-int|LTR|ERVL-MaLR 454.5 2521 227.593 144.358 0.0012 0.0011 0.9394 
ID|SINE|ID 59.3 8022 293.586 246.611 0.0016 0.0015 0.9389 
MER67A|LTR|ERV1 221.6 176 2.538 0 0.0011 0.0010 0.9389 
ORR1G-int|LTR|ERVL-MaLR 371.2 70 1.692 0 0.0011 0.0010 0.9389 
MLT1E|LTR|ERVL-MaLR 216.8 534 15.229 7.218 0.0011 0.0011 0.9388 
MYSERV-int|LTR|ERVK 448.9 1435 117.604 70.976 0.0012 0.0011 0.9388 
MamRep38|DNA|hAT 140.9 212 18.614 15.639 0.0016 0.0015 0.9386 
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MER91A|DNA|hAT-Tip100 115.6 370 19.46 15.639 0.0015 0.0014 0.9386 
MER5A1|DNA|hAT-Charlie 113.7 3905 62.609 31.278 0.0011 0.0011 0.9382 
Tigger6a|DNA|TcMar-Tigger 309.9 369 10.153 2.406 0.0011 0.0010 0.9378 
RLTR20A|LTR|ERVK 233.6 361 28.766 21.654 0.0013 0.0013 0.9371 
LTR84a|LTR|ERVL 185.2 136 1.692 0 0.0011 0.0010 0.9371 
ERVB7_2-LTR_MM|LTR|ERVK 302.3 425 27.92 18.045 0.0012 0.0011 0.9369 
MER44B|DNA|TcMar-Tigger 225.3 1493 62.609 37.292 0.0012 0.0011 0.9365 
MER20|DNA|hAT-Charlie 147.1 5994 365.502 286.31 0.0014 0.0013 0.9365 
RLTR11D|LTR|ERVK 347.5 529 25.382 12.03 0.0011 0.0011 0.9362 
MLTR31F_MM|LTR|ERVK 362.7 403 20.306 9.624 0.0011 0.0011 0.9358 
LTR81A|LTR|Gypsy 168 180 3.384 1.203 0.0011 0.0010 0.9351 
MLT1J|LTR|ERVL-MaLR 182.8 2943 142.986 98.644 0.0013 0.0012 0.9349 
UCON4|Unknown|Unknown 142.6 72 40.611 37.292 0.0050 0.0046 0.9348 
BGLII_B|LTR|ERVK 354.4 960 77.838 50.525 0.0012 0.0011 0.9347 
RMER12C|LTR|ERVK 187 4954 558.406 460.742 0.0016 0.0015 0.9342 
MIR3|SINE|MIR 98.4 16085 851.992 689.308 0.0015 0.0014 0.9332 
RLTR12C|LTR|ERVK 295.5 319 85.453 73.382 0.0019 0.0018 0.9328 
Tigger6b|DNA|TcMar-Tigger 216.2 217 3.384 0 0.0011 0.0010 0.9327 
MER2B|DNA|TcMar-Tigger 122.1 1093 35.535 24.06 0.0013 0.0012 0.9321 
ORR1G|LTR|ERVL-MaLR 193.4 4680 175.982 102.253 0.0012 0.0011 0.9318 
MLTR12|LTR|ERV1 247.8 477 17.767 8.421 0.0012 0.0011 0.9313 
IAPEY5_LTR|LTR|ERVK 285.5 237 7.615 2.406 0.0011 0.0010 0.9308 
MER3|DNA|hAT-Charlie 133.1 2967 188.673 147.967 0.0015 0.0014 0.9302 
RLTR9A|LTR|ERVK 308.1 648 25.382 9.624 0.0011 0.0010 0.9300 
IAPLTR2a2_Mm|LTR|ERVK 407 1541 124.372 70.976 0.0012 0.0011 0.9290 
MLTR13|LTR|ERVK 307.1 205 17.767 12.03 0.0013 0.0012 0.9289 
FordPrefect_a|DNA|hAT-Tip100 184.1 60 0.846 0 0.0011 0.0010 0.9289 
MER45A|DNA|hAT-Tip100 121.6 769 8.461 1.203 0.0011 0.0010 0.9288 
ERVB4_1B-LTR_MM|LTR|ERVK 472.9 648 75.3 48.119 0.0012 0.0012 0.9288 
RLTR49|LTR|ERVK 295.2 933 38.073 15.639 0.0011 0.0011 0.9284 
LTR101_Mam|LTR|ERVL 240.1 157 4.23 1.203 0.0011 0.0010 0.9278 
MurSatRep1|Unknown|Unknown 353.6 2600 467.876 366.909 0.0015 0.0014 0.9272 
L3b|LINE|CR1 109.5 2304 113.373 86.615 0.0014 0.0013 0.9268 
L1MEi|LINE|L1 215.1 478 21.152 12.03 0.0012 0.0011 0.9264 
MER5C1|DNA|hAT-Charlie 140.6 75 0.846 0 0.0011 0.0010 0.9257 
Tigger2b|DNA|TcMar-Tigger 237.2 176 3.384 0 0.0011 0.0010 0.9250 
PB1D7|SINE|Alu 96.5 24346 2132.095 1792.442 0.0019 0.0018 0.9242 
B1F2|SINE|Alu 110.9 16513 1382.477 1134.411 0.0018 0.0016 0.9228 
MLT1O|LTR|ERVL-MaLR 172 538 16.921 8.421 0.0012 0.0011 0.9223 
RLTR12D|LTR|ERVK 313.4 647 40.611 21.654 0.0012 0.0011 0.9221 
BC1_Mm|scRNA|scRNA 81 6758 860.453 750.66 0.0026 0.0024 0.9220 
RLTR10A|LTR|ERVK 348.3 800 86.299 57.743 0.0013 0.0012 0.9218 
RLTR41C|LTR|ERV1 291.4 157 31.305 25.263 0.0017 0.0016 0.9216 
hAT-N1_Mam|DNA|hAT? 160.1 185 2.538 0 0.0011 0.0010 0.9211 
L4_B_Mam|LINE|RTE-X 163.4 361 5.076 0 0.0011 0.0010 0.9208 
SRV_MM-int|LTR|ERVK 757.2 129 20.306 10.827 0.0012 0.0011 0.9197 
MLT1E1A-int|LTR|ERVL-MaLR 344.3 28 0.846 0 0.0011 0.0010 0.9193 
MER96|DNA|hAT-Tip100 117.4 104 7.615 6.015 0.0016 0.0015 0.9193 
MER31A|LTR|ERV1 239.2 707 34.689 18.045 0.0012 0.0011 0.9183 
Tigger15a|DNA|TcMar-Tigger 180.4 704 55.841 40.901 0.0014 0.0013 0.9183 
ERVB5_1-LTR_MM|LTR|ERVK 377.2 143 12.691 7.218 0.0012 0.0011 0.9179 
SSU-rRNA_Hsa|rRNA|rRNA 322.1 45 3584.796 3284.139 0.2483 0.2276 0.9165 
LTR28B|LTR|ERV1 117 144 30.458 26.466 0.0028 0.0026 0.9156 
UCON6|Unknown|Unknown 147.8 45 100.682 91.427 0.0161 0.0147 0.9138 
MLTR32C_MM|LTR|ERVK 282.3 127 3.384 0 0.0011 0.0010 0.9138 
Eulor9A|DNA|DNA 147.4 60 0.846 0 0.0011 0.0010 0.9127 
LTR81|LTR|Gypsy 163.3 70 5.076 3.609 0.0014 0.0013 0.9111 
RLTR12B2|LTR|ERVK 363 95 3.384 0 0.0011 0.0010 0.9106 
Charlie23a|DNA|hAT-Charlie 157.9 157 5.076 2.406 0.0012 0.0011 0.9106 
Kanga1d|DNA|TcMar-Tc2 160.1 131 3.384 1.203 0.0012 0.0011 0.9105 
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MER65D|LTR|ERV1 169.3 101 1.692 0 0.0011 0.0010 0.9100 
IAPA_MM-int|LTR|ERVK 296.3 126 16.921 12.03 0.0015 0.0013 0.9099 
LTR89|LTR|ERVL? 175.1 146 2.538 0 0.0011 0.0010 0.9097 
LTR48B|LTR|ERV1 209.1 302 7.615 1.203 0.0011 0.0010 0.9094 
Charlie10|DNA|hAT-Charlie 206.7 371 16.921 8.421 0.0012 0.0011 0.9092 
LTRIS_Mm|LTR|ERV1 452.9 555 225.054 181.65 0.0019 0.0017 0.9089 
MLT1N2|LTR|ERVL-MaLR 162.8 692 19.46 7.218 0.0012 0.0011 0.9073 
MTB_Mm-int|LTR|ERVL-MaLR 647.1 379 71.916 42.104 0.0013 0.0012 0.9060 
MLT1G1-int|LTR|ERVL-MaLR 319.7 51 1.692 0 0.0011 0.0010 0.9060 
UCON13|LINE?|Penelope? 193.5 42 0.846 0 0.0011 0.0010 0.9057 
Charlie15a|DNA|hAT-Charlie 123.7 217 25.382 20.451 0.0019 0.0018 0.9056 
RLTR31B_Mm|LTR|ERVK 361.4 349 39.765 24.06 0.0013 0.0012 0.9053 
MamRep605|LTR?|LTR? 185.5 629 13.537 1.203 0.0011 0.0010 0.9053 
L1MEb|LINE|L1 219.7 352 25.382 15.639 0.0013 0.0012 0.9051 
LTR80B|LTR|ERVL 208.3 116 2.538 0 0.0011 0.0010 0.9049 
MER117|DNA|hAT-Charlie 122 745 60.071 45.713 0.0017 0.0015 0.9049 
MER102c|DNA|hAT-Charlie 161.5 363 19.46 12.03 0.0013 0.0012 0.9048 
LTR86A1|LTR|ERVL 174.7 92 1.692 0 0.0011 0.0010 0.9048 
MLTR31C_MM|LTR|ERVK 389 227 18.614 8.421 0.0012 0.0011 0.9047 
MER97a|DNA|hAT-Tip100 302.9 53 1.692 0 0.0011 0.0010 0.9047 
MER81|DNA|hAT-Blackjack 89.2 512 10.153 4.812 0.0012 0.0011 0.9043 
MamGypLTR1c|LTR|Gypsy 164.8 145 2.538 0 0.0011 0.0010 0.9040 
MT2B2|LTR|ERVL 188 3655 522.025 405.405 0.0018 0.0016 0.9036 
RLTR20C1_MM|LTR|ERVK 82 5561 566.02 466.757 0.0022 0.0020 0.9029 
MER135|DNA|DNA 109.3 287 3.384 0 0.0011 0.0010 0.9026 
RLTR40|LTR|ERVK 339.1 2651 231.823 120.298 0.0013 0.0011 0.9014 
L1M2a|LINE|L1 277.7 208 14.383 7.218 0.0012 0.0011 0.9007 
UCON14|DNA?|DNA? 115.7 66 0.846 0 0.0011 0.0010 0.9003 
Ricksha|DNA|MuDR 265.2 85 2.538 0 0.0011 0.0010 0.8988 
MER92B|LTR|ERV1 241.8 238 11.845 4.812 0.0012 0.0011 0.8987 
RMER16B|LTR|ERVK 355.4 84 3.384 0 0.0011 0.0010 0.8982 
RMER17C|LTR|ERVK 260.9 6479 494.951 271.874 0.0013 0.0012 0.8979 
MLT1G|LTR|ERVL-MaLR 219.2 896 227.593 184.056 0.0022 0.0019 0.8973 
MLT1G-int|LTR|ERVL-MaLR 266.2 39 2.538 1.203 0.0012 0.0011 0.8967 
5S|rRNA|rRNA 80.5 1038 24.536 13.233 0.0013 0.0012 0.8954 
7SK|RNA|RNA 170.6 691 38.073 21.654 0.0013 0.0012 0.8947 
HERVL40-int|LTR|ERVL 227.9 204 10.999 4.812 0.0012 0.0011 0.8924 
LTR83|LTR|ERVL 196.7 161 9.307 4.812 0.0013 0.0012 0.8903 
MLT-int|LTR|ERVL-MaLR 281.1 846 65.993 32.48 0.0013 0.0011 0.8897 
X7C_LINE|LINE|CR1 95.9 155 5.922 3.609 0.0014 0.0012 0.8887 
Charlie26a|DNA|hAT-Charlie 164.9 98 10.153 7.218 0.0016 0.0014 0.8885 
RLTR31D_MM|LTR|ERVK 121.9 8270 488.182 321.196 0.0015 0.0013 0.8884 
MER54B|LTR|ERVL 270.2 114 9.307 4.812 0.0013 0.0012 0.8879 
Charlie1b|DNA|hAT-Charlie 194.7 952 46.534 20.451 0.0013 0.0011 0.8875 
Charlie4|DNA|hAT-Charlie 165 161 3.384 0 0.0011 0.0010 0.8870 
Ricksha_0|DNA|MULE-MuDR 242.6 82 2.538 0 0.0011 0.0010 0.8869 
RLTR41B|LTR|ERV1 295.8 98 5.076 1.203 0.0012 0.0010 0.8863 
L1MEg2|LINE|L1 199.8 112 4.23 1.203 0.0012 0.0011 0.8862 
PB1D11|SINE|Alu 83.6 18484 1176.036 863.74 0.0018 0.0016 0.8852 
RLTR30B_MM|LTR|ERV1 352.7 283 21.152 7.218 0.0012 0.0011 0.8848 
MER105|DNA|DNA 128.1 171 4.23 1.203 0.0012 0.0011 0.8842 
MER123|DNA|DNA 156.9 41 0.846 0 0.0011 0.0010 0.8838 
FordPrefect|DNA|hAT-Tip100 290.1 291 95.606 74.585 0.0021 0.0019 0.8832 
LTR50|LTR|ERVL 183 549 69.378 49.322 0.0017 0.0015 0.8819 
UCON28c|Unknown|Unknown 168.9 37 0.846 0 0.0011 0.0010 0.8808 
ERVB5_2-LTR_MM|LTR|ERVK 397.3 520 92.222 56.54 0.0014 0.0013 0.8806 
LTR58|LTR|ERV1 105 9 4.23 3.609 0.0055 0.0048 0.8800 
Charlie10b|DNA|hAT-Charlie 128.8 48 0.846 0 0.0011 0.0010 0.8796 
MER106A|DNA|hAT-Charlie 160.5 115 2.538 0 0.0011 0.0010 0.8791 
MERX|DNA|TcMar-Tigger 190.9 64 1.692 0 0.0011 0.0010 0.8784 
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MLTR31E_MM|LTR|ERVK 362.9 164 10.999 2.406 0.0012 0.0010 0.8781 
MamTip1|DNA|hAT-Tip100 147.9 82 30.458 25.263 0.0035 0.0031 0.8780 
Arthur1C|DNA|hAT-Tip100 151.9 155 10.153 6.015 0.0014 0.0013 0.8772 
MER47A|DNA|TcMar-Tigger 189.9 127 3.384 0 0.0011 0.0010 0.8770 
RLTR12F|LTR|ERVK 296.4 60 2.538 0 0.0011 0.0010 0.8751 
HAL1b|LINE|L1 194 763 40.611 16.842 0.0013 0.0011 0.8740 
RLTR34D_MM|LTR|ERVK 375.4 410 60.917 33.683 0.0014 0.0012 0.8732 
RLTR34C_MM|LTR|ERVK 365.3 402 50.764 25.263 0.0013 0.0012 0.8710 
Charlie13b|DNA|hAT-Charlie 204.7 114 7.615 3.609 0.0013 0.0012 0.8706 
4.5SRNA|scRNA|scRNA 69.9 1517 611.708 518.485 0.0068 0.0059 0.8701 
HAL1M8|LINE|L1 211.5 710 55.841 28.872 0.0014 0.0012 0.8691 
LTR109A2|LTR|ERV1 150.7 37 0.846 0 0.0012 0.0010 0.8683 
Charlie1|DNA|hAT-Charlie 283.1 977 109.143 57.743 0.0014 0.0012 0.8667 
RLTR53B_Mm|LTR|ERVK 195 160 5.076 0 0.0012 0.0010 0.8601 
RLTR14|LTR|ERV1 258.1 2341 221.67 105.862 0.0014 0.0012 0.8598 
RMER16_Mm|LTR|ERVK 354.1 435 44.842 16.842 0.0013 0.0011 0.8592 
MLTR25A|LTR|ERVK 424 2168 417.112 228.566 0.0015 0.0012 0.8589 
MLT2E|LTR|ERVL 189 126 6.769 2.406 0.0013 0.0011 0.8573 
L1MEh|LINE|L1 198.1 202 6.769 0 0.0012 0.0010 0.8553 
MER131|SINE?|SINE? 109.3 274 5.076 0 0.0012 0.0010 0.8551 
L1M|LINE|L1 101.3 459 9.307 1.203 0.0012 0.0010 0.8548 
RLTR26B_MM|LTR|ERVK 358.9 507 35.535 3.609 0.0012 0.0010 0.8532 
ETnERV2-int|LTR|ERVK 840.8 1805 603.247 291.121 0.0014 0.0012 0.8528 
MLT1F2-int|LTR|ERVL-MaLR 322.8 68 15.229 9.624 0.0017 0.0014 0.8492 
LTR108b_Mam|LTR|ERVL 250.5 19 0.846 0 0.0012 0.0010 0.8491 
MLT1B-int|LTR|ERVL-MaLR 255.3 165 11.845 3.609 0.0013 0.0011 0.8474 
MamTip3|DNA|hAT-Tip100 155.5 180 9.307 3.609 0.0013 0.0011 0.8472 
UCON31|Unknown|Unknown 156.4 89 2.538 0 0.0012 0.0010 0.8458 
MER5C|DNA|hAT-Charlie 164.5 242 10.153 2.406 0.0013 0.0011 0.8449 
X7A_LINE|LINE|CR1 100 159 38.919 30.075 0.0034 0.0029 0.8387 
Charlie8|DNA|hAT-Charlie 175.3 728 191.212 139.546 0.0025 0.0021 0.8380 
LTR81B|LTR|Gypsy 191.3 204 23.69 13.233 0.0016 0.0013 0.8333 
Charlie14a|DNA|hAT-Charlie 172.7 72 2.538 0 0.0012 0.0010 0.8305 
YREP_Mm|Unknown|Unknown 413.1 2800 644.705 327.211 0.0016 0.0013 0.8238 
MER130|Unknown|Unknown 177.1 89 3.384 0 0.0012 0.0010 0.8233 
X8_LINE|LINE|CR1 119.7 158 8.461 3.609 0.0014 0.0012 0.8227 
Charlie17b|DNA|hAT-Charlie 252.9 130 42.303 28.872 0.0023 0.0019 0.8213 
MER113A|DNA|hAT-Charlie 155.1 140 6.769 1.203 0.0013 0.0011 0.8046 
DNA1_Mam|DNA|TcMar 153.4 45 1.692 0 0.0012 0.0010 0.8031 
MER57D|LTR|ERV1 209.8 300 246.206 185.259 0.0049 0.0039 0.8029 
Tigger10|DNA|TcMar-Tigger 214.9 242 48.226 27.669 0.0019 0.0015 0.7949 
L1MEj|LINE|L1 225.8 178 19.46 7.218 0.0015 0.0012 0.7948 
X6B_LINE|LINE|CR1 93.9 274 29.612 18.045 0.0022 0.0017 0.7910 
LTR104_Mam|LTR|Gypsy 174.6 254 63.455 40.901 0.0024 0.0019 0.7908 
LTR40c|LTR|ERVL 211 248 17.767 2.406 0.0013 0.0010 0.7809 
LTRIS3|LTR|ERV1 379.5 165 25.382 6.015 0.0014 0.0011 0.7799 
Charlie19a|DNA|hAT-Charlie 181.4 240 16.921 3.609 0.0014 0.0011 0.7798 
LTR108d_Mam|LTR|ERVL 198.3 30 1.692 0 0.0013 0.0010 0.7786 
MLTR25C|LTR|ERVK 559.8 504 137.909 44.51 0.0015 0.0012 0.7776 
X5B_LINE|LINE|CR1 73.1 79 1.692 0 0.0013 0.0010 0.7734 
HAL1_SS|LINE|L1 259.7 79 9.307 2.406 0.0015 0.0011 0.7686 
LTR45|LTR|ERV1 103.3 31 2.538 1.203 0.0018 0.0014 0.7674 
LTR53B|LTR|ERVL 247.6 83 10.999 3.609 0.0015 0.0012 0.7658 
MER97d|DNA|hAT-Tip100 193.2 28 1.692 0 0.0013 0.0010 0.7617 
Eulor2B|DNA?|DNA? 145 42 5.076 2.406 0.0018 0.0014 0.7609 
RLTR12A|LTR|ERVK 352.1 829 228.439 102.253 0.0018 0.0014 0.7575 
Tigger1a_Art|DNA|TcMar-Tigger 137.1 37 1.692 0 0.0013 0.0010 0.7499 
LTR16D1|LTR|ERVL 192.5 90 21.998 12.03 0.0023 0.0017 0.7465 
Charlie4z|DNA|hAT-Charlie 114.2 431 21.998 3.609 0.0014 0.0011 0.7418 
MER87|LTR|ERV1 104.1 46 1.692 0 0.0014 0.0010 0.7389 
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Tigger12c|DNA|TcMar-Tigger 169.8 97 7.615 1.203 0.0015 0.0011 0.7338 
MER129|LTR?|LTR? 182.4 63 4.23 0 0.0014 0.0010 0.7309 
FAM|SINE|Alu 60 117 7.615 3.609 0.0021 0.0015 0.7263 
Zaphod2|DNA|hAT-Tip100 238.4 169 31.305 9.624 0.0018 0.0012 0.6972 
Eulor5A|DNA?|DNA? 154.2 80 7.615 1.203 0.0016 0.0011 0.6786 
LTR88a|LTR|Gypsy? 146.8 64 11.845 4.812 0.0023 0.0015 0.6689 
MER66C|LTR|ERV1 85.5 19 0.846 0 0.0015 0.0010 0.6576 
LTR108a_Mam|LTR|ERVL 203.2 39 11.845 4.812 0.0025 0.0016 0.6443 
UCON23|DNA|hAT? 121.7 22 1.692 0 0.0016 0.0010 0.6128 
MER50-int|LTR|ERV1 184.5 14 1.692 0 0.0017 0.0010 0.6042 
Arthur1A|DNA|hAT-Tip100 127.7 148 17.767 1.203 0.0019 0.0011 0.5483 
X6A_LINE|LINE|CR1 103.3 145 16.921 2.406 0.0021 0.0012 0.5450 
MER34B-int|LTR|ERV1 204.9 81 40.611 14.436 0.0034 0.0019 0.5425 
HY3|scRNA|scRNA 65.5 15 0.846 0 0.0019 0.0010 0.5373 
LTR9|LTR|ERV1 112.2 13 1.692 0 0.0022 0.0010 0.4630 
LTR28|LTR|ERV1 107.6 10 4.23 1.203 0.0049 0.0021 0.4295 
Eulor6E|DNA?|DNA? 134.2 18 3.384 0 0.0024 0.0010 0.4165 
Ricksha_b|DNA|MuDR 182.5 2 1.692 0 0.0056 0.0010 0.1774 
LTR44|LTR|ERV1 71.3 3 1.692 0 0.0089 0.0010 0.1122 
MER50B|LTR|ERV1 91.4 14 11.845 0 0.0103 0.0010 0.0975 
 
 
 
 
 
Figure 5.1 Enforced Bcl2 expression partially rescues B cell development in Setdb1
Mb1
 pro B cells  
a) Setdb1
Mb1
; VavBcl2 and VavBcl2 bone marrow B cells stained with the Hardy scheme. b) 
Bargraphs depicting average and standard deviation of 6 biological replicates. 
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 Material and methods 6
 
6.1 Materials 
 
6.1.1 Mice  
 
Transgenic mouse Strain 
Wild type (CD45.2) C57BL/6 
Suv4-20h2ko C57BL/6 
Setdb1 flox; flox C57BL/6 
Mb1cre C57BL/6 
VavBcl2 mice C57BL/6 
Vavcre C57BL/6 
Wild type (CD45.1) B6/SJL 
 
6.1.2 Cell lines 
 
Mouse embryonic fibroblasts (MEFs) 
 
OP-9 (stromal cells) 
 
6.1.3 Antibodies and dyes 
 
ANTIBODY CLONE FLUOROCHROME DILUTION PROVIDER 
CD45R/B220 RA3-6B2 PE 1/1000 Pharmigen 
CD138/Synd 281-2 Biotinylated 1/1000 Pharmigen 
IgD 11-26c.2a FITC 1/250 Pharmigen 
CD24 (HSA) M1/69 FITC 1/500 Pharmigen 
CD11b/Mac-1 M1/70 PE  Pharmigen 
CD25 PC61.5 APC-AlexaFluor750 1/500 eBioscience 
Ter119 TER119 APC-AlexaFluor750 1/500 eBioscience 
CD8a 53-6.7 PE-Cy7 1/2501/1000 eBioscience 
CD45.1 A20 PE-Cy7 1/250 eBioscience 
CD5 53-7.3 PE 1/500 Pharmigen 
CD19 1D3 PE 1/1000 Pharmigen 
CD11c HL3  PE 1/250 Pharmigen 
Sca-1 D7 FITC 1/500 Pharmigen 
CD4 (L3T4)(PM4-5) PE 1/5000 Pharmigen 
CD8a 53-6.7 PE 1/1000 Pharmigen 
CD95R Jo2 PE 1/1000 Pharmigen 
CD25 PC61 PE-Cy5 1/500  eBioscience 
CD45.2  104 APC 1/250 eBioscience 
IgM II/41 FITC 1/250 Pharmigen 
CD117 2B8 APC-Alexa Fluor780 1/500 Pharmigen 
IgM II/41 PE-Cy7 1/250 eBioscience 
CD34 RAM34 Alexa-Fluor 647 1/200 eBioscience 
CD45R/B220 RA3-SB2 APC-Alexa-Fluor750 1/250 eBioscience 
CD21/CD35 7G6 APC 1/500 Pharmigen 
CD8a 53-6.7 PE-Cy7 1/1000 eBioscience 
Ly-6G(Gr-1) RB6-8C5 PE 1/5000 eBioscience 
CD19 1D3 APC 1/500 Pharmigen 
CD19 1D3 APC-Cy7 1/1000 Pharmigen 
CD117 2B8 PE 1/500 Pharmigen 
Streptavidin  APC 1/1000 Pharmigen 
CD3e 145-2C11 PE 1/250 Pharmigen 
Streptavidin  APC-Cy7 1/1000 Pharmigen 
Streptavidin  PE-Cy7 1/1000 Pharmigen 
Streptavidin  PE-Cy5 1/1000 Pharmigen 
Streptavidin  PE 1/1000 Pharmigen 
PNA  FITC 1/500 Vector 
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Cd11b/Mac1-α M1/70 APC-Cy7 1/4000 eBioscience 
CD44 IM7 FITC 1/1000 eBioscience 
CD115 AFS98 APC 1/3500 eBioscience 
Ly6-C HK1.4 PE-Cy5 1/2500 eBioscience 
DX-5 DX5 PE 1/1000 eBioscience 
Ter119 Ter-119 PE 1/1000 eBioscience 
CD127(IL7Rα) A7R34 PE-Cy5 1/500 eBioscience 
F4/80 BM8 PE 1/1000 Biolegend 
CD62L MEL-14 FITC 1/1000 eBioscience 
CD16/32 93 PE-Cy7 1/1000 eBioscience 
CD25  BC96 APC 1/500 Biolegend 
BP-1 6C3 PE 1/200 eBioscience 
CD43 S7 APC 1/500 Pharmigen 
CD40 3/23 PE 1/500 Biolegend 
CD279 (PD-1) RMP1-30 Bio 1/1000 eBioscience 
CD278 (Icos) C398.4A FITC 1/250 eBioscience 
CD278 (Icos) C398.4A APC 1/250 eBioscience 
7-AAD none PE-Cy5 1/100 eBioscience 
CD44 IM7 PECy7 1/100 eBioscience 
CD4 GK1.5 FITC 1/1000 eBioscience 
CD185(CXCR5) SPRCL5 PE 1/100 eBioscience 
CD34 RAM34 eFluor660 1/100 eBioscience 
Fcblock(CD16/CD32) 2.4G2 N/A 1/500 Pharmigen 
α-H3K9me3  N/A  Active motif 
α-H3K4me3  N/A  Diagenode  
α-H3K9ac  N/A   
α-Setdb1  N/A   
 
6.1.4 Technical devices and material 
 
Product Provider 
Axiovert 200 M Zeiss 
  
Optical microscope (DM IL) Leica 
  
Centrifuge (Haereus Multifuge 4KR) Thermo Scientific 
  
Banchtop centrifuge (Haereus Pico 17) Thermo Scientific 
  
Thermoblock/shaker Eppendorf  
  
Casy counter Innovatis 
  
Facs Canto  BD Bioscience  
  
MoFlo Beckman Coulter  
  
Facs Aria BD Bioscience 
  
Polystyrene round-bottom tubes  12x75 mm (5ml) Falcon 
  
Tissue culture hoods (Hera cell)  Thermo Scientific 
  
Scissors F.T.S. 
  
Rollermixer SRT6 STUART 
  
Microtome Thermo Scientific 
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Embedding blocks  Sigma Aldrich 
  
Light cycler 480II Roche 
  
PCR machine PeQLabBiotechnology/Applied 
Biosystems 
  
Infrared lamp Beurer 
  
Tailveiner (small) Biomedical Instruments 
  
Cell strainer 40 and 70 µm Falcon 
  
AutoMACS Miltenyi Biotec 
  
Quadro MACS Miltenyi Biotec 
  
Magnetic columns Miltenyi Biotec 
  
Syringes B/Braun 
  
Needles  B/Braun 
  
Blunt end needles  Stemcell Technology 
  
Syringes (colony forming assay) Stemcell Technology 
  
Syringes transplantation BD Bioscience 
  
Tissue culture dishes  Cell Star/Corning 
  
Colony forming assay dishes  Stemcell Technology 
  
Transilluminator Syngene 
  
Slides for microscopy Roth 
  
Cytospin Thermo Scientific 
 
 
6.1.5 Kits 
 
Product Provider 
Lineage Cell Depletion Kit, mouse Miltenyi Biotec 
  
CD45R (B220) MicroBeads, mouse Miltenyi Biotec 
  
B Cell Isolation Kit, mouse Miltenyi Biotec 
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Annexin V kit eBioscience 
  
Rneasy mini kit  QIAGEN 
  
Rneasy Plus micro kit QIAGEN 
  
DNeasy Blood and tissue kit QIAGEN 
 
6.1.6 Tissue culture media, cytokines and immunostimulants 
 
Product Provider 
RPMI Gibco 
  
DMEM Sgma Aldrich/PAA 
  
IMDM Gibco 
  
Methylcellulose 3434 Stemcell Technology 
  
Methylcellulose 3630  Stemcell Technology 
  
Serum  Sigma Aldrich/PAA 
  
β-mercaptoethanol Sigma Aldrich 
  
Non-essential amminoacids Sigma Aldrich 
  
Penicillin/Streptomycin Sigma Aldrich 
  
Interleukin-7 (IL-7) Pepro Tech 
  
LPS (lipopolysaccharide) Sigma Aldrich 
  
CpG Axxora 
  
Interleukin-4 (IL-4) Pepro Tech 
  
CD40 eBioscience 
 
6.1.7 Reagents and buffers 
 
Product Provider 
Formaldehyde   Roth 
  
Formaldehyde ChIP Sigma Aldrich 
  
May-Grünwald Roth 
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GIEMSA Roth 
  
BD PharmLyse (erythrocytes lysis) BD Bioscience 
  
PBS Homemade 
  
EDTA Sigma Aldrich 
  
Haematoxylin  Roth 
  
Eosin Roth 
  
Ethidium bromide  Roth 
  
TBA (Tris-borate-EDTA) Homemade 
  
 FACS buffer  Homemade 
  
 MACS buffer  Homemade 
  
Fast SYBR green master mix Applied Biosystems 
  
Superscript III kit Invitrogen 
  
RNasin® Plus Promega  
  
EGTA Roth 
  
Triton Roth 
  
SDS Fluka 
  
Na-deoxycholate Sigma Aldrich 
  
Protease inhibitor cocktail Roche 
  
Proteinase K Bioline  
  
Glycogen  Roche 
  
RnaseA Sigma Aldrich/ Roche 
  
NaCl Promega 
  
Ethanol  Porlabo chemicals 
  
Dynabeads Applied technology 
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6.1.8 Oligonucleotides   
 
Primer Sequence Experiment 
MLV1-gag F  TCTTGGCCACCGTAGTTACAG qRT-PCR 
MLV1-gag R CCAGTGTCCCTTTTCTTTGCAG qRT-PCR 
MLV1-env F AGAGGCAGCCACAAAAACAG qRT-PCR 
MLV1-env R ATTATAGGTGGCCCCCAGTTC qRT-PCR 
MLV5-gag F AGCTCCAAAGAATCCGAAACG qRT-PCR 
MLV5-gag R ATCTGTATCTGGCGGTTCCG qRT-PCR 
MLV5-pol F ATCATAGGTGGCTCCCAGTTC qRT-PCR 
MLV5-pol R AACCGAATGGCAGATCAAGC qRT-PCR 
MLV5-env F GTCAAAGAGAACAGGGTCACC qRT-PCR 
MLV5-env R CGGGTAAAAGGGCCAGCTG qRT-PCR 
MLV5-LTR F ATCCTGTTTGGCCTCTGTCTC qRT-PCR 
MLV5-LTR R ACGCCATTTTGCAAGGCATG qRT-PCR 
MLV8-gag F TGACCCAGCGTCTCTTCTTG qRT-PCR 
MLV8-gag R GGACCGCTTCTAAAAACATGGG qRT-PCR 
MLV8-LTR F CCTAGTCCCGGTACTTTCCAG qRT-PCR 
MLV8-LTR R ACTGCAGTAACGCCATCTTG qRT-PCR 
MLV8-env (spliced) F CCAGGGACCACCGACCCACCGT qRT-PCR 
MLV8-env (spliced) R TAGTCGGTCCCGGTAGGCCTCG qRT-PCR 
AI506816 F CCTGCTATGAAGGGGACAAAG qRT-PCR 
AI506816 R ATCTTCGGAAGAGCAGTCAGTG qRT-PCR 
Fcgr2b F GGAAGGACACTGCACCAGTC qRT-PCR 
Fcgr2b R CCAGTGACAGCAGCCACAAT qRT-PCR 
Tubb3 F GGCAACTATGTAGGGGACTCAG qRT-PCR 
Tubb3 R ATGGTTCCAGGTTCCAAGTC qRT-PCR 
Gapdh F TCAAGAAGGTGGTGAAGCAG qRT-PCR 
Gapdh R GTTGAAGTCGCAGGAGACAA qRT-PCR 
Hprt F ATGAGCGCAAGTTGAATCTG qRT-PCR 
Hprt R CAGATGGCCACAGGACTAGA qRT-PCR 
MLV1-gag F TCTTGGCCACCGTAGTTACAG ChIP-qPCR 
MLV1-gag R CCAGTGTCCCTTTTCTTTGCAG ChIP-qPCR 
MLV5-gag F AGCTCCAAAGAATCCGAAACG ChIP-qPCR 
MLV5-gag R ATCTGTATCTGGCGGTTCCG ChIP-qPCR 
MLV8-gag F TGACCCAGCGTCTCTTCTTG ChIP-qPCR 
MLV8-gag R GGACCGCTTCTAAAAACATGGG ChIP-qPCR 
IAPs-gag F AGCAGGTGAAGCCACTG ChIP-qPCR 
IAPs-gag R CTTGCCACACTTAGAGC ChIP-qPCR 
IAPs-global F CGGGTCGCGGTAATAAAGGT ChIP-qPCR 
IAPs-global R ACTCTCGTTCCCCAGCTGAA ChIP-qPCR 
Tubb3-intron1 F TTCTGACTCGCATTCCCATCC ChIP-qPCR 
Tubb3-intron2 R GGCTTAAGTGGCAACCTCAAAG ChIP-qPCR 
Def8-intron1 F TGAGCCTTCGGTTTCACAAC ChIP-qPCR 
Def8-intron2 R CAAAGCGCACCTCACATTTC ChIP-qPCR 
H19 F AGCTTTGAGTACCCCAGGTTCA ChIP-qPCR 
H19 R GCCTCTGCTTTTATGGCTATGG ChIP-qPCR 
Gapdh F CCATCCCACGGCTCTGCAC ChIP-qPCR 
Gapdh R GCAAGGCTTCCGTGCTCTCG ChIP-qPCR 
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6.1.9 Software and databases  
 
Flowjo 
 
http://www.immgen.org/ 
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6.2 Methods 
6.2.1 Mice and cell lines 
 
Suv420h2 ko mice were generated as previously described (Schotta et al., 2008). Mice 
carrying engineered Setdb1 floxed (Setdb1p) or delta (Setdb1∆) allele were purchased at 
EUCOMM. Mb1cre, VavBcl2, Vavcre transgenic animals have been previously described 
(Georgiades et al., 2002; Hobeika et al., 2006; Ogilvy et al., 1999). Mouse colonies were 
housed in ventilated cages in the mouse facility at the Adolf Butenandt Institute, in agreement 
with EU regulations.  
OP9 stromal cells were cultivated in IMDM medium, while splenic B cells and progenitors 
were expanded in RPMI medium (Gibco). Media were supplemented with 10% FSC, 1% non-
essential amino acid, 1% penicillin streptomycin and 0.2% β-mercaptoethanol (Sigma). For 
progenitor cell short-term culture RPMI was supplemented with IL-7 (PeproTech). MethoCult 
3630 used for Pre B cell differentiation was purchased from Stem Cell Technology. 
6.2.2 Flow cytometry and cell sorting  
 
Bone marrow cells were obtained flushing tibiae and femurs. These cells were then filtered 
through 70 µm cell strainer to eliminate debris and pieces of non-hematopoietic tissue. 
Hematopoietic cells were also taken from spleen and thymus gently smashing the organs on 
the surface of a 70 µm cell strained using a syringe piston. For FACS analysis single cell  
suspension from bone marrow, spleen and thymus were stained for 20 minutes at 4°C using 
combinations of antibodies conjugated with FITC, PE, PE-Cy5, Pe-Cy7, APC, APC-Cy7.  All 
samples were pre-incubated for 20 minutes at 4°C with unconjugated CD16/CD32 Fc-
blocking antibody to avoid unspecific binding, unless otherwise indicated. The antibodies 
were purchased from BD bioscience, ebioscience and BioLegend (see Materials). Labelled 
cells population were discriminated using FACS Canto. After staining cells were washed with 
FACS buffer, centrifuged at 4°C 10 minutes at 1300 rpm to remove excess of antibody.  
For magnetic and non-magnetic cell sorting cells were filtered through a 40 µm filter to avoid 
stromal cell contamination. Sorted samples were pre-treated with red blood cell lysis buffer 
(BD Bioscience) or pre-enriched B Cell Isolation Kit, mouse (Miltenyi). Magnetically labelled 
cells were separated with AutoMACS or QuadroMACS.  
6.2.3 Red blood cell lysis 
 
Erythrocytes lysis was performed using BD Pharm Lyse
TM
 purchased form BD Pharmingen.  
10X RBC buffer was diluted using bidistilled water kept at room temperature. 3 ml of 1X 
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RBC lysis buffer were used to treat bone marrow cells derived from one mouse. Bone marrow 
cells were washed with 1X PBS and centrifuged at RT for 10 minutes at 1300 rpm. Pellets 
were incubated for 15 minutes at RT with appropriate amount of lysis buffer and then 
centrifuged RT for 10 minutes at 1300 rpm. Cell pellets were then washed with 1X PBS to 
remove traces of lysis buffer and broken erythrocytes.  
6.2.4 Definition of hematopoietic cell types for FACS analysis and FACS sorting 
 
Cell population Gating strategy 
Immature B   *living cells, lymph, doublets, IgD-, B220+, IgM+ 
Mature B   living cells, lymph, doublets, IgM-, B220+, IgD+ 
Pro B   living cells, lymph, doublets, CD19+, IgD-, IgM-, c-kit+ CD25- 
Pre B   living cells, lymph, doublets, CD19+, IgD-, IgM-, c-kit- CD25+ 
Fr. A  living cells, lymph, doublets, CD43+, B220+, HSA/CD24-/ low, BP-1-  
Fr. B   living cells, lymph, doublets, CD43+, B220+, HSA/CD24+/high, BP-1- 
Fr. C  living cells, lymph, doublets, CD43+, B220+, HSA/CD24 high, BP-1+ 
LSK  living cells, doublets, lin-, Sca+, c-kit+ 
CLP  living cells, doublets, lin-, IL7rα+, Sca low, c-kit low 
CMP  living cells, doublets, lin-, IL7rα-, c-kit high, Sca-, CD34+, CD16/32-/ 
low 
GMP  living cells, doublets,  lin-, IL7rα-, c-kit high, Sca-,  CD34+, CD16/32+ 
MEP  living cells, doublets, lin-, IL7rα-, c-kit high, Sca-, CD34-, CD16/32- 
Pre-pro  living cells, lymph, doublets,  lin-, IL7rα+, c-kit low, CD43low,  B220+, 
CD93+ 
PF  living cells, lymph, doublets, B220+, PNA+, Fas+ 
TFH  living cells, lymph,  doublets,  CD4+, CXCR5+, PD-1+, ICOS+  
Naive CD4  living cells, lymph, doublets, CD4+, CD25- , CD62L+, CD44-/low 
T mem CD4  living cells, lymph, doublets, CD4+, CD25- , CD62L+, CD44+ 
T eff like-CD4  living cells, lymph, doublets, CD4+, CD25- , CD62L low/-, CD44+ 
Naïve CD8  living cells, lymph, doublets, CD8+ , CD62L+, CD44- 
T mem CD8  living cells, lymph, doublets, CD8+, CD62L+, CD44+ 
T eff like-CD8  living cells, lymph, doublets, CD8+, CD62L low/-, CD44+ 
Immature B sp  living cells, lymph, doublets, CD19, B220, IgM+, IgD- 
Mature B sp  living cells, lymph, doublets, CD19, B220, IgM-, IgD+ 
Trans B sp  living cells, lymph, doublets, CD19, B220, IgM+, IgD low/+ 
GM   living cells, granulocytes, doublets, Gr+, Mac+ 
Erythroblasts 1   living cells, c-kit-, Ter119-, CD71- 
Erythroblasts 2   living cells, c-kit-, Ter119-, CD71+ 
Erythroblasts 3   living cells, c-kit-, Ter119+, CD71+ 
Erythroblasts 4   living cells, c-kit-, Ter119+, CD71- 
DN1   living cells, lymph, doublets, CD4-, CD8-, CD44-, CD25- 
DN2   living cells, lymph, doublets, CD4-, CD8-, CD44+, CD25- 
DN3  living cells, lymph, doublets, CD4-, CD8-, CD44+, CD25+ 
DN4  living cells, lymph, doublets, CD4-, CD8-, CD44-, CD25+ 
CD4/CD8   living cells, lymph, doublets, CD4+, CD8+ 
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*To set the “living cells” gate we performed exclusion of debris and dead cells using FSC and 
SSC parameters. 
6.2.5 Envelope protein and Fcγr2b staining  
 
To detect the envelope protein on the pro B cell surface, 4x10
6
 bone marrow cells were 
resuspended in a volume of 50 µl and incubated 30 minutes at RT with rat α-env (83A25) 
diluted 1:5. Subsequently cells were incubated for 1 hour at RT with an anti-rat secondary 
antibody conjugated Alexa647. Bone marrow cells were then stained with IgD, IgM, CD19 
and c-kit to discriminate the pro B cell population (IgD-, IgM-, CD19+ and c-kit+). Because 
all antibodies used for the pro B cell staining were rat antibodies, env staining had to be 
performed in the absence of Fc-block and before the pro B cell staining to avoid non-specific 
bonding of the secondary α-ratAlexa647.  
Detection of the Fcγr2b was also achievable in the absence of Fc-block which directly 
recognizes and covers Fcγr2b on the cells surface. Pro B cells were stained with the same 
marker combination described above with the implementation of CD25 to discriminate the pre 
B cell population (IgD-, IgM-, CD19+, c-kit-, CD25+). After every incubation step, cells were 
washed with FACS buffer to remove the excess of antibody and centrifuged at 4°C for 10 
minutes at 1300 rpm. 
6.2.6 Bone marrow transplantation  
 
3-4 before transplantation control and mutant mice were injected with 5-fluorouracil (5-FU) to 
eliminate enriched for low cycling hematopoietic progenitors. 
5-FU treated bone marrow cells were harvested from CD45.1 wild type and CD45.2 donor 
mice. To perform competitive bone marrow transplantation assay, 1x10
6
 cells from CD45.1 
wild type mice were mixed 1:1 with either control (+,+; +/Mb1) or Setdb1
Mb1 
mice. The 
mixture was transplanted in sublethally irradiated wild type mice through tail vein injection. 
CD45.1 and CD45.2 surface markers were used to discriminate between the donors. Bone 
marrow and spleen from recipients were analysed by flow cytometry 7 to 9 weeks after 
transplantation. 
6.2.7 Immunohistochemistry 
 
For immunohistochemistry, spleens were fixed overnight with 4% formaldehyde and 
embedded in paraffin.  
To perform haematoxylin/eosin staining embedded sample were cut with a microtome 
to generate mm section which were deposited onto polarized slide and let adhere. Slides were 
deparaffinised through rehydration using a descending gradient of ethanol. Splenic sections 
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were then incubated in haematoxylin solution and washed. Next, slides were counterstained 
with eosin, washed and dehydrated using an increasing graded series of ethanol. Once 
dehydration was completed slides were washed in X-TRA-Solv solution and mounted.  
To perform ki-67 staining sections were deparaffinised through rehydration using a 
descending gradient of ethanol and incubated in 10 mM citrate buffer 1 hour at 90°C in the 
water bath. Samples were then passively cooled at RT. Next, slides were incubated in 3% 
hydrogen peroxide solution in the dark at RT for 10 minutes. Before proceeding with primary 
antibody incubation, tissue epitopes were blocked with blocking solution to avoid non-specific 
binding. α-ki67 diluted in blocking solution was then distributed on the slides which were 
incubated overnight at 4°C. The day after samples were washed to remove the excess of 
antibody and incubated in the dark for 1 hour at RT with secondary antibody conjugated with 
biotin. A second series of washing step was performed to remove unbound secondary 
antibody. In the following steps horseradish peroxidase (HRP) conjugated streptavidin was 
used for detection of the biotinylated secondary antibody. After washing away HRP 
conjugated streptavidin, slides were incubated with DAB buffer for 10 minutes at RT to allow 
detection. 
6.2.8 Autoantibodies detection test on MEFs  
 
Blood was quickly taken from the heart of wild type and Suv420h2 ko mice. Samples were left 
at RT to promote coagulation. Afterwards the non-coagulated upper phase (serum) was 
transferred in a fresh 1.5 ml tube and centrifuged at full speed to eliminate residual traces of 
cellular components. The upper phase was transferred again in a fresh tube and sored at -20°C. 
To test the presence of autoantibodies, 1x10
5
 MEFs were seeded on 12 mm coverslips placed 
in 24 well plates. Following overnight incubation, medium was aspirate and MEFs were fixed 
with 3,7% formaldehyde and permeabilized. To avoid non-specific binding fixed cells were 
incubated for 30 minutes at RT with blocking solution containing bovine serum albumin. 200 
µl of serum diluted 1:80 from wild type and Suv420h2 ko mice were distribute on MEFs and 
incubated overnight at 4°C. Next day the plate was equilibrated for 30 minutes at RT and 
incubated with α-mouse antibody conjugated with Alexa488 for 1 hour. After secondary 
incubation coverslips were embedded with Vectaschield containing DAPI and sealed with nail 
polish on a microscope slide.  
6.2.9 ELISA 
 
ELISA test was performed in collaboration with Strobl laboratory (Helmholtz Zentrum, 
Munich). 
 
Materials and methods 
 
 
123 
6.2.10 B cell proliferation assay 
 
MACS depleted B cells were counted and resuspended in appropriate volume to achieve 
20x10
6
cells/ml. Sterile warm PBS was used to pre-dilute 10 mM CFSE stock solution 1:5000. 
This solution was then mixed 1:1 ratio with B cell suspension and incubated in the water bath 
at 37°C 10 minutes. During this step cells incorporated CFSE. Stained cells were then washed 
with FCS and centrifuged at 4°C 10 minutes at 1300 rpm to stop CFSE labeling. A further 
washing was performed with supplemented medium. Because CFSE labeling induces cells 
loss, cell were counted again and suspended at a concentration of 0,5-1x10
6
cells/ml in RPMI. 
0,5-1x10
5 
cells were seeded on 96 well plate together with the following immunostimulants: 
LPS (0,5; 1 and 5µg/ml); combination of IL-4 (1; 3 and 10 ng/ml) and CD40 (5 µg/ml); IgM 
(5 µg/ml) and CpG (10 µM). Cell proliferation monitored via CFSE dilution peaks was 
checked 3-4 days after stimulation with FACS Canto. 
6.2.11 Colony forming assay and B cell differentiation on OP9 cells 
 
To test B cell differentiation, lineage negative or bulk bone marrow cells treated with red 
blood cell lysis buffer were seeded (1x10
5
 cells/ml) in duplicate in 60 mm dishes on 
MethoCult 3630 (Stem Cell Technology) containing IL-7 according to the manufacturer´s 
protocol. Cells were grown at 37°C 5% CO2 and checked every each day to monitor colony 
formation. After 10-12 day of culture colonies were scored and subsequently analysed by flow 
cytometry. 
Additionally, lineage negative bone marrow cells were enriched via magnetic sorting using the 
lineage cell depletion kit (Miltenyi) and seeded on OP9 stromal cells in the presence of IL-7 
(10 ng/ml). Every other day cells were split in fresh IL-7 supplemented medium as previously 
described (Holmes and Zuniga-Pflucker, 2009). At day 10 of coculture cells were harvested 
and analysed by flow cytometry for pre B cell differentiation using Hardy scheme (Hardy et 
al., 1991).  
6.2.12 Annexin V staining  
 
1-2 x10
6
 bone marrow cells were pre stained with pro B cell markers and then prepared for 
Annexin V staining. Next, cells were washed once with PBS and then with 1 ml of 1X 
Annexin V buffer. Pellets were resuspended in 100 µl of   Annexin V buffer to which 5 µl of 
Annexin V were added. Cells were incubated in the dark at RT for 15 minutes. To remove 
unbound Annexin V cells were washed with 1-2 ml of Annexin V buffer and immediately 
analysed by FACS. 
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The above described protocol faithfully follows the manufacture‟s instruction 
(http://media.ebioscience.com/data/pdf/best-protocols/annexin-v-staining.pdf).  
6.2.13 Cytospin  
 
1x10
6 
cells were suspended in 200 µl of PBS and loaded in a cytospin chamber. Cells were 
centrifuged at 180 g for 10 minutes. Slides were then stained with May-Grünwald solution for 
3 minutes and washed with water. A second staining step was performed with ready to use 
GIEMSA solution. Excess of the colorant was removed by rinsing with water the slides 
chamber and samples were air dried before proceeding to microscope analysis. 
6.2.14 RNA-Seq and qRT-PCR 
 
RNA-Seq was performed in collaboration with Busslinger laboratory (IMP, Vienna).  
Confirmation of the deregulated genes via qRT-PCR was achieved after RNA purification 
using RNeasy kit or RNeasy Plus kit from QIAGEN. Both kits allowed elimination of 
genomic DNA. Purified RNA was then used to produce cDNA. RNA was first incubated at 
70°C for 10 minutes with random hexamers. Subsequently, each tube was provided with a mix 
containing 5X First strand buffer, DTT, dNTPs and RNasin. Half volume from each sample 
was then transferred in a fresh 1.5 ml tube. One tube was provided with water as negative 
control while to the other one was given appropriated amount of SuperscriptIII.  Samples were 
incubated for 50 minutes at 50°C and to allow retrotranscription and afterwards 15 minutes at 
70°C to stop the reaction. The newly synthesized cDNA was diluted 1:20 to perform qRT-
PCR. Quantification of the transcripts was performed using the Ct values obtained using the 
SYBR green dye.   
6.2.15 Microarray analysis 
 
Microarray analysis was performed in collaboration with the Patrick Kremer laboratory (Gene 
Center, Munich). 
6.2.16 Chromatin immunoprecipitation and ChIP-Seq 
 
ChIP-Seq was performed in collaboration with Busslinger laboratory (IMP, Vienna). 
For fixation cells were resuspended in PBS containing 1% formaldehyde and 10% FBS. The 
mixture was incubated 10 minutes at RT with gentle shaking. Fixation reaction was stopped by 
adding glycine (0.125 M final concentration) for 5 minutes with gentle shaking. Fixed cells 
were centrifuged 1600 g for 5 minutes and supernatant was discarded. Cell pellets were then 
washed twice by rotation upon adding PBS 10% FCS. After the last wash, cells were 
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centrifuged again at 1600 g for 5 minutes. Supernatant was carefully removed and pellets were 
flash frozen.  
Before shearing cells were lysed by adding 130 µl of buffer B to the pellet and vortexed till 
complete re-suspension. Sonication was performed using Covaris E220 for 20 minutes. Cell 
lysates were transferred to AFA Fiber microtubes with Snap-Cap were sheared with the 
following settings: 
Duty cycle 2% 
Peak Incident Power 105 Watts (for S220/E220) 
Cycles per Burst 200 
Processing Time 20 minutes (for 1x10
6
 mouse pro B cells) 
Temperature (bath) 4°C 
Degassing Mode Continuous 
Volume 130 µL in microtubes AFA Fiber with Snap-Cap 
 
For the immunoprecipitation step the antibodies of choice have been bound to magnetic 
Dynabeads. Next, 100 µL of sheared chromatin (diluted in buffer A) were added to the 
appropriate tubes containing antibody conjugated magnetic beads. Chromatin was incubated 
for 4 hours at 4°C on a rotator at 35 rpm for immunoprecipitation. All tubes containing 
immunoprecipitated material were placed in the magnetic rack which captures the beads, to 
allow proceeding with subsequent washing steps. To remove unwanted immunoprecipitated 
material, beads were first washed 3 times with 100 µl ice cold buffer A and then once with 
buffer C. After washing, supernatants were discarded and chromatin eluted from the beads by 
resuspending samples in 210 µl of elution buffer and incubating them for 20 minutes at 65°C 
and 800 rpm in a termomixer. To take out the eluted chromatin, samples were spin down and 
placed back in the magnetic rack which allows the separation of the beads from the eluted 
chromatin. The supernatant (200 µl) was transferred to a fresh tube and incubated in a PCR 
machine overnight at 65°C for reverse cross-linking. To digest cellular protein and RNA all 
samples have been treated with Rnase A and proteinase K. After this step, chromatin has been 
cleaned using phenol/chloroform purification. 1 µl of this material was used for qRT-PCR 
quantification. 
 
Buffers composition: 
Buffer A - IP and wash buffer (for 10 mL): 
- 100 µL 1M Tris HCl pH7.5 (10 mM) 
- 20 µL 0.5M EDTA (1 mM) 
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- 10 µL 0.5M EGTA (0.5 mM) 
- 1000 µL 10% Triton 100 X (1%) 
- 50 µL 20% SDS (0.1%) 
- 100 µL 0.1% Na-deoxycholate 
- 280 µL 5M NaCl (140 mM) 
Total (1560 µL) 
- 8240µL H2O Milli-Q 
* The 200 µL left to complete to 10 mL are completed with protease inhibitor cocktail 50X, 
but it is added right before the use of the buffer. 
  
Buffer B - lysis buffer (for 10 mL): 
- 500 µL 1M Tris-HCl pH 8.0 (50 mM) 
- 200 µL 0.5M EDTA (10 mM) 
- 500 µL 20% SDS (1%) 
Total (1200 µL) 
- 8600 µL H2O Milli-Q 
The 200µL left to complete to 10mL are completed with protease inhibitor cocktail 50x, but it 
is added right before the use of the buffer. 
  
Buffer C - wash buffer (for 10 mL): 
- 100 µL 1M Tris-HCl pH 8.0 (10 mM) 
- 200 µL 0.5M EDTA (10 mM) 
Total: 1200 µL 
- 9700 µL H2O Milli-Q 
  
Elution buffer (for 10 mL): 
- 500 µL 1M Tris-HCl pH 8.0 (50 mM) 
- 200 µL 0.5M EDTA (10 mM) 
- 500 µL 20% SDS (1%) 
Total 1200 µL 
- 8800 µL H2O Milli-Q 
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 Abbreviations 7
 
5-FU 5-fluorouracil 
7AAD 7-Aminoactinomycin 
AID Activation Induced Cytidine Deaminase 
AnnV Annexin V 
APC Antigen presenting cells 
APC Allophycocyanin 
APC-Cy7 Allophycocyanin-Cy7 conjugated 
Ascl2; ASCL2 Achaete-scute complex homolog 2 
ASCOM ASC-2/NCOA6 complex 
ASH2L (absent, small, or homeotic)-like 
BACH2 BTB and CNC homology 2 
BATF Basic leucine zipper transcription factor, ATF-like 
Bcl2; BCL2 B cell leukemia/lymphoma 2 
Bcl6; BCL6 B cell leukemia/lymphoma 6 
BCL-XL B-cell lymphoma-extra large 
BLIMP-1 B-Lymphocyte-Induced Maturation Protein 1 
BMI BMI1 proto-oncogene, polycomb ring finger 
C/EBPα CCAAT-enhancer-binding proteins α 
CCL12 Chemokine (C-C motif) ligand 12 
CCR7 Chemokine (C-C motif) receptor 7 
cDNA Complementary DANN 
CFSE Carboxyfluorescein succinimidyl ester 
ChIP Chromatin immunoprecipitation 
CLP Common lymphoid progenitor 
c-MAF Musculoaponeurotic fibrosarcoma AS42 oncogene homolog 
CMP Common myeloid progenitor 
CXCL13 Chemokine (C-X-C motif) ligand 13 
Cxcr5; CXCR5 Chemokine (C-X-C motif) receptor 5 
DC Dendritic cell 
Def8 Defensin 8 
DN Double negative 
DNMT1 DNA methyltransferase (cytosine-5) 1 
DNMT2 (TRDMT1) tRNA aspartic acid methyltransferase 1 
DNMT3A DNA methyltransferase 3A 
DNMT3B DNA methyltransferase 3B 
DNMT3L DNA methyltransferase 3-like 
Dntt Deoxynucleotidyltransferase, terminal 
DP Double positive 
E Embryoni stage 
E2A; E2a (Tcf3) Transcription factor 3 
Ebf1; EBF1 Early B cell factor 1 
EED Embryonic ectoderm development 
EKLF Erythroid Krüppel-like factor 
ELISA Enzyme-linked immunosorbent assay 
ELP Early lymphoid progenitor 
env Envelope 
ERV Endogenous retroviruses 
mESCs Murine embryonic stem cells 
ETS E26 transformation-specific or E-twenty-six 
EZH1/2; Ezh1/2 Enhancer of zeste homolog 1 
FACS Fluorescence activated cell soring 
FACT Facilitates Chromatin Transcription 
FITC Fluorescein isothiocyanate 
FLI-1 Friend leukemia integration 1 
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Flt-3; FLT-3 FMS-related tyrosine kinase 3 
Flt-3l FMS-like tyrosine kinase 3 ligand 
FO Z B Follicular zone B cells 
FOG-1 Friend Of GATA-1 
FoXO Forkhead box O 
Foxo1 Forkhead box O1 
Gata1-3; GATA1-3 Globin transcription factor 1 
Gfi1; GFI1 Growth factor independent 1 
GO Gene ontology 
Gr-1 Granulocyte-1 
H Histone 
H3K14ac Histone 3 Lysine 14 acetylation 
H3K18ac Histone 3 Lysine 18 acetylation 
H3K23ac Histone 3 Lysine 23 acetylation 
H3K27me3 Histone 3 Lysine 27 trimethylation 
H3K36me3 Histone 3 Lysine 36 trimethylation 
H3K4me3 Histone 3 Lysine 4 trimethylation 
H3K79me3 Histone 3 Lysine 79 trimethylation 
H3K9ac Histone 3 Lysine 9 acetylation 
H3K9me2/3 Histone 3 Lysine 9 dimethylation or trimethylation 
H4K12ac Histone 3 Lysine 12 acetylation 
H4K16ac Histone 3 Lysine 16 acetylation 
H4k20me3 Histone 4 Lysine 20 trimethylation 
H4K5ac Histone 4 Lysine 5 acetylation 
H4K8ac Histone 4 Lysine 8 acetylation 
HPR Horseradish peroxidase 
HSC Hematopoietic stem cells 
IAP Internal A-type Particle  
IAP-Ez Internal A-type Particle containing an envelope gene 
ICOS Inducible T cell co-stimulator 
Id2/3 Inhibitor of DNA binding 2/3 
Ikzf1 IKAROS family zinc finger 1 
Ikzf3 IKAROS family zinc finger 3 
IL-12 Interleukin 12 
IL-21 Interleukin 21 
IL-4 Interleukin 4 
IL-6 Interleukin 6 
Il-7rα; IL-7Rα Interleukin 7 receptor-α 
Imm B Immature B cells 
INF-γ Interferon-γ 
Irf4/8; IRF4/8 Interferon regulatory factor 4/8 
KAP-1 (Trim28) KRAB-associated protein-1; tripartite motif-containing 28 
Ko Knockout  
KRAB-ZFN Krüppel associated box-zinc finger 
LDB1 LIM domain binding 1 
Lin- Lineage negative 
LMPP Lymphoid mltipotent primed progenitors 
LPS Lipopolysaccharide  
LSK Lineage negative Sca+ c-kit +  
LT-HSC Long term hematopoietic stem cells 
LTR Long terminal repeat 
Mac-1 Macrophage-1 
MACS Magnetic activatd cell sorting 
Mat B Mature B cells 
MBD Methyl binding domain 
MCL-1 Myeloid cell leukemia sequence 1 
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MEF Mouse embryonic fibroblast 
MegE Megakaryocyte/erythrocyte 
MEP Megakaryocyte/erythrocyte progenitor 
MITF Microphthalmia-associated transcription factor 
Mll ; MLL  Myeloid/lymphoid or mixed-lineage leukemia 
MLV or MuLV Murine leukemia virus 
MMTV Mouse mammary tumor virus  
MMVL30 Interspersed repeat subfamiliy 
MPP Multipotent progenitor 
MTA3 Metastasis associated 3 
Myb Myeloblastosis oncogene 
Myz Myc-Interacting Zn Finger Protein-1 
MZ B Marginal zone B cells 
NK Natural killer 
NOTCH1-4 Notch Homolog 1-4, Translocation-Associated 
Oct25 POU class 5 homeobox 3, gene 2 
OP9 Stroma cell line derived from (C57BL/6 x C3H)F2 -op/op mice 
 
PARP-γ Poly (ADP-ribose) polymerase-γ 
Pax5; PAX5 Paired box 5 
PBS (1) Phosphate saline buffer 
PBS (2) Primer binding site 
PE Phycoerythrin 
PE-Cy5 Phycoerythrin-Cy5 conjugated 
PE-Cy7 Phycoerythrin-Cy7 conjugated 
PH Patch deletion region 
PRC1 Polycomb-group repressive complex 1 
PRC2 Polycomb-group repressive complex 2 
Pre B Precursor B cells 
Pre-Pro B  Precursors of progenitor B cells 
Prmd1 PR domain containing 1, with ZNF domain 
Pro B Progenitor B cells 
PSC Posterior sex combs 
Rag1/2; RAG1/2 Recombination activating gene 1/2 
RbBP5 Retinoblastoma-binding protein 5 
RING Ring finger protein 1 
Rorc RAR-related orphan receptor gamma 
RPKM Reads Per Kilobase of transcript per Million mapped reads 
RT Room temperature 
SCML Sex comb on midleg-like 
SET domain Su(var)3-9 and 'Enhancer of zeste' protein domain 
Setdb1; SETDB1 SET domain, bifurcated 1 
Sfpi1 (PU.1) Spleen focus forming virus (SFFV) proviral integration oncogene 
SLC Surrogate light chain 
SLP65 Src Homology 2 Domain-Containing Leukocyte Protein Of 65 KDa 
Sp Spleen 
STAT3 Signal transducer and activator of transcription 3 
STAT5 A/B Signal transducer and activator of transcription 5 A/B 
ST-HSC Short term hematopoietic stem cells  
Suv39h; SUV39H Suppressor of variegation 3-9 homolog 1 
Suv420h1/2; SUV420H1/2 Suppressor of variegation 4-20 homolog 1/2 
SUZ12 Suppressor of zeste 12 homolog 
T eff-like T cell effector-like 
T mem Memory T cell 
Tbx21 T-box 21 
TEC Thymic epithelial cell 
TF Transcription factor 
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TFH Follicular helper T cells 
TGFβ Transforming growth factor, beta 
TH1 T helper 1 
TH17 T helper 17 
TH2 T helper 2 
TH9 T helper 9 
Trans B Transitory B cells 
T reg Regulatory T cells 
TSS Transcriptional start site 
Tubb3 Tubulin, beta 3 class III 
URE Upstream regulatory element 
Vav Vav 1 oncogene 
VCAM Vascular cell adhesion molecule 1 
Wnt Wingless-type 
XBP-1 X-box binding protein 1 
ZFN Zinc finger 
Zfx Zinc finger protein X-linked 
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